
<html lang="en"     class="pb-page"  data-request-id="5d855e8b-1af4-44bb-bf11-7e60be3e79a8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c02081;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2021.64.issue-14"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate" /></meta><meta name="dc.Creator" content="Huikai  Sun" /></meta><meta name="dc.Creator" content="Holger  Monenschein" /></meta><meta name="dc.Creator" content="Hans H.  Schiffer" /></meta><meta name="dc.Creator" content="Holly A.  Reichard" /></meta><meta name="dc.Creator" content="Shota  Kikuchi" /></meta><meta name="dc.Creator" content="Maria  Hopkins" /></meta><meta name="dc.Creator" content="Todd K.  Macklin" /></meta><meta name="dc.Creator" content="Stephen  Hitchcock" /></meta><meta name="dc.Creator" content="Mark  Adams" /></meta><meta name="dc.Creator" content="Jason  Green" /></meta><meta name="dc.Creator" content="Jason  Brown" /></meta><meta name="dc.Creator" content="Sean T.  Murphy" /></meta><meta name="dc.Creator" content="Nidhi  Kaushal" /></meta><meta name="dc.Creator" content="Deanna R.  Collia" /></meta><meta name="dc.Creator" content="Steve  Moore" /></meta><meta name="dc.Creator" content="William J.  Ray" /></meta><meta name="dc.Creator" content="Nicole Marion  English" /></meta><meta name="dc.Creator" content="Mark Beresford Lewis  Carlton" /></meta><meta name="dc.Creator" content="Nicola L.  Brice" /></meta><meta name="dc.Description" content="Parkinson’s disease (PD) is a chronic and progressive movement disorder with the urgent unmet need for efficient symptomatic therapies with fewer side effects. GPR6 is an orphan G-protein coupled r..." /></meta><meta name="Description" content="Parkinson’s disease (PD) is a chronic and progressive movement disorder with the urgent unmet need for efficient symptomatic therapies with fewer side effects. GPR6 is an orphan G-protein coupled r..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 16, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02081" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02081" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02081" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02081" /></link>
        
    
    

<title>First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02081" /></meta><meta property="og:title" content="First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0013.jpeg" /></meta><meta property="og:description" content="Parkinson’s disease (PD) is a chronic and progressive movement disorder with the urgent unmet need for efficient symptomatic therapies with fewer side effects. GPR6 is an orphan G-protein coupled receptor (GPCR) with highly restricted expression in dopamine receptor D2-type medium spiny neurons (MSNs) of the indirect pathway, a striatal brain circuit which shows aberrant hyperactivity in PD patients. Potent and selective GPR6 inverse agonists (IAG) were developed starting from a low-potency screening hit (EC50 = 43 μM). Herein, we describe the multiple parameter optimization that led to the discovery of multiple nanomolar potent and selective GPR6 IAG, including our clinical compound CVN424. GPR6 IAG reversed haloperidol-induced catalepsy in rats and restored mobility in the bilateral 6-OHDA-lesioned rat PD model demonstrating that inhibition of GPR6 activity in vivo normalizes activity in basal ganglia circuitry and motor behavior. CVN424 is currently in clinical development to treat motor symptoms in Parkinson’s disease." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02081"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02081">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-8/abseba.2021.7.issue-8/20210809/abseba.2021.7.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-15/accacs.2021.11.issue-15/20210806/accacs.2021.11.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-31/acsodf.2021.6.issue-31/20210810/acsodf.2021.6.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-31/ascecg.2021.9.issue-31/20210809/ascecg.2021.9.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-31/ancham.2021.93.issue-31/20210810/ancham.2021.93.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-31/bichaw.2021.60.issue-31/20210810/bichaw.2021.60.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-8/bomaf6.2021.22.issue-8/20210809/bomaf6.2021.22.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-29/cgeabj.2021.99.issue-29/20210809-01/cgeabj.2021.99.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-15/cmatex.2021.33.issue-15/20210810/cmatex.2021.33.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-15/enfuem.2021.35.issue-15/20210805/enfuem.2021.35.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-8/estlcu.2021.8.issue-8/20210810/estlcu.2021.8.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-8/jceda8.2021.98.issue-8/20210810/jceda8.2021.98.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-8/jctcce.2021.17.issue-8/20210810/jctcce.2021.17.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-15/joceah.2021.86.issue-15/20210806/joceah.2021.86.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-30/jpcafh.2021.125.issue-30/20210805/jpcafh.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-30/jpcbfk.2021.125.issue-30/20210805/jpcbfk.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-30/jpccck.2021.125.issue-30/20210805/jpccck.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-30/jpclcd.2021.12.issue-30/20210805/jpclcd.2021.12.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-8/jprobs.2021.20.issue-8/20210806/jprobs.2021.20.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-31/langd5.2021.37.issue-31/20210810/langd5.2021.37.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-15/mamobx.2021.54.issue-15/20210810/mamobx.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-15/orlef7.2021.23.issue-15/20210806/orlef7.2021.23.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-15/orgnd7.2021.40.issue-15/20210809/orgnd7.2021.40.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02081&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02081&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02081&amp;href=/doi/10.1021/acs.jmedchem.0c02081" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 9875-9890</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00790" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.1c01065" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Huikai Sun</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huikai Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><span class="conrtib-corresp"><strong>*</strong>(H.S.) Phone: 619-930-8349. Email: <a href="/cdn-cgi/l/email-protection#236b564a48424a0d50564d635742484647420d404c4e"><span class="__cf_email__" data-cfemail="7c340915171d15520f09123c081d1719181d521f1311">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huikai++Sun">Huikai Sun</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4593-1306" title="Orcid link">https://orcid.org/0000-0002-4593-1306</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Holger Monenschein</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Holger Monenschein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><span class="conrtib-corresp"><strong>*</strong>(H.M.) Email: <a href="/cdn-cgi/l/email-protection#bbd3d4d7dcdec995d6fbcfdad0dedfda95d8d4d6"><span class="__cf_email__" data-cfemail="99f1f6f5fefcebb7f4d9edf8f2fcfdf8b7faf6f4">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Holger++Monenschein">Holger Monenschein</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hans H. Schiffer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hans H. Schiffer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hans+H.++Schiffer">Hans H. Schiffer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Holly A. Reichard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Holly A. Reichard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Holly+A.++Reichard">Holly A. Reichard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shota Kikuchi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shota Kikuchi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shota++Kikuchi">Shota Kikuchi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria Hopkins</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria Hopkins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Hopkins">Maria Hopkins</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Todd K. Macklin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Todd K. Macklin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Todd+K.++Macklin">Todd K. Macklin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen Hitchcock</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Hitchcock</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Hitchcock">Stephen Hitchcock</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Adams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Adams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Adams">Mark Adams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason Green</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason Green</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Green">Jason Green</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason Brown</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Brown">Jason Brown</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sean T. Murphy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sean T. Murphy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sean+T.++Murphy">Sean T. Murphy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nidhi Kaushal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nidhi Kaushal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nidhi++Kaushal">Nidhi Kaushal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Deanna R. Collia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Deanna R. Collia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Deanna+R.++Collia">Deanna R. Collia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steve Moore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steve Moore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Moore">Steve Moore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William J. Ray</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William J. Ray</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William+J.++Ray">William J. Ray</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicole Marion English</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicole Marion English</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicole+Marion++English">Nicole Marion English</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Beresford Lewis Carlton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Beresford Lewis Carlton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cerevance Ltd, 418 Cambridge Science Park, Cambridge, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+Beresford+Lewis++Carlton">Mark Beresford Lewis Carlton</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Nicola L. Brice</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicola L. Brice</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cerevance Ltd, 418 Cambridge Science Park, Cambridge, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicola+L.++Brice">Nicola L. Brice</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02081&amp;href=/doi/10.1021%2Facs.jmedchem.0c02081" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 9875–9890</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 16, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 December 2020</li><li><span class="item_label"><b>Published</b> online</span>16 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02081" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02081</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9875%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHuikai%2BSun%252C%2BHolger%2BMonenschein%252C%2BHans%2BH.%2BSchiffer%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D14%26contentID%3Dacs.jmedchem.0c02081%26title%3DFirst-Time%2BDisclosure%2Bof%2BCVN424%252C%2Ba%2BPotent%2Band%2BSelective%2BGPR6%2BInverse%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BParkinson%25E2%2580%2599s%2BDisease%253A%2BDiscovery%252C%2BPharmacological%2BValidation%252C%2Band%2BIdentification%2Bof%2Ba%2BClinical%2BCandidate%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9890%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02081"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2287</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02081" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Huikai&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Holger&quot;,&quot;last_name&quot;:&quot;Monenschein&quot;},{&quot;first_name&quot;:&quot;Hans&quot;,&quot;last_name&quot;:&quot;H. Schiffer&quot;},{&quot;first_name&quot;:&quot;Holly&quot;,&quot;last_name&quot;:&quot;A. Reichard&quot;},{&quot;first_name&quot;:&quot;Shota&quot;,&quot;last_name&quot;:&quot;Kikuchi&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Hopkins&quot;},{&quot;first_name&quot;:&quot;Todd&quot;,&quot;last_name&quot;:&quot;K. Macklin&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Hitchcock&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Adams&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Green&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Brown&quot;},{&quot;first_name&quot;:&quot;Sean&quot;,&quot;last_name&quot;:&quot;T. Murphy&quot;},{&quot;first_name&quot;:&quot;Nidhi&quot;,&quot;last_name&quot;:&quot;Kaushal&quot;},{&quot;first_name&quot;:&quot;Deanna&quot;,&quot;last_name&quot;:&quot;R. Collia&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Moore&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;J. Ray&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;Marion English&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Beresford Lewis Carlton&quot;},{&quot;first_name&quot;:&quot;Nicola&quot;,&quot;last_name&quot;:&quot;L. Brice&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;9875-9890&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02081&quot;},&quot;abstract&quot;:&quot;Parkinson’s disease (PD) is a chronic and progressive movement disorder with the urgent unmet need for efficient symptomatic therapies with fewer side effects. GPR6 is an orphan G-protein coupled receptor (GPCR) with highly restricted expression in dopamine receptor D2-type medium spiny neurons (MSNs) of the indirect pathway, a striatal brain circuit which shows aberrant hyperactivity in PD patients. Potent and selective GPR6 inverse agonists (IAG) were developed starting from a low-potency screening hit (EC50 = 43 μM). Herein, we describe the multiple parameter optimization that led to the discovery of multiple nanomolar potent and selective GPR6 IAG, including our clinical compound CVN424. GPR6 IAG reversed haloperidol-induced catalepsy in rats and restored mobility in the bilateral 6-OHDA-lesioned rat PD model demonstrating that inhibition of GPR6 activity in vivo normalizes activity in basal ganglia circuitry and motor behavior. CVN424 is currently in clinical development to treat motor symptoms in Parkin&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02081&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02081" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02081&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02081" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02081&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02081" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02081&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02081&amp;href=/doi/10.1021/acs.jmedchem.0c02081" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02081" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02081" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02081%26sid%3Dliteratum%253Aachs%26pmid%3D33861086%26genre%3Darticle%26aulast%3DSun%26date%3D2021%26atitle%3DFirst-Time%2BDisclosure%2Bof%2BCVN424%252C%2Ba%2BPotent%2Band%2BSelective%2BGPR6%2BInverse%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BParkinson%25E2%2580%2599s%2BDisease%253A%2BDiscovery%252C%2BPharmacological%2BValidation%252C%2Band%2BIdentification%2Bof%2Ba%2BClinical%2BCandidate%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D14%26spage%3D9875%26epage%3D9890%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Parkinson’s disease (PD) is a chronic and progressive movement disorder with the urgent unmet need for efficient symptomatic therapies with fewer side effects. GPR6 is an orphan G-protein coupled receptor (GPCR) with highly restricted expression in dopamine receptor D2-type medium spiny neurons (MSNs) of the indirect pathway, a striatal brain circuit which shows aberrant hyperactivity in PD patients. Potent and selective GPR6 inverse agonists (IAG) were developed starting from a low-potency screening hit (EC<sub>50</sub> = 43 μM). Herein, we describe the multiple parameter optimization that led to the discovery of multiple nanomolar potent and selective GPR6 IAG, including our clinical compound CVN424. GPR6 IAG reversed haloperidol-induced catalepsy in rats and restored mobility in the bilateral 6-OHDA-lesioned rat PD model demonstrating that inhibition of GPR6 activity <i>in vivo</i> normalizes activity in basal ganglia circuitry and motor behavior. CVN424 is currently in clinical development to treat motor symptoms in Parkinson’s disease.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction and Biological Rationale</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75585" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75585" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Parkinson’s disease (PD) is a chronic and progressive movement disorder.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> Neurodegeneration and loss of dopamine-producing neurons in the substantia nigra pars compacta is one of the hallmarks of PD pathology and leads to dopamine (DA) depletion in the striatum.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> On the basis of the classical model of basal ganglia function, dopamine release into the striatum fine-tunes basal ganglia output by modulating two opposing motor control circuits in the brain—the direct (striatonigral) and the indirect (striatopallidal) pathways.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In the striatum, direct pathway medium spiny neurons expressing dopamine D1 receptors (D1-type MSN) are intermingled with indirect pathway MSN expressing dopamine D2 receptors (D2-type MSN). Loss of DA in PD is believed to cause hypoactivity in the direct and hyperactivity in the indirect pathways, which produces a net increase of inhibitory GABAergic output from the basal ganglia and suppresses movement in PD patients.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Replacing DA with levodopa (<span class="smallcaps smallerCapital">l</span>-DOPA), a prodrug of DA, is still the gold standard treatment to manage motor symptoms of PD.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> However, long-term use can result in significant dyskinesia and thus substantially decreases the quality of life of patients.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Other dopaminergic therapies with clinical effectiveness have been developed: catechol-<i>O</i>-methyltransferase (COMT) inhibitors,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> monoamine oxidase-B (MAO) inhibitors,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and dopamine receptor agonists,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> they but are associated with various side effects.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Multiple non-dopaminergic therapies for PD have been developed,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> including the adenosine A2A antagonist istradefylline (KW6002), which achieved approval in the United States and Japan as an adjunctive therapy to <span class="smallcaps smallerCapital">l</span>-DOPA.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Deep brain stimulation (DBS) in the globus pallidus or subthalamic nucleus of the indirect pathway is FDA approved and significantly improves the motor symptoms of PD.<a onclick="showRef(event, 'ref1 ref17'); return false;" href="javascript:void(0);" class="ref ref1 ref17">(1,17)</a> Importantly, because of the localized placement of the DBS probes, it avoids modulating the direct pathway known to be a major driver of <span class="smallcaps smallerCapital">l</span>-DOPA-induced dyskinesia (LID). Therefore, development of a drug that selectively targets the indirect pathway in PD could avoid invasive DBS procedures and provide therapeutic benefit without increased risk of drug-induced dyskinesia.</div><div class="NLM_p">GPR6 is a highly constitutively active orphan G-protein coupled receptor,<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> with highly restricted expression in the indirect pathway D2-type MSNs in the striatum<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and minimal expression in the direct pathway D1-type MSNs, other brain regions, and peripheral tissues. GPR6 receptors efficiently couple to Gs proteins in heterologous expression systems and constitutively stimulate adenylate cyclase activity and cyclic adenosine monophosphate (cAMP) accumulation in cells <i>in vitro.</i><a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> cAMP levels are reduced in striatal tissue derived from GPR6 knock out mice, which is consistent with GPR6 Gs protein coupling and cAMP signaling <i>in vivo.</i><a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> In contrast to GPR6, dopamine D2 receptors expressed in the indirect pathway D2-type MSN are Gi protein coupled and inhibit cAMP signaling.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> We hypothesize that inhibition of GPR6 and D2 receptors coexpressed in the indirect pathway D2-type MSN antagonize each other with respect to cAMP modulation. Consequently, targeting GPR6 with antagonists or inverse agonists could be a novel non-dopaminergic treatment to improve motor symptoms in PD through selective modulation of the indirect pathway by compensating for the lack of DA acting on D2 receptors. In addition, pharmacological inhibition of GPR6 is expected to have only a low risk for drug-induced dyskinesia because of the restricted expression in striatal D2-type MSN.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> The phenotype of GPR6 receptor knock out mice support a role of GPR6 receptors in basal ganglia function and its potential use as a PD drug target. They display a two-fold increased phosphorylation of Thr43 of the DARPP32 protein in the striatum, which is a key regulator of DA signaling. They also display increased locomotor activity and a reduced abnormal induced movement (AIM) in a dyskinesia PD rodent model.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p last">Herein we report the discovery of the first potent and selective GPR6 inverse agonists and their pharmacological validation in preclinical PD behavioral animal models.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73870" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73870" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A GPR6-selective high throughput screen (HTS) campaign was run to identify novel GPR6 inverse agonists as starting points for medicinal chemistry efforts. In total, 360 000 compounds were screened for inverse agonist activity in a GPR6-selective, cell-based time-resolved fluorescence resonance energy transfer (TR-FRET) cAMP assay using a stable and inducible CHO-K1-based cell line expressing human GPR6 receptor (see <a class="ref internalNav" href="#sec5_1" aria-label="Materials and Methods">Materials and Methods</a>). Only one very low-potency hit, compound <b>1</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), was identified in the screen and validated in a secondary full concentration–response repeat assay (EC<sub>50</sub> = 43 μM). Compound <b>1</b> did not modulate the baseline cAMP level or forskolin-stimulated cAMP levels in the uninduced CHO-K1-GPR6 cell line, which did not express GPR6 (data not shown). Furthermore, compound <b>1</b> did not modulate cAMP signaling in a cannabinoid receptor CB1-specific counterscreening assay (data not shown). Structure–activity relationship (SAR) optimization was initiated with the aim to improve the potency and druglike properties of compound <b>1</b> despite the fact that it contains a [1,2,5]-oxadiazole-containing bicyclic aromatic ring, which is a structural feature frequently found in pan-assay interference compounds (PAINS) that often show up as false positives in HTS.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Major SAR on the Right-Hand Side (RHS) Bicyclic Ring System</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0008.gif" alt="" id="gr1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0009.gif" alt="" id="gr2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">TR-FRET cAMP inverse agonist assay using a human GPR6 CHO-K1 cell line (<a class="ref internalNav" href="#sec5_1" aria-label="Materials and Methods">Materials and Methods</a>); EC<sub>50</sub> values are the means of at least two individual experiments with each concentration tested in triplicate.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Mixture of two regioisomers (2:1).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Efficacy (<i>Y</i><sub>max</sub>) is normalized to the efficacy of a reference compound, which was validated to inhibit the apparent constitutive activity of GPR6 receptors expressed in cAMP TR-FRET assays (<a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).</p></div></div><div></div></div><div class="NLM_p">Accordingly, our initial focus was to explore less problematic bicyclic ring systems with more vectors to explore for SAR and to remove the structural alert at the onset of the program. Fortunately, our first attempt to replace the five-membered oxadiazole ring with an unsubstituted phenyl ring was tolerated and even provided a modest improvement in potency (3-fold; EC<sub>50</sub> = 14 μM; <b>2a</b> in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). This new quinoxaline scaffold served as the basis for further systematic SAR exploration. While it was found that other small alkyl amines were also accommodated as cyclopropyl replacements, the cyclopropylamine was superior in terms of both potency and physicochemical properties (data not shown) in this early SAR. Next, introduction of small alkyl or phenyl groups on any carbon of the piperazine ring was not tolerated (data not shown). Modification of the benzyl group with one or two substituents showed a more significant impact on the potency as demonstrated by the initial compound <b>2b</b> bearing a 2,5-dichlorophenyl ring (EC<sub>50</sub> = 2.1 μM) and providing a seven-fold improvement in potency compared to <b>2a</b>, likely as a result of increased lipophilic interactions of the protein–ligand complex.</div><div class="NLM_p">However, the most significant functional potency improvement during the early phase of the project resulted from the modification of the quinoxaline phenyl ring. Introduction of a hydrophobic methyl group (<b>2c)</b> reduced the potency by eight-fold. Although the introduction of an electron-withdrawing F atom (<b>2e</b>) or the electron-donating OMe group (<b>2d</b>) was better tolerated, no sub-micromolar potency breakthrough was realized. In contrast, a strong electron-withdrawing group like CN (<b>2f</b>) or dimethyl amide (<b>2g</b>) was found to significantly enhance the potency to the 100 nM range. Incorporation of a nitrogen atom into the phenyl ring at either the 6 or 7 position (<b>3a</b> and <b>3b</b>) also boosted potency (50 nM), with no regiochemical preference observed between these two positions. In addition, this introduction of a ring nitrogen provided the benefit of improved physicochemical properties, such as lower lipophilicity (cLogP), and higher lipophilic ligand efficiency (LLE), which are known to correlate with improved metabolic stability and solubility.</div><div class="NLM_p">In order to further lower lipophilicity of <b>3a</b> and <b>3b</b> (cLogP > 4.5), we conducted an extensive SAR investigation on the more potent pyrido[3,4-<i>b</i>]pyrazine scaffold, focused on the western side of the molecule with the goal to replace the two very hydrophobic chlorine atoms. Gratifyingly, we found that replacement of the 2-chloro group on that phenyl ring with a fluorine atom was tolerated (<b>3c</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In contrast, replacing both Cl atoms with F atoms at the 2 and 5 position decreased the potency by five-fold (<b>3d</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Upon further investigation into the optimal substitution pattern on the benzyl moiety, we found that moving the 5-F atom to the 4 position (compound <b>3e</b>) was much preferred and provided potency below 50 nM. In addition, the lipophilicity of <b>3e</b> (cLogP = 3.2) was now within our acceptable range.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Optimization on the Pyrido[3,4-<i>b</i>]pyrazine Scaffold to Balance Selectivity and ADMET Properties</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0010.gif" alt="" id="gr3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">analogue</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center">selectivity over GPR3 (fold)</th><th class="colsep0 rowsep0" align="center">selectivity over GPR12 (fold)</th><th class="colsep0 rowsep0" align="center" char=".">P450 (2D6) pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center" char=".">hERG binding % @10 uM</th><th class="colsep0 rowsep0" align="center" char=".">cLogP<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3c</b></td><td class="colsep0 rowsep0" align="left">5-Cl</td><td class="colsep0 rowsep0" align="left">c-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">638×</td><td class="colsep0 rowsep0" align="left">15×</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3d</b></td><td class="colsep0 rowsep0" align="left">5-F</td><td class="colsep0 rowsep0" align="left">c-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">151</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3e</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">c-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">21×</td><td class="colsep0 rowsep0" align="left">80×</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3f</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">c-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">14×</td><td class="colsep0 rowsep0" align="left">78×</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3g</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">9×</td><td class="colsep0 rowsep0" align="left">14×</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3h</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">5×</td><td class="colsep0 rowsep0" align="left">19×</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">c-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">19×</td><td class="colsep0 rowsep0" align="left">105×</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4b</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">13×</td><td class="colsep0 rowsep0" align="left">27×</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4c</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">6×</td><td class="colsep0 rowsep0" align="left">13×</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4d</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">c-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="left">19×</td><td class="colsep0 rowsep0" align="left">105×</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4e</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">61</td><td class="colsep0 rowsep0" align="left">19×</td><td class="colsep0 rowsep0" align="left">47×</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">TR-FRET cAMP inverse agonist assay using a CHO-K1-based cell line; EC<sub>50</sub> values are the means of two or more individual experiments with each done in triplicate.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">cLogP values are calculated with ChemAxon.</p></div></div></div><div class="NLM_p">Additional pharmacological and physiochemical properties of compound <b>3e</b> are depicted in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. In addition to the cAMP functional potency on GPR6 receptor, <b>3e</b> possesses strong binding affinity: <i>K</i><sub>i</sub> = 7.0 nM (<i>in vitro</i> competition binding assay using a tritium-labeled tracer compound; see <a class="ref internalNav" href="#sec5_1" aria-label="Materials and Methods">Materials and Methods</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>3e</b> also exhibited high passive permeability and did not behave as a P-gp substrate as indicated by the low efflux ratio (ER) in the LLC-PK1-MDR1 cell monolayer assay. On the basis of these <i>in vitro</i> pharmacology properties in combination with acceptable subcutaneous rodent PK (absorption and central uptake—data not shown), we were enabled to explore for the first time the effect of GPR6 inhibition on rodent behavior in pharmacodynamic PD models.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacological and Physicochemical Properties of Tool Compound <b>3e</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">binding affinity <i>K</i><sub>i</sub> (nM)</td><td class="colsep0 rowsep0" align="left">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">functional EC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLC-PK1-MDR1 A to B (nm/s)</td><td class="colsep0 rowsep0" align="left">160</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-gp efflux ratio</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP</td><td class="colsep0 rowsep0" align="left">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CNS MPO</td><td class="colsep0 rowsep0" align="left">4.8</td></tr></tbody></table></div></div><div class="NLM_p">Haloperidol, a potent dopamine receptor D2 antagonist, activates striatal D2-type MSN of the indirect pathway, causing catalepsy in rats. GPR6 IAG <b>3e</b> dose-dependently (0.1–30 mg/kg sc) reversed haloperidol-induced catalepsy (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a<b>)</b>. This result suggests that inhibition of GPR6 reduces activity of the indirect pathway, which is expected to reduce inhibition of movement.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Studies on compound <b>3e</b> in a haloperidol-induced catalepsy model. (a) Compound <b>3e</b> reverses haloperidol-induced catalepsy in male rats. Haloperidol-induced catalepsy was measured 120 min after dosing Sprague-Dawley rats (<i>n</i> = 9–10 per group) at the same time with haloperidol (1 mg/kg, ip) and either vehicle (10% DMSO, 0.5% methylcellulose) or compound <b>3e</b> (0.1, 1, 10, and 30 mg/kg sc) or positive control compound KW6002 (0.6 mg/kg ip; adenosine A2A antagonist) treatments. (b) Compound <b>3e</b> reverses catalepsy in wild-type (WT) but not in male GPR6 knock out (KO) mice. Haloperidol-induced catalepsy was measured in wild-type (C57BL/6J) and GPR6 knock out mice 120 min after dosing animals at the same time (<i>n</i> = 6 per group) with haloperidol (1 mg/kg, ip) and vehicle (10% DMSO, 0.5% methylcellulose) or after dosing at the same time with haloperidol and either compound <b>3e</b> (30 mg/kg sc) or positive control compound KW6002 (0.3 mg/kg ip; adenosine A2A antagonist). Applied statistics: one-way ANOVA using Dunnett’s post hoc tests, significant effect of genotype difference or treatment as indicated: *<i>p</i> < 0.05 and **<i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">GPR6 knock out mice show similar sensitivity for haloperidol to induce catalepsy than wild-type mice (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b). However, compound <b>3e</b> (30 mg/kg sc) was unable to reverse haloperidol-induced catalepsy in GPR6 knock out mice, confirming that GPR6 receptor inhibition is mediating the efficacy of GPR6 IAG <b>3e</b> to reverse catalepsy in this PD model. As expected, the adenosine receptor A2A antagonist KW6002 was able to reverse haloperidol-induced catalepsy in both wild-type and GPR6 knock out mice (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b). Together, these results support the concept that GPR6 IAG reduce activity of the indirect pathway and might have potential as a therapeutic to treat motor symptoms of Parkinson’s disease.</div><div class="NLM_p">With the results from the catalepsy experiment, our confidence in the mechanism of action as described earlier had increased significantly. Therefore, we initiated lead optimization of compound <b>3e</b> by posing the question: What properties of the tool compound need to be improved in order to develop the candidate suitable for clinical development? This analysis revealed numerous areas to focus the lead optimization efforts on, and most of them could be addressed by applying established medicinal chemistry strategies:<ul class="NLM_list-list_type-bullet"><li><p class="inline">strong cytochrome P450 inhibition (mostly isoform 2D6): likely a result of the exposed eastern N atom</p></li><li><p class="inline">poor metabolic stability in human microsomes and hepatocytes leading to unacceptable human PK predictions</p></li><li><p class="inline">putative risk for time-dependent clearance inhibition resulting from the cyclopropyl amine<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a></p></li><li><p class="inline">insufficient selectivity over the closest neighbors GPR3 and GPR12, two G-protein coupled receptors in the same GPCR subfamily as GPR6<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a></p></li></ul>With the above mitigation strategies, we embarked on a few “quick wins”. Strong inhibition of one cytochrome P450 isoform (2D6) from <b>3e</b> (pIC50 = 7.3) was diminished through the strategic introduction of a methyl group on the carbon adjacent to the pyridyl nitrogen (<b>3f</b>), minimally impacting cLogP. Unfortunately, this modification also led to the further erosion of the already poor selectivity ratios over GPR3 and GPR12. Our initial goal was to keep a minimal 30-fold selectivity, ideally higher, but with the very poor selectivity observed from many of our pyridopyrazine analogues especially against GPR3, this fused bicyclic scaffold was deprioritized. Moreover, “quick win” attempt number two failed for the same reason—the introduction of an isopropylamine group (compound <b>3g</b> and <b>3h</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) to replace the cyclopropyl amine (a potential structural alert) also afforded a loss of selectivity revealed by pairwise comparison with the corresponding cyclopropylamine (compound <b>3e</b>).</div><div class="NLM_p">As these initial tactics had not proven successful, we switched our focus toward improving metabolic stability. A metabolite identification (Met ID) study revealed the major route of oxidative metabolism takes place at the benzyl-piperazine subunit via benzylic oxidation and subsequent N-debenzylation (data not shown). Among many structural iterations, it was found that a phenolic-piperidine replacement was tolerated and maintained potency, and importantly, this structural change appeared to be feasible to reduce oxidative metabolism as demonstrated by comparing human microsomal turnover rates of selected pairs such as <b>3f</b> and <b>4a</b> (74 mL/min/kg over 45 mL/min/kg, respectively). The improved metabolic stability of compounds containing the phenolic-piperidine vs the benzyl-piperazine was consistent throughout the program.</div><div class="NLM_p">Interestingly, a slight improvement in the selectivity profiles versus GPR3 and GPR12 was also observed in pairwise comparisons for the phenolic-piperidines (<b>4a</b> and <b>3f</b>, and <b>4b</b> and <b>3h</b>; <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Expanding this SAR briefly to explore additional potential selectivity gains, the pyridyl nitrogen was moved from position 6 to 7 (<b>4d</b> and <b>4a</b>, and <b>4e</b> and <b>4b</b>), which did not afford a change in selectivity, unfortunately. The introduction of the electron-withdrawing group CN (<b>4c</b>) at the carbon adjacent to the pyridyl nitrogen decreased the selectivity versus both GPR3 and GPR12.</div><div class="NLM_p">The SAR described in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> seemed to be moderately promising; however, another concerning liability was introduced and had to be carefully monitored. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, hERG binding affinity was significantly increased for compounds (<b>4a</b>,<b>b</b> and <b>4e</b>).</div><div class="NLM_p">After only limited success was achieved thus far, we explored more incisive modifications on the bicyclic aromatic ring system. We hypothesized that lowering lipophilicity and increasing fraction sp<sup>3</sup> of the rather flat and highly aromatic system could be beneficial to addressing some key areas for optimization on a more overall compound quality and balanced property basis, decreasing promiscuity and increasing chances of clinical success.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> Accordingly, compounds <b>5a</b>–<b>c</b> and <b>6a</b>–<b>i</b> with saturation of the RHS pyridine ring were synthesized. We anticipated that removal of the exposed N atom and the increased three-dimensional character would lead to decreased CYP2D6 inhibition, decreased hERG activity, and improved selectivity over GPR3 and GPR12. The results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Saturation of the Right-Hand Side (RHS) Pyridine Ring Leading to the Lead Compound <b>6h</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0011.gif" alt="" id="gr5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">analogue</th><th class="colsep0 rowsep0" align="center">X-R</th><th class="colsep0 rowsep0" align="center">Y-R</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">selectivity over GPR3 (fold)</th><th class="colsep0 rowsep0" align="center">selectivity over GPR12 (fold)</th><th class="colsep0 rowsep0" align="center">P450 (2D6) pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center" char=".">hERG binding % @ 10 μM</th><th class="colsep0 rowsep0" align="center" char=".">cLogP<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">-NCOMe</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="left">25×</td><td class="colsep0 rowsep0" align="left">30×</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">-NCOEt</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="left">20×</td><td class="colsep0 rowsep0" align="left">16×</td><td class="colsep0 rowsep0" align="left"><5.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">-NSO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="left">7×</td><td class="colsep0 rowsep0" align="left">8×</td><td class="colsep0 rowsep0" align="left">5.7<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left">-NCOMe</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="left">15×</td><td class="colsep0 rowsep0" align="left">15×</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">-NCOMe</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">c-Pr</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="left">40×</td><td class="colsep0 rowsep0" align="left">120×</td><td class="colsep0 rowsep0" align="left"><5.2</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">-NH</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">1.6×</td><td class="colsep0 rowsep0" align="left">16×</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">-NMe</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="char" char=".">89</td><td class="colsep0 rowsep0" align="left">21×</td><td class="colsep0 rowsep0" align="left">69×</td><td class="colsep0 rowsep0" align="left"><5.0</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">-NSO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="char" char=".">65</td><td class="colsep0 rowsep0" align="left">15×</td><td class="colsep0 rowsep0" align="left">26×</td><td class="colsep0 rowsep0" align="left"><5.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6f</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">NCOOMe</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="char" char=".">158</td><td class="colsep0 rowsep0" align="left">190×</td><td class="colsep0 rowsep0" align="left">34×</td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6g</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">-NCOMe</td><td class="colsep0 rowsep0" align="left">c-Pr</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="left">52×</td><td class="colsep0 rowsep0" align="left">272×</td><td class="colsep0 rowsep0" align="left"><5.0</td><td class="colsep0 rowsep0" align="char" char=".">81</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6h</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">-NCOMe</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="left">110×</td><td class="colsep0 rowsep0" align="left">97×</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">TR-FRET cAMP inverse agonist assay using a human GPR6 CHO-K1 cell line (<a class="ref internalNav" href="#sec5_1" aria-label="Materials and Methods">Materials and Methods</a>); EC<sub>50</sub> values are the means of at least two individual experiments with each concentration tested in triplicate.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Over P450 isoform 1A2.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">cLogP values are calculated with ChemAxon.</p></div></div></div><div class="NLM_p">After saturation of the aromatic bicyclic ring system in combination with the LHS piperazine ring motif, the newly generated basic nitrogen was masked as either an amide or a sulfonamide (<b>5a</b>–<b>5c</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Encouragingly, all compounds exhibited potency levels in the desired range and, indeed, demonstrated lower hERG binding in many compounds as hypothesized earlier (<b>5a</b>). Moreover, <b>5a</b> showed a 2–3-fold improvement in selectivity over both GPR3 and GPR12. However, sterically more demanding N-masking groups were detrimental to the selectivity.</div><div class="NLM_p">The next important breakthrough in the project was achieved when the newly developed western phenolic-piperidine subunit was combined with the new partially saturated RHS core, leading to a number of notable improvements. To our surprise, <b>6b</b> (R<sup>1</sup> = cyclopropyl) exhibited much improved selectivity, 40-fold over GPR3 and 120-fold over GPR12. Although the selectivity trend of the cyclopropylamine over isopropylamine was evidenced again by comparing <b>6b</b> with <b>6a</b>, it was difficult to manifest a clear selectivity strategy lacking a more reliable SAR trend. With this observation, we attempted a similar idea as described for the aromatic analogues from <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and also synthesized <b>6g</b> and <b>6h</b> as the regioisomers of <b>6a</b> and <b>6b,</b> respectively. In contrast to the aromatic analogues, a significant selectivity improvement was achieved. Both <b>6g</b> and <b>6h</b> showed selectivity values for both GPR3 and GPR12 well above our criteria of 30 fold. Our investigation on the RHS saturated ring was expanded, but none of these attempts were successful. These efforts either led to the loss of potency, like <b>6c</b> (unmasked nitrogen), <b>6d</b> (methylated nitrogen), and <b>6f</b> (N masked as a carbamate), or were not tolerable to the selectivity, like <b>6e</b> (masked as sulfonamides). After a careful review of all relevant data, we realized that compound <b>6h</b> was the most promising of all late-stage lead optimization contenders, eliminating all the concerns that were identified with compound <b>3e</b>. Compound <b>6h</b> was selected as the project’s first advanced lead and <i>in vivo</i> tool compound. A snapshot of the relevant data contributing to the selection process of compound <b>6h</b> is depicted in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. Summarizing a few key features, <b>6h</b> exhibited 16 nM binding affinity in competitive radioligand binding assays, similar to its functional potency in cell-based cAMP TR-FRET assays (EC<sub>50</sub> = 34 nM). LLC-PK1-MDR1 efflux assays indicated a high brain permeability, and robust metabolic stability was observed in human hepatocyte (hHep) stability assays. A follow-up hERG functional assay gave IC<sub>50</sub> = 6.2 μM, consistent with its hERG binding affinity.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Summary of Other Key Properties for Lead Compound <b>6h</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center"><b>6h</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">binding affinity <i>K</i><sub>i</sub> (nM)</td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">functional EC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">selectivity over GPR3 (fold)</td><td class="colsep0 rowsep0" align="left">110×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">selectivity over GPR12 (fold)</td><td class="colsep0 rowsep0" align="left">97×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">logD</td><td class="colsep0 rowsep0" align="left">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLE (logEC50-clogP)</td><td class="colsep0 rowsep0" align="left">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLC-PK1-MDR1 A to B (nm/s)</td><td class="colsep0 rowsep0" align="left">160</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-gp efflux ratio</td><td class="colsep0 rowsep0" align="left">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLM, Cl<sub>int</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HHep, Cl<sub>int</sub> (mL/min/kg)/fu (%)</td><td class="colsep0 rowsep0" align="left">5.7/16%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG screen (Cerep) functional IC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">6.2 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog CV (CorDynamics) no <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="82e4ebece6ebece5f1c2">[email protected]</a></td><td class="colsep0 rowsep0" align="left">30 mg/kg p.o.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog Cmax (total/free) at 30 mpk</td><td class="colsep0 rowsep0" align="left">11.0 μM/11 nM</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Properties of Lead Compound <b>6h</b> in Male Sprague-Dawley Rats</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">subject (<i>n</i> = 3)</th><th class="colsep0 rowsep0" align="center">AUC (0 – τ) (h*ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC (0 – ∞) (h*ng/mL)</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>dss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">term <i>t</i><sub>1/2</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">i.v.</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">mean</td><td class="colsep0 rowsep0" align="left">339</td><td class="colsep0 rowsep0" align="left">341</td><td class="colsep0 rowsep0" align="left">49.7</td><td class="colsep0 rowsep0" align="char" char=".">3.68</td><td class="colsep0 rowsep0" align="char" char=".">1.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SD</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">7.9</td><td class="colsep0 rowsep0" align="char" char=".">0.37</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">subject (<i>n</i> = 3)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">F</th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p.o.</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">mean</td><td class="colsep0 rowsep0" align="char" char=".">62.5</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SD</td><td class="colsep0 rowsep0" align="char" char=".">9.9</td><td class="colsep0 rowsep0" align="char" char=".">0.87</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div><div class="NLM_p">As a result of the identification of <b>6h</b>, the project objectives were revised, leading to a parallel three-prong approach:<ul class="NLM_list-list_type-bullet"><li><p class="inline">Objective 1: initiate the development of a quantitative receptor occupancy (RO) assay, either <i>in vivo</i> or <i>ex vivo</i></p></li><li><p class="inline">Objective 2: initiate all required <i>in vivo</i> tolerability, pharmacology, and pharmacokinetic studies with <b>6h</b> and explore the feasibility of generating a candidate selection package</p></li><li><p class="inline">Objective 3: continue the lead optimization to mitigate for a potential failure of <b>6h</b></p></li></ul>Executing on the newly devised research plan, objective 1 started with the search for a suitable tool tracer compound to measure RO in vivo. First, we focused on developing an isotope (label)-free LC-MS/MS-based in vivo RO method for GPR6 receptors in rodents, based on previously reported successful strategies.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The use of LC-MS/MS techniques to quantify levels of unlabeled tracer compound in discrete brain regions expressing the target of interest offers an attractive alternative to assess real <i>in vivo</i> RO, circumventing the need to identify and generate radiolabeled tracer, reducing associated costs and increasing turnaround time. First, we applied compound selection criteria (e.g., high potency, high selectivity, rapid brain uptake, and rapid wash out),<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> dosed animals intravenously (i.v.), dissected brain regions, and screened for brain penetrant compounds that demonstrated strong enrichment in the striatum compared to the cerebellum, using LC-MS/MS-based quantification methods. A suitable GPR6 tracer compound is expected to show a several fold enrichment in the striatum due to the high expression of GPR6 in striatal D2-type MSN, compared to nonspecific binding in the cerebellum, a brain region that lacks significant expression of GPR6 receptors. The time course of tracer enrichment and knowledge of the lowest tracer dose that achieved largest fold enrichment are additional criteria to be considered for tracer selection and validation. Most importantly, after successful optimization and assay development, the enrichment of a suitable tracer can be blocked by predosing the test compound at therapeutically relevant doses, which allows quantification of receptor occupancy for the test compound.</div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a, the selected cold tracer molecule RL-338 achieved baseline enrichment of roughly nine-fold in mouse striatum over background tissue (cerebellum) where GPR6 is not present. Striatal enrichment of compound RL-338 was absent in GPR6 knock out mice, confirming the high specificity of RL-338 for GPR6 receptor binding in vivo (data not shown). Rewardingly, predosing <b>6h</b> (0.03, 0.3, 3, 30 mg/kg; p.o.) achieved a clear and dose-dependent blockage of the striatal enrichment of tracer RL-338, confirming that <b>6h</b> efficiently occupies GPR6 receptors <i>in vivo</i> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>,b). To the best of our knowledge, this is the first time that the successful application of the isotope-free LC-MS/MS RO method is reported for an orphan GPCR. A plasma exposure of <b>6h (</b>2.8 ng/mL; 6.1 nM<b>)</b> was required to achieve 50% maximal GPR6 receptor occupancy (Occ50). To further study compound <b>6h</b> receptor occupancy, we additionally developed an ex vivo GPR6 receptor occupancy assay, using a tritium-labeled form of our tracer compound RL-338 (<a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>). After oral dosing, compound <b>6h</b> dose-dependently achieved ex vivo-based RO in rats with a plasma Occ50 of 3.4 ng/mL (7.5 nM), which is similar to the Occ50 determined using the LC-MS/MS-based RO method (data not shown). Both methods together confirmed that compound <b>6h</b> efficiently achieved RO in vivo.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vivo label-free LC-MS/MS-based GPR6 receptor occupancy (RO) of lead compound <b>6h</b> in male Sprague-Dawley rats. (a) GPR6 IAG tracer compound RL-338 (0.04 μg/kg, i.v.) accumulates nine-fold in the rat striatum (STR), a brain region expressing a high level of GPR6, in comparison to the cerebellum (CB), a brain region without GPR6 expression (90 min post dosing). Compound <b>6h</b> (0.03, 0.3,3 and 30 mg/kg, p.o.) dose-dependently reduced striatal enrichment of tracer RL-338 compared to vehicle (Tween-80, 0.5% methylcellulose) 90 min post dosing—an in vivo measure of isotope-free GPR6 receptor occupancy. (b) Correlation of compound <b>6h</b> plasma exposure and striatal receptor occupancy using <i>in vivo</i> label-free RO method (compound <b>6h</b> Occ<sub>50</sub> (plasma) = 2.8 ng/mL). Data are mean ± s.e.m. (<i>n</i> = 5 per group) after 90 min postinjection of <b>6h</b>; *<i>P</i> < 0.05, ****<i>P</i> < 0.0001 vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Executing on objective 2, compound <b>6h</b> did not show any signals in our internal collection of <i>in vitro</i> safety assessments including mutagenicity. To derisk the moderate hERG signal, a cardiovascular study in dogs was conducted, and no adverse effects (AEs) were detected at a dose of 30 mpk. Likewise, 14-day toxicological studies in rat and dog did not unveil any findings at the highest doses of 300 mpk and 30 mpk in rats and dogs, respectively, despite achieving very high total plasma.</div><div class="NLM_p">To further understand the efficacy of GPR6 inhibition to treat the motor symptoms of PD, we focused on testing our lead compound <b>6h</b> in the bilateral 6-OHDA-lesion PD model that exhibits the loss of dopaminergic neurons in the substantia nigra and dopamine depletion in the striatum, reflecting one of the pathological hallmarks of Parkinson’s disease. Rats with bilateral 6-OHDA lesions develop loss of mobility (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) and are used as preclinical behavioral in vivo models to study compounds for efficacy to treat the motor symptoms in PD.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>6h</b> shows anti-Parkinsonian efficacy in the bilateral 6-OHDA-lesioned rat model of Parkinson’s disease. 6-OHDA-lesioned female animals are dosed with vehicle (0.5% methylcellulose) or compound <b>6h</b> (1 mg/kg, p.o.). Animals are placed in automated activity monitors for 3 h post dosing to assess mobility. The pen field activity of unperturbed study animals before the introduction of a bilateral 6-OHDA lesion is shown as control. Collected data are mean ± s.e.m. (<i>n</i> = 10 per group) of total counts over 3 h. *<i>P</i> < 0.05 vs vehicle; repeated measures one-way ANOVA followed by Newman-Keuls test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Oral dosage (1 mg/kg) of compound <b>6h</b> restored mobility of 6-OHDA-lesioned animals to presurgery level (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This result is consistent with the proposed mechanism of action: inhibition of GPR6 receptors normalizes dopamine-like cAMP signaling in dopamine D2 type MSNs and reduces hyperactivity in the indirect pathway in the striatum. The results of our initial in vivo pharmacology studies characterizing selective GPR6 IAG <b>3e</b> and <b>6h</b> in the catalepsy model and the 6-OHDA-lesion PD model, respectively, provide first preclinical evidence that efficient GPR6 inhibition in vivo could represent a novel mechanism to treat motor symptoms in Parkinson’s disease. A manuscript expanding the study of GPR6 biology and the pharmacological characterization of compound <b>6h</b> is in preparation (unpublished).</div><div class="NLM_p">The commitment to objective 3 led to the discovery of compound <b>6i</b>, which has many of the favorable druglike properties of <b>6h</b> but with some advantages such as lower lipophilicity and higher in vivo toxicity margins. Therefore, <b>6i</b> was selected for candidate development over <b>6h</b>. Compound <b>6i</b>, now named CVN424, is currently in phase 2 clinical development to treat motor symptoms in PD by Cerevance, Inc. A manuscript describing the preclinical <i>in vitro</i> and <i>in vivo</i> pharmacological characterization of CVN424 (<b>6i</b>) is in press.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">A selection of key data is summarized in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> for compound <b>6i</b>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Summary of Key in Vitro ADMET and Pharmacological Properties of Lead Compound <b>6i</b> (CVN424)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0012.gif" alt="" id="GRAPHIC-d7e2469-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center"><b>6i</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">binding affinity <i>K</i><sub>i</sub> (nM)</td><td class="colsep0 rowsep0" align="left">9.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">functional EC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">selectivity over GPR3 (fold)</td><td class="colsep0 rowsep0" align="left">265×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">selectivity over GPR12 (fold)</td><td class="colsep0 rowsep0" align="left">68×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">logD</td><td class="colsep0 rowsep0" align="left">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLE (logEC50-cLogP)</td><td class="colsep0 rowsep0" align="left">5.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLC-PK1-MDR1 A to B (nm/s)</td><td class="colsep0 rowsep0" align="left">170</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-gp efflux ratio</td><td class="colsep0 rowsep0" align="left">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLM, Cl<sub>int</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HHep, Cl<sub>int</sub> (mL/min/kg)/fu (%)</td><td class="colsep0 rowsep0" align="left">48/51%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG Screen (Cerep) functional IC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">3.5 μM</td></tr></tbody></table></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62777" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62777" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Pharmacological modulation of the indirect pathway in Parkinson’s disease is a novel therapeutic strategy to reduce motor deficits in PD, without the risk of developing drug-induced dyskinesia. GPR6 is an orphan G-protein coupled receptor, with highly restricted expression in dopamine receptor D2-type medium spiny neurons (MSNs) of the indirect pathway, which triggered our interest to explore GPR6 as a novel non-dopaminergic drug target for PD. We started our SAR optimization campaign with a weak HTS hit <b>1</b> (EC<sub>50</sub> = 43 μM) and were able to achieve a 1000-fold boost in functional potency by introduction of electron density reducing heteroatom features on the bicyclic aromatic ring system. Other major issues, including P450 enzyme inhibition, poor selectivity over GPR3 and GPR12, and high lipophilicity were simultaneously overcome by the partial saturation of the RHS bicyclic aromatic ring system. We identified multiple GPR6 IAG compounds suitable for pharmacological validation of our therapeutic hypothesis in behavioral PD models. Tool compound <b>3e</b> reversed haloperidol-induced catalepsy, and early lead compound <b>6h</b> demonstrated anti-parkinsonian efficacy in the bilateral 6-OHDA-lesioned PD model, providing for the first-time experimental evidence that pharmacological inhibition of GPR6 <i>in vivo</i> could be a feasible non-dopaminergic therapeutic strategy to reduce motor deficits in human PD patient. Compound <b>6i</b>(CVN424) has successfully progressed through clinical phase I safety testing and is currently in clinical phase II trials to validate the therapeutic efficacy to treat motor symptoms in PD.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Synthesis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87413" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87413" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Some common amine intermediates were prepared via a reaction sequence of reductive amination and subsequent Boc deprotection with HCl as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The initial hit <b>1</b> was resynthesized by sequentially reacting <b>9</b> with cyclopropylamine and then 1-(3-methylbenzyl)piperazine (commercially available) at 0 °C in a one-pot reaction.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>2a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH(OAc)<sub>3</sub>, DCE, rt; (b) HCl, dioxane, rt; (c) (i) cyclopropylamine, DIPEA, DCM, 0 °C; (ii) 1-(3-methylbenzyl)piperazine, DIPEA, rt. (d) (i) cyclopropylamine, dioxane, 80 °C; (ii) 1-(3-methylbenzyl)piperazine or <b>8a</b>, dioxane, 150 °C; for <b>2a</b>–<b>e</b> and <b>2g</b>; (e) (i) <b>8a</b>, DIPEA DCM, rt; (ii) cyclopropylamine, DIPEA, dioxane, 100 °C, for <b>2f</b>; (f) (i) <b>2g</b>, KOH, MeOH, rt; (ii) Me<sub>2</sub>NH, HATU, DIPEA, DMF.</p></p></figure><div class="NLM_p">Intermediates <b>10</b> with different substituents (R<sup>2</sup> = H, 7-Me, 7-OMe, 7-F and 6-CO<sub>2</sub>Me) underwent one SN<sub>Ar</sub> reaction with cyclopropylamine, followed by a second SN<sub>Ar</sub> reaction with 1-(3-methylbenzyl)piperazine or <b>8a</b> to afford compounds <b>2a</b>–<b>e</b> and <b>2g</b>. The different electron-withdrawing or -donating effect of the substituents on the phenyl ring resulted in different regioselectivities during the first SN<sub>Ar</sub> reaction. <b>2C</b> (7-Me) was obtained as a mixture of two regioisomers (2:1 ratio). In contrast, <b>2e</b> (7-F) was separated as one single isomer, but it is likely that the other regioisomer was lost during the purification process. <b>2d</b> with a strong electron-donating methoxy group and <b>2g</b> with a strong electron-withdrawing ester group were afforded as one single observed isomer; however, the directing effect of these two substituents for the regioselectivity is opposite during the first SN<sub>Ar</sub> reaction. Ester <b>2g</b> was hydrolyzed to the corresponding acid, which then reacted with dimethylamine to provide amide compound <b>2h</b>. By following the same directing effect as the ester group, <b>2f</b> (7-CN) was prepared as the only isomer by reversing the reaction order of the two SN<sub>Ar</sub> reactions, starting with <b>8a</b> first.</div><div class="NLM_p">Compounds <b>3a</b>–<b>h</b> and <b>4a</b>–<b>f</b> were prepared as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, in which the presence of the pyridine nitrogen (<b>11a</b>–<b>c</b>) also played a critical directing effect during the first SN<sub>Ar</sub> reaction for the synthesis of <b>12a</b>–<b>e</b> and <b>13a</b>–<b>b</b> when the reaction temperature and addition rate of the corresponding amine were carefully controlled. The second SN<sub>Ar</sub> reaction with corresponding amines gave rise to <b>3a</b>–<b>h</b>, <b>4a</b>–<b>b</b>, and <b>4d</b>–<b>f</b>, respectively. Palladium-catalyzed cyanation with Zn(CN)<sub>2</sub> based on substrate <b>4f</b> afforded final compound <b>4c</b> (10).</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>3a</b>–<b>h</b> and <b>4a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>8a</b> or 4-(2,4-difluorophenoxy)piperidine, DIPEA, DCM, 0 °C; (b) cyclopropylamine or isopropylamine, DIPEA, dioxane, 110 °C in a sealed tube; (c) cyclopropylamine or isopropylamine, DIPEA dioxane or DCM, 0 °C; (d) <b>8a</b>, <b>8b</b>, <b>8c</b>, <b>8d</b>, or 4-(2,4-difluorophenoxy)piperidine, DIPEA, dioxane, 80 °C; (e) <b>4f</b>, 1,1′-bis(diphenylphosphino) ferrocene, Pd<sub>2</sub>(dba)<sub>3</sub>, Zn(CN)<sub>2</sub>, NMP, 120 °C.</p></p></figure><div class="NLM_p">Intermediate <b>14</b> was constructed with both LHS amines via the same reaction sequence as <b>3a</b>, but the second SN<sub>Ar</sub> reaction with isopropylamine was significantly facilitated by adding KF as a promoter. The pyridine ring in the bicyclic ring system was then saturated after activation with acetic anhydride and <i>in situ</i> hydrogenation catalyzed by palladium to afford intermediate <b>5a</b> (11), which was readily hydrolyzed to the corresponding secondary amine <b>15</b> by treating it with sodium hydroxide in MeOH at 65 °C. The resulting amine was reacted with either propionic anhydride or methanesulfonyl chloride to provide <b>5b</b> and <b>5c</b>, respectively.</div><div class="NLM_p">As for the preparation of <b>6a</b>–<b>i</b><named-content content-type="anchor" rid="sch3" type="simple"></named-content>(<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), it also requires a saturation process on the pyridine ring. A two-step reaction sequence (benzylation followed by reduction with sodium triacetoxyborohydride) was developed to saturate the pyridine ring in this case (12–13). This optimized two-step procedure proved to be a more practical and scalable process in comparison to the one-pot reaction as described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The subsequent debenzylation under hydrogenation conditions afforded common secondary amine intermediates <b>6c</b>, <b>19a</b>, <b>18a</b>–<b>b</b>, with no purification needed over three steps. Final compounds <b>6a</b>–<b>i</b> were generated from the respective secondary amines using methylation, acylation, or sulfonation reaction conditions.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>5a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (a) <b>8d</b>, DIPEA, DCM, 0 °C; (b) isopropylamine, DIPEA, dioxane, 100 °C in a sealed tube; (c) Ac<sub>2</sub>O, H<sub>2</sub>, 10% Pd/C, acetone/dioxane, 45 °C; (d) NaOH, MeOH, 65 °C; (e) propionic anhydride or MeSO<sub>2</sub>Cl, DIPEA, DCM, 0 °C.</p></p></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0007.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>6a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i). BnBr, MeCN, 80 °C; (ii). NaBH(OAc)<sub>3</sub>, DCM, rt; (iii). H<sub>2</sub>, Pd/C, MeOH, rt; (b) <b>18a</b> or <b>18b</b>, Ac<sub>2</sub>O, DIPEA, DCM, 0 °C to rt; (c) <b>19a</b> or <b>6c</b>, MeSO<sub>2</sub>Cl or Ac<sub>2</sub>O or MeO<sub>2</sub>CCl, DIPEA, DCM, 0 °C to rt.</p></p></figure></div><div id="sec5_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Materials and Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34523" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34523" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Methods</h3><div class="NLM_p">All reagents and solvents were purchased from commercial suppliers and used without purification unless otherwise noted. All reactions were performed at ambient temperature and in anhydrous solvents unless otherwise noted. Flash chromatography was performed on ISCO CombiFlash with prepacked silica gel columns and eluted with ethyl acetate in heptane. Preparative HPLC was performed on a Shimadzu LC-8A (UV/vis: SPD-20A; Software: LCSolution) with a Phenomenex Gemini C18, 5 μm, ID 30 × 100 mm column using either acid (0.1% TFA) or base (0.1% NH<sub>4</sub>OH) modified MeCN/H<sub>2</sub>O gradients. <sup>1</sup>H NMR spectra were recorded on a 500 or 400 MHz Bruker instrument. Chemical shifts are expressed in parts per million (ppm) δ relative to residual solvent as an internal reference. The mass spectra were obtained using liquid chromatography mass spectrometry (LC-MS) on an Agilent 1260 Infinity instrument using electrospray ionization (ESI). All test compounds showed >95% purity as determined by LC-MS. All animal experiments performed in the manuscript were conducted in compliance with institutional guidelines.</div><div id="sec5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Synthesis of <i>N</i>-Cyclopropyl-6-(4-(3-methylbenzyl)piperazin-1-yl)-[1,2,5]oxadiazolo[3,4-<i>b</i>]pyrazin-5-amine (<b>1</b>)</h4><div class="NLM_p last">To a solution of 5,6-dichloro-[1,2,5]oxadiazolo[3,4-<i>b</i>]pyrazine (200 mg, 1.05 mmol, 1.0 equiv) in DCM (5.0 mL) were added DIPEA (547.2 μL, 3.14 mmol, 3.0 equiv) and cyclopropanamine (59.79 mg, 1.05 mmol, 72.56 μL, 1 equiv). The mixture was stirred at 0 °C for 2 h. 1-(<i>m</i>-Tolylmethyl)piperazine (241.6 mg, 1.26 mmol, 1.2 equiv) was then added, and stirring was continued for 3 h at 20 °C. The mixture was concentrated under reduced pressure, and the resulting residue was purified by prep-HPLC (column: Boston Prime C18 150 × 30 mm × 5 μm; mobile phase: [water (0.05% NH<sub>3</sub>H<sub>2</sub>O + 10 mM NH<sub>4</sub>HCO<sub>3</sub>)-ACN]; B%: 55–85%,7 min) to give <i>N</i>-cyclopropyl-5-[4-(<i>m</i>-tolylmethyl)piperazin-1-yl]-[1,2,5] oxadiazolo[3,4-<i>b</i>]pyrazin-6-amine (100.7 mg, 25.8% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.21 (t, <i>J</i> = 7.5 Hz, 1H), 7.14–7.06 (m, 3H), 5.88 (br s, 1H), 3.53 (s, 2H), 3.47–3.36 (m, 4H), 2.98 (dt, <i>J</i> = 3.4, 7.1 Hz, 1H), 2.61 (br d, <i>J</i> = 4.4 Hz, 4H), 2.34 (s, 3H), 1.04–0.95 (m, 2H), 0.69–0.57 (m, 2H); ESI-MS calcd for C<sub>19</sub>H<sub>23</sub>N<sub>7</sub>O [M + H]<sup>+</sup> = 365.20; found 366.1.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Synthesis of <i>N</i>-Cyclopropyl-3-(4-(3-methylbenzyl)piperazin-1-yl)quinoxalin-2-amine (<b>2a</b>)</h4><div class="NLM_p">Step 1: A solution of 2,3-dichloroquinoxaline (400 mg, 2.010 mmol), cyclopropanamine (149 mg, 2.61 mmol), and DIPEA (526 μL, 3.01 mmol) in dioxane (2871 μL) was heated at 80 °C for 2 days. The solvent was removed under reduced pressure, and the residue obtained was purified by silica gel column chromatography (10–40% EtOAc/hexanes) that afforded 3-chloro-<i>N</i>-cyclopropylquinoxalin-2-amine as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.79 (br d, <i>J</i> = 7.9 Hz, 2H), 7.58 (br t, <i>J</i> = 7.6 Hz, 1H), 7.39 (br t, <i>J</i> = 7.7 Hz, 1H), 5.72 (br s, 1H), 3.01–2.91 (m, 1H), 0.93 (br d, <i>J</i> = 6.8 Hz, 2H); ESI-MS calcd for C<sub>11</sub>H<sub>10</sub>ClN<sub>3</sub> [M + H]<sup>+</sup> = 219.06; found: 219.9.</div><div class="NLM_p">Step 2: A solution of 3-chloro-<i>N</i>-cyclopropylquinoxalin-2-amine (30 mg, 0.137 mmol), 1-(3-methylbenzyl)piperazine (39.0 mg, 0.205 mmol), and N-ethyl-<i>N</i>-isopropylpropan-2-amine (0.072 mL, 0.410 mmol) in dioxane (0.25 mL) was heated at 150 °C overnight. HPLC purification afforded the title compound <b>2a</b> (30% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.71 (br t, <i>J</i> = 8.7 Hz, 2H), 7.42 (br t, <i>J</i> = 7.5 Hz, 1H), 7.35–7.28 (m, 1H), 7.24–7.18 (m, 1H), 7.18–7.11 (m, 2H), 7.07 (br d, <i>J</i> = 7.1 Hz, 1H), 5.51 (br s, 1H), 3.55 (s, 2H), 3.22 (br s, 4H), 2.91 (dt, <i>J</i> = 3.0, 6.6 Hz, 1H), 2.61 (br s, 4H), 2.35 (s, 3H), 0.95–0.84 (m, 2H), 0.61–0.52 (m, 2H); ESI-MS calcd for C<sub>23</sub>H<sub>27</sub>N<sub>5</sub> [M + H]<sup>+</sup> = 373.23, found: 374.1.</div><div class="NLM_p last">Using similar reaction conditions as described above, and utilizing intermediates prepared as described above or commercially available piperazines, the following compounds were synthesized, and purified by either HPLC or silica gel column chromatography:</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-Cyclopropyl-3-(4-(2,5-dichlorobenzyl)piperazin-1-yl)quinoxalin-2-amine (<b>2b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.72 (t, <i>J</i> = 8.2 Hz, 2H), 7.54 (d, <i>J</i> = 2.2 Hz, 1H), 7.43 (t, <i>J</i> = 7.4 Hz, 1H), 7.32 (br t, <i>J</i> = 7.4 Hz, 1H), 7.27 (d, <i>J</i> = 8.4 Hz, 1H), 7.16 (dd, <i>J</i> = 2.3, 8.5 Hz, 1H), 5.52 (br s, 1H), 3.66 (s, 2H), 3.25 (br s, 4H), 2.92 (br dd, <i>J</i> = 3.3, 6.6 Hz, 1H), 2.69 (br s, 4H), 0.93–0.88 (m, 2H), 0.64–0.53 (m, 2H); ESI-MS calcd for C<sub>22</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>5</sub> [M + H]<sup>+</sup> = 427.13, found: 428.0.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-Cyclopropyl-3-(4-(2,5-dichlorobenzyl)piperazin-1-yl)-7-methylquinoxalin-2-amine (<b>2c</b>)</h4><div class="NLM_p last">The titled compound was obtained as a mixture of two regioisomers (2:1 ratio). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 0.87–0.98 (m, 2H), 1.11 (ddt, <i>J</i> = 6.96, 3.45, 1.82, 1.82 Hz, 2H), 2.37–2.46 (m, 3H), 2.65–2.85 (m, 4H), 2.92 (ddt, <i>J</i> = 10.79, 7.22, 3.54, 3.54 Hz, 1H), 3.21–3.29 (m, 4H), 3.73 (s, 2H), 7.17–7.24 (m, 1H), 7.30 (dd, <i>J</i> = 8.53, 2.76 Hz, 1H), 7.37–7.42 (m, 1H), 7.50–7.62 (m, 2H), 7.66–7.81 (m, 1H); ESI-MS calcd for C<sub>23</sub>H<sub>25</sub>Cl<sub>2</sub>N<sub>5</sub> [M + H]<sup>+</sup> = 441.2, found: 442.0.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-Cyclopropyl-3-(4-(2,5-dichlorobenzyl)piperazin-1-yl)-7-methoxyquinoxalin-2-amine (<b>2d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 0.81–0.90 (m, 2H), 1.04–1.13 (m, 2H), 2.88 (dt, <i>J</i> = 7.09, 3.36 Hz, 1H), 3.58 (br d, <i>J</i> = 2.76 Hz, 8H), 3.94 (s, 3H), 4.56 (s, 2H), 7.15 (dd, <i>J</i> = 9.03, 2.51 Hz, 1H), 7.34 (d, <i>J</i> = 2.76 Hz, 1H), 7.53–7.58 (m, 1H), 7.59–7.63 (m, 1H), 7.72 (d, <i>J</i> = 9.03 Hz, 1H), 7.78 (d, <i>J</i> = 2.26 Hz, 1H); ESI-MS calcd for C<sub>23</sub>H<sub>25</sub>Cl<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 457.1, found: 458.0.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-Cyclopropyl-3-(4-(2,5-dichlorobenzyl)piperazin-1-yl)-7-fluoroquinoxalin-2-amine (<b>2e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 0.61–0.68 (m, 2H), 0.90–0.99 (m, 2H), 2.78 (br s, 4H), 2.86 (tt, <i>J</i> = 7.03, 3.64 Hz, 1H), 3.23–3.31 (m, 4H), 3.74 (s, 2H), 7.10 (td, <i>J</i> = 8.66, 2.76 Hz, 1H), 7.24 (dd, <i>J</i> = 8.53, 2.51 Hz, 1H), 7.35 (d, <i>J</i> = 8.53 Hz, 1H), 7.39 (dd, <i>J</i> = 10.29, 2.76 Hz, 1H), 7.56 (d, <i>J</i> = 2.51 Hz, 1H), 7.70 (dd, <i>J</i> = 8.91, 5.90 Hz, 1H); ESI-MS calcd for C<sub>22</sub>H<sub>22</sub>Cl<sub>2</sub>FN<sub>5</sub> [M + H]<sup>+</sup> = 445.1, found: 446.0.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Synthesis of 2-(Cyclopropylamino)-3-(4-(2,5-dichlorobenzyl)piperazin-1-yl)-<i>N</i>,<i>N</i>-dimethylquinoxaline-6-carboxamide (<b>2h</b>)</h4><div class="NLM_p">Step 1: To a solution of methyl 2-(cyclopropylamino)-3-(4-(2,5-dichlorobenzyl)piperazin-1-yl)quinoxaline-6-carboxylate (<b>2g</b>, prepared by following the procedures for the synthesis of <b>2a</b>) (100 mg, 0.206 mmol, 1.0 equiv) in a mixture of dioxane (3.0 mL) and methanol (1.0 mL) was added an aqueous solution of KOH (2 N, 0.185 mL, 0.370 mmol, 1.8 equiv). The resulting reaction mixture was stirred at rt overnight and then neutralized by the addition of HCl (1.0 N, 0.37 mL). Concentration under reduced pressure gave 2-(cyclopropylamino)-3-(4-(2,5-dichlorobenzyl)piperazin-1-yl)quinoxaline-6-carboxylic acid as a white solid (78% purity), which was used directly in the next step without further purification.</div><div class="NLM_p last">Step 2: A solution of 2-(cyclopropylamino)-3-(4-(2,5-dichlorobenzyl)piperazin-1-yl)quinoxaline-6-carboxylic acid (45 mg, 0.095 mmol, 1.0 equiv) and HATU (36.2 mg, 0.095 mmol, 1.0 equiv) in DMF (1.5 mL) was stirred at rt for 5 min, and then DIPEA (36.9 mg, 0.286 mmol, 3.0 equiv) and dimethylamine hydrochloride (11.7 mg, 0.143 mmol, 1.5 equiv) were added. The resulting solution was stirred at rt for 3 h. The solvent was removed under reduced pressure, and then the residue was purified by silica gel column chromatography (1–5% MeOH in DCM) to give the titled compound <b>2h</b> as an off-white solid (29 mg, 59% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 0.89–0.96 (m, 2H), 1.06–1.13 (m, 2H), 2.78 (br d, <i>J</i> = 2.76 Hz, 4H), 2.91–2.99 (m, 1H), 3.03 (br s, 3H), 3.12 (br s, 3H), 3.22–3.28 (m, 4H), 3.71–3.77 (m, 2H), 7.21–7.29 (m, 1H), 7.31 (d, <i>J</i> = 2.01 Hz, 1H), 7.34–7.38 (m, 1H), 7.38–7.43 (m, 1H), 7.55 (d, <i>J</i> = 2.51 Hz, 1H), 7.66–7.75 (m, 1H); ESI-MS calcd for C<sub>25</sub>H<sub>28</sub>Cl<sub>2</sub>FN<sub>6</sub>O [M + H]<sup>+</sup> = 498.1, found: 499.1.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Synthesis of 3-(Cyclopropylamino)-2-(4-(2,5-dichlorobenzyl)piperazin-1-yl)quinoxaline-6-carbonitrile (<b>2f</b>)</h4><div class="NLM_p">Step 1: To a solution of 2,3-dichloroquinoxaline-6-carbonitrile (400 mg, 1.785 mmol, 1.0 equiv) and 1-(2,5-dichlorobenzyl)piperazine hydrogen chloride (<b>8a</b>) (601 mg, 2.14 mmol, 1.2 equiv) in DCM (30 mL) was added DIPEA (0.780 mL, 4.46 mmol, 2.5 equiv) at 20 °C, and the resulting reaction mixture was stirred for 6 h. Water was added, and the reaction was extracted with DCM. The combined organic layers were concentrated, and the residue was purified by silica gel column chromatography (PE/EtOAc = 50:1) to afford 3-chloro-2-(4-(2,5-dichlorobenzyl)piperazin-1-yl)quinoxaline-6-carbonitrile (657 mg, 85% yield) as a yellow solid.</div><div class="NLM_p last">Step 2: A solution of 3-chloro-2-(4-(2,5-dichlorobenzyl)piperazin-1-yl)quinoxaline-6-carbonitrile (30 mg, 0.069 mmol, 1.0 equiv), cyclopropanamine (12 mg, 0.208, 3.0 equiv), and DIPEA (0.030 mL, 0.173 mmol, 2.5 equiv) in dioxane (2.0 mL) in a sealed vial was heated at 100 °C overnight. HPLC purification under acidic conditions afforded the title compound <b>2f</b> (21 mg, 66%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 0.67–0.73 (m, 2H), 0.88–0.97 (m, 2H), 2.88 (tt, <i>J</i> = 7.15, 3.64 Hz, 1H), 3.60 (br s, 8H), 4.58 (s, 2H), 7.55–7.57 (m, 1H), 7.58 (d, <i>J</i> = 1.00 Hz, 1H), 7.60–7.64 (m, 1H), 7.77 (s, 1H), 7.78 (d, <i>J</i> = 5.77 Hz, 1H), 8.04 (d, <i>J</i> = 1.76 Hz, 1H); ESI-MS calcd for C<sub>23</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 452.1, found: 453.1.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Synthesis of <i>N-</i>Cyclopropyl-2-(4-(2,5-dichlorobenzyl)piperazin-1-yl)pyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>3a</b>)</h4><div class="NLM_p">To a solution of 3-chloro-2-[4-[(2,5-dichlorophenyl)methyl]piperazin-1-yl]pyrido [3,4-<i>b</i>]pyrazine (<b>13a</b>) (70 mg, 171.3 μmol, 1.0 equiv) and cyclopropanamine (9.8 mg, 171.3 μmol, 1.0 equiv) in dioxane (3.0 mL) was added DIPEA (89.5 μL, 513.8 μmol, 3.0 eq). The resulting mixture was stirred in a 30 mL sealed tube at 100 °C for 30 h. The reaction mixture was evaporated to dryness and purified by prep-HPLC (column: Phenomenex Gemini-NX150 × 30 mm × 5 μm; mobile phase: [water (0.05% NH<sub>3</sub>H<sub>2</sub>O)-ACN]; B%: 60–90%,7 min) to give <i>N</i>-cyclopropyl-2-[4-[(2,5-dichlorophenyl)methyl]piperazin-1-yl]pyrido[3,4-<i>b</i>]pyrazin-3-amine (7.6 mg, 10.2% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.02 (s, 1H), 8.38 (br d, <i>J</i> = 6.0 Hz, 1H), 7.61 (d, <i>J</i> = 5.7 Hz, 1H), 7.54 (br s, 1H), 7.31–7.27 (m, 1H), 7.21–7.17 (m, 1H), 5.51 (br s, 1H), 3.69 (s, 2H), 3.51 (br s, 4H), 2.93 (br dd, <i>J</i> = 3.6, 6.7 Hz, 1H), 2.72 (br s, 4H), 1.02–0.91 (m, 2H), 0.68–0.58 (m, 2H); ESI-MS calcd for for C<sub>21</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 428.13, found: 429.1.</div><div class="NLM_p last">Using similar reaction conditions as described above and utilizing intermediates prepared as described above or commercially available piperazines, the following compounds were synthesized and purified by either HPLC or silica gel column chromatography:</div></div><div id="sec5_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-Cyclopropyl-2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-7-methylpyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>4d</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to <b>3a</b> using 10 equiv of cyclopropanamine and <b>13b</b> at 110 °C to give a dark yellow semisolid (23.8% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 0.70–0.74 (m, 2H), 0.88–0.90 (m, 2H), 1.93 (dt, <i>J</i> = 6.83, 3.42 Hz, 2 H) 2.06–2.15 (m, 2 H), 2.71 (s, 3H), 2.90 (dt, <i>J</i> = 7.44, 3.36 Hz, 1H), 3.77–3.80 (m, 2H), 3.99–4.02 (m, 2H), 4.57–4.58 (m, 1H), 6.87–6.89 (m, 1H), 6.99–7.01 (m, 1H), 7.18–7.19 (m, 1H), 7.65 (s, 1H), 8.73 (s, 1H); ESI-MS calcd for C<sub>22</sub>H<sub>23</sub>F<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 411.2, found: 412.4.</div></div><div id="sec5_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-(4-(2,4-Difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-7-methylpyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>4e</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to <b>3a</b> using 10 equiv of propan-2-amine and <b>13b</b> at 110 °C to give a yellow solid (15.6% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 1.32 (d, <i>J</i> = 6.35 Hz, 6H), 1.93–1.96 (m, 2H), 2.09–2.11 (m, 2H), 2.70 (s, 3H), 3.83–3.84 (m, 2H), 4.05–4.06 (m 2H), 4.42–4.44 (m, 1H), 6.89 (m, 1H), 7.00–7.02 (m, 1H), 7.19–7.20 (m, 1H), 7.62 (s, 1H), 8.64 (s, 1H); ESI-MS calcd for C<sub>22</sub>H<sub>25</sub>F<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 413.2, found: 414.4.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Synthesis of <i>N</i>-Cyclopropyl-3-(4-(2,5-dichlorobenzyl)piperazin-1-yl)pyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>3b</b>)</h4><div class="NLM_p">A solution of 3-chloro-<i>N</i>-cyclopropyl-pyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>12a</b>) (50 mg, 172.2 μmol, 1.0 equiv), 1-[(2,5-dichlorophenyl)methyl]piperazine (42.2 mg, 172.2 μmol, 1.0 equiv), and DIPEA (90.0 μL, 516.6 μmol, 3.0 equiv) in dioxane (3.0 mL) was stirred at 80 °C for 24 h. The reaction mixture was concentrated under reduced pressure and then purified by prep-HPLC (column: Phenomenex Gemini-NX 150 × 30 mm × 5 μm; mobile phase: [water (0.05% NH<sub>3</sub>H<sub>2</sub>O)-ACN]; B%: 54–84%,7 min) to give <i>N</i>-cyclopropyl-3-[4-[(2,5-dichlorophenyl)methyl]piperazin-1-yl]pyrido[3,4-<i>b</i>]pyrazin-2-amine (17.4 mg, 23.5% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 8.98 (s, 1H), 8.46 (d, <i>J</i> = 5.5 Hz, 1H), 7.57–7.46 (m, 2H), 7.28 (d, <i>J</i> = 8.4 Hz, 1H), 7.17 (dd, <i>J</i> = 2.4, 8.6 Hz, 1H), 5.80 (br s, 1H), 3.66 (s, 2H), 3.33–3.19 (m, 4H), 2.96 (dt, <i>J</i> = 3.2, 6.9 Hz, 1H), 2.70 (br s, 4H), 1.01–0.89 (m, 2H), 0.66–0.56 (m, 2H); ESI-MS calcd for C<sub>21</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 428.13, found: 429.0.</div><div class="NLM_p last">Using similar reaction conditions as described above and utilizing intermediates prepared as described above or commercially available piperazines, the following compounds were synthesized and purified by either HPLC or silica gel column chromatography:</div></div><div id="sec5_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-(4-(5-Chloro-2-fluorobenzyl)piperazin-1-yl)-<i>N</i>-cyclopropylpyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>3c</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to <b>3b</b> using 1-(5-chloro-2-fluorobenzyl)piperazine hydrogen chloride and <b>12a</b> at 80 °C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 0.78–0.86 (m, 2H), 0.93–1.02 (m, 2H), 3.12 (tt, <i>J</i> = 7.40, 3.76 Hz, 1H), 3.45 (br t, <i>J</i> = 4.77 Hz, 4H), 3.74 (br s, 4H), 4.37 (s, 2H), 7.30 (t, <i>J</i> = 9.16 Hz, 1H), 7.56 (ddd, <i>J</i> = 8.78, 4.52, 2.76 Hz, 1H), 7.65 (dd, <i>J</i> = 6.27, 2.76 Hz, 1H), 7.86 (d, <i>J</i> = 6.78 Hz, 1H), 8.41 (dd, <i>J</i> = 6.53, 1.00 Hz, 1H), 8.98 (s, 1H); ESI-MS calcd for C<sub>21</sub>H<sub>22</sub>ClFN<sub>6</sub> [M + H]<sup>+</sup> = 412.2, found: 413.3.</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-Cyclopropyl-3-(4-(2,5-difluorobenzyl)piperazin-1-yl)pyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>3d</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to <b>3b</b> using 1-(2,5-difluorobenzyl)piperazine hydrogen chloride and <b>12a</b> at 80 °C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 0.76–0.86 (m, 2H), 0.93–1.02 (m, 2H), 3.08–3.17 (m, 1H), 3.38 (br d, <i>J</i> = 4.02 Hz, 4H) 3.71 (br s, 4H), 4.30 (s, 2H), 7.24–7.32 (m, 2H), 7.37 (ddd, <i>J</i> = 7.28, 5.27, 1.76 Hz, 1H), 7.85 (d, <i>J</i> = 6.53 Hz, 1H), 8.40 (dd, <i>J</i> = 6.52, 0.75 Hz, 1H), 8.96 (s, 1H); ESI-MS calcd for C<sub>21</sub>H<sub>22</sub>F<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 396.2, found: 397.4.</div></div><div id="sec5_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-Cyclopropyl-3-(4-(2,4-difluorobenzyl)piperazin-1-yl)pyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>3e</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to <b>3b</b> using 1-(2,4-difluorobenzyl)piperazine hydrogen chloride and <b>12a</b> at 80 °C (90% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 0.61–0.65 (m, 2 H), 0.94–0.99 (m, 2H), 2.67 (br. s., 4H), 2.93–3.00 (m, 1H), 3.26 (t, <i>J</i> = 4.64 Hz, 4H), 3.65 (s, 2H), 6.79–6.85 (m, 1H), 6.86–6.92 (m, 1H), 7.37–7.44 (m, 1H), 7.54 (d, <i>J</i> = 5.37 Hz, 1H), 8.47 (d, <i>J</i> = 5.86 Hz, 1H), 8.98 (s, 1H); ESI-MS calcd for C<sub>21</sub>H<sub>22</sub>F<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 396.2, found: 397.9.</div></div><div id="sec5_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-Cyclopropyl-3-(4-(2,4-difluorobenzyl)piperazin-1-yl)-7-methylpyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>3f</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to <b>3b</b> using 1-(2,4-difluorobenzyl)piperazine hydrogen chloride and <b>12c</b> at 80 °C and obtained as a white solid (22% yield). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 0.77–0.86 (m, 2H), 0.94–2.04 (m, 2H), 2.75 (S, 3H), 3.13 (tt, <i>J</i> = 7.44, 3.78 Hz, 1H), 3.54 (br, s., 8H), 4.48 (s, 2H), 7.12–7.25 (m, 2H), 7.66 (td, <i>J</i> = 8.54, 6.35 Hz, 1H), 7.71 (s, 1H), 8.88 (s, 1H); ESI-MS calcd for C<sub>22</sub>H<sub>24</sub>F<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 410.2, found: 411.0.</div></div><div id="sec5_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 3-(4-(2,4-Difluorobenzyl)piperazin-1-yl)-<i>N</i>-isopropylpyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>3g</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to <b>3b</b> using 1-(2,4-difluorobenzyl)piperazine hydrogen chloride and <b>12b</b> at 80 °C and obtained as a gray solid (82% yield). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 1.32 (d, <i>J</i> = 6.35 Hz, 6H), 2.74 (t, <i>J</i> = 4.64 Hz, 4H), 3.36 (br. s., 4H), 3.68 (s, 2H), 4.45 (dt, <i>J</i> = 13.06, 6.41 Hz, 1H), 6.90–7.03 (m, 2H), 7.41–7.56 (m, 2H), 8.29 (d, <i>J</i> = 5.37 Hz, 1H), 8.75 (s, 1H); ESI-MS calcd for C<sub>21</sub>H<sub>24</sub>F<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 398.2, found: 399.3.</div></div><div id="sec5_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3-(4-(2,4-Difluorobenzyl)piperazin-1-yl)-<i>N</i>-isopropyl-7-methylpyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>3h</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to <b>3b</b> using 1-(2,4-difluorobenzyl)piperazine hydrogen chloride and <b>12d</b> at 80 °C and obtained as a white solid (97% yield). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 1.35 (d, <i>J</i> = 6.83 Hz, 6H), 2.73 (s, 4H), 3.57 (br. s., 6H), 4.48 (s, 2H), 4.66 (quin, <i>J</i> = 6.59 Hz, 1H), 7.11–7.24 (m, 2H), 7.61 (s, 1H), 7.68 (td, <i>J</i> = 8.54, 6.35 Hz, 1H), 8.83 (s, 1H); ESI-MS calcd for C<sub>22</sub>H<sub>26</sub>F<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 412.2, found: 413.00.</div></div><div id="sec5_11_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-Cyclopropyl-3-(4-(2,4-difluorophenoxy)piperidin-1-yl)-7-methylpyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>4a</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to <b>3b</b> using 4-(2,4-difluorophenoxy)piperidine hydrogen chloride and <b>12c</b> at 80 °C and obtained as a light yellow solid (35% yield). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 1.59–1.64 (m, 2H), 1.64–1.70 (m, 2H), 2.55–2.74 (m, 2H), 2.82–2.98 (m, 2H), 3.45 (s, 3H), 3.82–3.96 (m, 1H), 4.04–4.17 (m, 3H), 4.48 (br. s., 2H), 5.44 (dt, <i>J</i> = 7.57, 4.03 Hz, 1H), 7.77–7.91 (m, 1H), 8.03–8.22 (m, 2H), 8.47 (s, 1H), 9.27 (d, <i>J</i> = 4.39 Hz, 1H), 9.78 (s, 1H); ESI-MS calcd for C<sub>22</sub>H<sub>23</sub>F<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 411.2, found: 412.9.</div></div><div id="sec5_11_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 3-(4-(2,4-Difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-7-methylpyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>4b</b>)</h4><div class="NLM_p last">The title compound was prepared in a manner similar to <b>3b</b> using 4-(2,4-difluorophenoxy)piperidine hydrogen chloride and <b>12d</b> at 60 °C and obtained as an off-white solid (43% yield). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 1.35 (d, <i>J</i> = 6.35 Hz, 6H), 1.99 (tdd, <i>J</i> = 10.25, 10.25, 7.32, 3.42 Hz, 2H), 2.12–2.22 (m, 2H), 2.71 (s, 3H), 3.45 (ddd, <i>J</i> = 13.06, 7.69, 3.66 Hz, 2H), 3.74–3.83 (m, 2H), 4.58 (tt, <i>J</i> = 6.83, 3.42 Hz, 1H), 4.64 (quin, <i>J</i> = 6.71 Hz, 1H), 6.90 (dddd, <i>J</i> = 9.34, 7.87, 3.05, 1.71 Hz, 1H), 7.00 (ddd, <i>J</i> = 11.35, 8.66, 2.93 Hz, 1H), 7.20 (td, <i>J</i> = 9.28, 5.37 Hz, 1H), 7.56 (s, 1H), 8.73 (s, 1H); ESI-MS calcd for C<sub>22</sub>H<sub>25</sub>F<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 413.2, found: 414.0.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Synthesis of 3-(4-(2,4-Difluorobenzyl)piperazin-1-yl)-2-(isopropylamino)pyrido[3,4-<i>b</i>]pyrazine-7-carbonitrile (<b>4c</b>)</h4><div class="NLM_p last">A vial containing a mixture of 7-bromo-<i>N</i>-isopropyl-3-(4-(2,4-difluorobenzyl)piperazin-1-yl)pyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>4g</b>, prepared in a manner similar to <b>3b</b> using 4-(2,4-difluorophenoxy)piperidine hydrogen chloride and <b>12e</b>) (17 mg, 0.035 mmol, 1.0 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (1.581 mg, 1.726 μmol, 0.05 equiv), dicyanozinc (2.433 mg, 0.021 mmol, 0.6 equiv) and 1,1′-bis(diphenylphosphino) ferrocene (dppf) (1.914 mg, 3.4 μmol, 0.1 equiv) in NMP (345 μL) was evacuated and filled with N<sub>2</sub> three times then heated at 120 °C for 2 h. The crude reaction mixture was filtered through a Millipore filter, and purified by HPLC to afford the title compound <b>4c</b> as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 1.32 (d, <i>J</i> = 6.53 Hz, 6H), 1.29–1.29 (m, 1H), 1.95–2.07 (m, 2H), 2.11–2.24 (m, 2H), 3.35–3.44 (m, 2H), 3.68–3.79 (m, 2H), 4.41–4.51 (m, 1H), 4.55 (td, <i>J</i> = 7.15, 3.51 Hz, 1H), 6.83–6.92 (m, 1H), 6.99 (ddd, <i>J</i> = 11.32, 8.50, 3.01 Hz, 1H), 7.19 (td, <i>J</i> = 9.19, 5.46 Hz, 1H), 7.87 (s, 1H), 8.76 (s, 1H); ESI-MS calcd for C<sub>22</sub>H<sub>23</sub>F<sub>2</sub>N<sub>7</sub> [M + H]<sup>+</sup> = 423.2, found: 424.4.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Synthesis of 1-(2-(4-(2,4-Difluorobenzyl)piperazin-1-yl)-3-(isopropylamino)-7,8-dihydropyrido[3,4-<i>b</i>]pyrazin-6(5<i>H</i>)-yl)ethan-1-one (<b>5a</b>)</h4><div class="NLM_p last">To a pressure reactor charged with a red-orange solution of 2-(4-(2,4-difluorobenzyl)piperazin-1-yl)-<i>N</i>-isopropylpyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>14</b>) (0.5 g, 1.255 mmol) in acetone (25 mL) and dioxane (25 mL) was added palladium, 10 wt % on activated carbon (0.053 g, 0.502 mmol) as a slurry in dioxane (3 mL) under nitrogen. Next, acetic anhydride (1.179 mL, 12.55 mmol) was added at 23 °C. The mixture was stirred under hydrogen at 45 °C and 310 kPa for 9.5 h. The reaction mixture was filtered through Celite, rinsed with EtOAc, and concentrated via rotary evaporation. The crude material was dissolved in toluene (5 mL) and purified via medium pressure chromatography using a 10% to 100% gradient eluant of EtOAc in heptane on an NH column. The pure fractions were combined, concentrated via rotary evaporation, and dried <i>in vacuo</i> to provide the title compound <b>5a</b> (341 mg, 61.1%) as an off-white foam. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, mixture of rotamers) δ ppm 1.14–1.19 (m, 6H), 2.08 (s, 1.2H), 2.09 (s, 1.8H), 2.52–2.65 (m, 5H), 2.70 (t, <i>J</i> = 5.9 Hz, 1H), 2.98 (br s, 4H), 3.58 (s, 2H), 3.70 (dt, <i>J</i> = 12.0, 5.7 Hz, 2H), 4.00–4.15 (m, 1H), 4.40 (s, 0.8H), 4.43 (s, 1.2H), 5.35 (d, <i>J</i> = 7.8 Hz, 0.4H), 5.38 (d, <i>J</i> = 8.3 Hz, 0.6H) 7.08 (td, <i>J</i> = 8.3, 2.4 Hz, 1H), 7.21 (td, <i>J</i> = 10.0, 2.4 Hz, 1H), 7.44–7.51 (m, 1H); ESI-MS calcd for C<sub>23</sub>H<sub>30</sub>F<sub>2</sub>N<sub>6</sub>O [M + H]<sup>+</sup> = 444.2, found: 445.0.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Synthesis of 2-(4-(2,4-Difluorobenzyl)piperazin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>15</b>)</h4><div class="NLM_p last">To a solution of 1-(2-(4-(2,4-difluorobenzyl)piperazin-1-yl)-3-(isopropylamino)-7,8-dihydropyrido[3,4-<i>b</i>]pyrazin-6(5<i>H</i>)-yl)ethanone (<b>5a</b>) (0.367 g, 0.826 mmol) in MeOH (4 mL) was added NaOH, 15% solution (2.201 g, 8.26 mmol) at 23 °C. The reaction mixture was stirred at 65 °C for 16 h, cooled to 23 °C, and neutralized with 1 N HCl (9.5 mL) to furnish a suspension. The crude mixture was concentrated via rotary evaporation, and stirred overnight. The resulting solid was filtered, rinsed with water, and dried <i>in vacuo</i> to provide the title compound <b>15</b> (253 mg, 76%) as a yellow foam. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.15 (d, <i>J</i> = 6.8 Hz, 6H), 2.42 (br s, 1H), 2.51–2.61 (m, 6H), 2.89–3.00 (m, 6H), 3.58 (s, 2H), 3.63 (s, 2H), 4.00–4.10 (m, 1H), 5.15 (d, <i>J</i> = 8.3 Hz, 1H), 7.04–7.11 (m, 1H), 7.21 (td, <i>J</i> = 10.0, 2.4 Hz, 1H), 7.44–7.52 (m, 1H); ESI-MS calcd for C<sub>21</sub>H<sub>28</sub>F<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> = 402.2, found: 403.0.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Synthesis of 1-(2-(4-(2,4-Difluorobenzyl)piperazin-1-yl)-3-(isopropylamino)-7,8-dihydropyrido[3,4-<i>b</i>]pyrazin-6(5<i>H</i>)-yl)propan-1-one (<b>5b</b>)</h4><div class="NLM_p last">To a solution of 2-(4-(2,4-difluorobenzyl)piperazin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine <b>15</b> (50 mg, 0.124 mmol) and DIPEA (0.032 mL, 0.186 mmol) in DCM (1 mL) was added propionic anhydride (0.019 mL, 0.149 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, then warmed to 23 °C, and concentrated via rotary evaporation. The resulting crude material was partitioned between EtOAc and water. The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, rinsed with EtOAc, and concentrated via rotary evaporation. The crude material was dissolved in EtOAc and MeOH, adsorbed on silica gel (0.75 g), and purified via medium pressure silica gel column chromatography using a 20% to 100% gradient of EtOAc in heptane. The pure fractions were combined, concentrated via rotary evaporation, and dried <i>in vacuo</i> to provide the title compound <b>5b</b> (48 mg, 84% yield) as an off-white foam. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, mixture of rotamers) δ ppm 0.94–1.05 (m, 3H), 1.16–1.18 (m, 6H), 2.41 (quin, <i>J</i> = 7.8 Hz, 2H), 2.52–2.65 (m, 5H), 2.69 (t, <i>J</i> = 5.6 Hz, 1H), 2.98 (br s, 3H), 3.58 (s, 2H), 3.70 (t, <i>J</i> = 5.9 Hz, 1.1H), 3.73 (t, <i>J</i> = 5.9 Hz, 0.9H), 4.03 (q, <i>J</i> = 7.2 Hz, 2H), 4.06–4.15 (m, 1H), 4.42 (br s, 2H), 5.34 (d, <i>J</i> = 7.8 Hz, 0.6H), 5.37 (d, <i>J</i> = 8.3 Hz, 0.4H), 7.08 (td, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.21 (td, <i>J</i> = 9.9, 2.7 Hz, 1H), 7.44–7.52 (m, 1 H); ESI-MS calcd for C<sub>24</sub>H<sub>32</sub>F<sub>2</sub>N<sub>6</sub>O [M + H]<sup>+</sup> = 458.2, found: 459.0.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Synthesis of 2-(4-(2,4-Difluorobenzyl)piperazin-1-yl)-<i>N</i>-isopropyl-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>5c</b>)</h4><div class="NLM_p">To a solution of 2-(4-(2,4-difluorobenzyl)piperazin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine (50 mg, 0.124 mmol) and DIPEA (0.032 mL, 0.186 mmol) in DCM (1 mL) was added methanesulfonyl chloride (10.6 μL, 0.137 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h and then concentrated via rotary evaporation. The resulting crude material was partitioned between EtOAc (2 mL) and water (1 mL). The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, rinsed with EtOAc, and concentrated via rotary evaporation. The crude material was dissolved in EtOAc and MeOH, adsorbed on silica gel (0.75 g), and purified via medium pressure silica gel column chromatography using a gradient eluant of 50% to 100% EtOAc in heptane. The pure fractions were combined, concentrated via rotary evaporation, and dried <i>in vacuo</i> to provide the title compound <b>5c</b> (50.6 mg, 85%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.12–1.19 (m, 6H), 2.53–2.61 (m, 4H), 2.74 (t, <i>J</i> = 5.9 Hz, 2H), 2.97 (s, 3H), 3.00 (d, <i>J</i> = 7.3 Hz, 4H), 3.44–3.48 (m, 1H), 3.59 (s, 2H), 4.02–4.10 (m, 1H), 4.16 (s, 2H), 5.41 (d, <i>J</i> = 7.8 Hz, 1H), 7.08 (td, <i>J</i> = 8.4, 2.2 Hz, 1H), 7.22 (td, <i>J</i> = 9.9, 2.7 Hz, 1H), 7.44–7.54 (m, 1H); ESI-MS calcd for C<sub>22</sub>H<sub>30</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> = 480.2, found: 480.9.</div><div class="NLM_p last">Substrates <b>16a</b>,<b>b</b> were prepared under the reaction conditions similar to <b>3b</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) through double SNAr reactions on <b>11a</b> with isopropylamine (or cyclopropylamine) and 4-(2,4-difluorophenoxy)piperidine sequentially. Substrates <b>17a</b>,<b>b</b> were prepared under the reaction conditions similar to <b>3a</b> through double SNAr reactions on <b>11a</b> with 4-(2,4-difluorophenoxy)piperidine and isopropylamine (or cyclopropylamine) sequentially.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Synthesis of 2-(4-(2,4-Difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido [3,4-<i>b</i>]pyrazin-3-amine (<b>6c</b>)</h4><div class="NLM_p">Step 1: To a yellow-orange suspension of 2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropylpyrido[3,4-<i>b</i>]pyrazin-3-amine <b>17a</b> (5.1 g, 12.77 mmol) in MeCN (63.8 mL) was added benzyl bromide (2.184 g, 12.77 mmol) over 1 min at rt. The mixture was stirred at 80 °C for 4 h to furnish a red-brown solution, cooled to 23 °C, and then concentrated via rotary evaporation to provide 6-benzyl-2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino)pyrido[3,4-<i>b</i>] pyrazin-6-ium bromide (7.30 g) as a red-brown solid, which was used directly in the next step without further purification.</div><div class="NLM_p">Step 2: To a solution of 6-benzyl-2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino)pyrido[3,4-<i>b</i>]pyrazin-6-ium bromide (7.2 g, 12.62 mmol) in DCM (126 mL) was added NaBH(OAc)<sub>3</sub> (16.05 g, 76 mmol) in one portion at rt. The resulting solution was stirred at rt for 3 days. The solvent was removed under reduced pressure, and EtOAc (200 mL) was added to redissolve the residue. Saturated NaHCO<sub>3</sub> (150 mL) was added, and the mixture was vigorously stirred for 30 min. The organic layer was washed with water (50 mL) and brine (50 mL), and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> overnight. Removal of the solvent gave 6-benzyl-2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido [3,4-<i>b</i>]pyrazin-3-amine (6.43 g) as a yellow solid, which was used without further purification. ESI-MS calcd for C<sub>28</sub>H<sub>33</sub>F<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 493.3, found: 494.1.</div><div class="NLM_p">Step 3: A mixture of 6-benzyl-2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine (6.43 g, 13.03 mmol) and 10% Pd/C (640 mg) in MeOH (86 mL) under H<sub>2</sub> in a balloon was stirred at rt overnight. Removal of the solvent gave 2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido [3,4-<i>b</i>]pyrazin-3-amine (<b>6c)</b> (4.4 g, 84%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 1.24 (d, <i>J</i> = 6.4 Hz, 6H), 1.89–1.99 (m, 2H), 2.09–2.17 (m, 2H), 2.74 (t, <i>J</i> = 5.9 Hz, 2H), 2.95 (ddd, <i>J</i> = 12.3, 8.7, 3.4 Hz, 2H), 3.11 (t, <i>J</i> = 6.1 Hz, 2H), 3.82 (s, 2H), 4.14 (septet, <i>J</i> = 6.4 Hz, 1H), 4.46 (tt, <i>J</i> = 7.7, 3.5 Hz, 1H), 6.85–6.92 (m, 1H), 6.99 (ddd, <i>J</i> = 11.4, 8.4, 3.2 Hz, 1H), 7.18 (td, <i>J</i> = 9.3, 5.4 Hz, 1H); ESI-MS calcd for C<sub>21</sub>H<sub>27</sub>F<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 403.2, found: 404.0.</div><div class="NLM_p last">Compounds <b>18a</b>, <b>18b</b>, and <b>19a</b> were prepared in a reaction sequence similar to the synthesis of <b>6c</b>, starting with <b>16a</b>, <b>16b</b>, and <b>17b</b>, respectively.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Preparation of 1-(3-(4-(2,4-Difluorophenoxy)piperidin-1-yl)-2-(isopropylamino)-7,8-dihydropyrido[3,4-<i>b</i>]pyrazin-6(5<i>H</i>)-yl)ethanone (<b>6a</b>)</h4><div class="NLM_p last">Acetic anhydride (5 μL, 0.058 mmol) was added to a solution of 3-(4-(2,4-difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-2-amine TFA salt (<b>18a</b>) (15.1 mg, 0.029 mmol) and pyridine (7 μL, 0.088 mmol) in DCM (290 μL) at rt. After being stirred for 1 h, the mixture was purified by HPLC to afford the title compound <b>6a</b> as its TFA salt (12.7 mg, 78%) as a yellow film. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, mixture of two rotamers) δ ppm 1.33 (d, <i>J</i> = 6.6 Hz, 6H), 1.91–2.02 (m, 2H), 2.09–2.18 (m, 2H), 2.19 (s, 1.4H), 2.21 (s, 1.6H), 2.77–2.83 (m, 0.9H), 2.88–2.94 (m, 1.1H), 3.12 (td, <i>J</i> = 8.5, 4.0 Hz, 2H), 3.43–3.51 (m, 2H), 3.80–3.85 (m, 1.1H), 3.86–3.91 (m, 0.9H), 4.10–4.18 (m, 1H), 4.47–4.54 (m, 1H), 4.55 (br s, 2H), 6.85–6.92 (m, 1H), 6.99 (ddd, <i>J</i> = 11.4, 8.6, 3.0 Hz, 1H), 7.18 (td, <i>J</i> = 9.2, 5.6 Hz, 1H); ESI-MS calcd for C<sub>23</sub>H<sub>27</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 445.2, found: 446.4.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Preparation of 1-(2-(Cyclopropylamino)-3-(4-(2,4-difluorophenoxy)piperidin-1-yl)-7,8-dihydropyrido[3,4-<i>b</i>]pyrazin-6(5<i>H</i>)-yl)ethenone (<b>6b</b>)</h4><div class="NLM_p last">To a solution of <i>N</i>-cyclopropyl-3-(4-(2,4-difluorophenoxy)piperidin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-2-amine (<b>18b</b>) (1.76 g, 4.38 mmol) in DCM (50 mL) at 0 °C was added acetyl chloride (0.467 mL, 6.58 mmol) and DIPEA (2.291 mL, 13.15 mmol) dropwise. The resulting solution was stirred at rt for 10 min and then concentrated under reduced pressure. The residue was purified by HPLC to give the title compound <b>6b</b> (699 mg, 36%) as a white solid. Melting point: 106.8 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 0.66–0.75 (m, 2 H) 1.03–1.13 (m, 2 H) 1.94–2.03 (m, 2 H) 2.08–2.15 (m, 2 H) 2.23–2.28 (m, 3 H) 2.96–3.14 (m, 5 H) 3.38–3.47 (m, 2 H) 3.75–3.83 (m, 1 H) 3.90–3.97 (m, 1 H) 4.38–4.45 (m, 1 H) 4.51–4.56 (m, 1 H) 4.66–4.70 (m, 1 H) 6.78–6.85 (m, 1 H) 6.86–6.92 (m, 1 H) 6.97–7.04 (m, 1 H); ESI-MS calcd for C<sub>23</sub>H<sub>27</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 443.2, found: 444.4.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Preparation of 2-(4-(2,4-Difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-6-methyl-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>6d</b>)</h4><div class="NLM_p last">Sodium triacetoxyhydroborate (9.9 mg, 0.047 mmol) was added to a solution of DIPEA (8 μL, 0.047 mmol), 2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>6c</b>) (12.1 mg, 0.023 mmol) and formaldehyde (2 μL, 0.023 mmol) in MeOH (230 μL) at rt. After 30 min, the mixture was purified by HPLC to afford the title compound <b>6d</b> as a TFA salt (8.9 mg, 71.6%) as a yellow film. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 1.24 (d, <i>J</i> = 6.3 Hz, 6H), 1.90–2.00 (m, 2H), 2.08–2.17 (m, 2H), 2.95–3.06 (m, 3H), 3.12 (br s, 4H), 3.35–3.53 (m, 3H), 3.76 (br s, 1H), 4.15 (dt, <i>J</i> = 13.1, 6.5, 6.5 Hz, 1H), 4.19–4.38 (m, 2H), 4.48 (tt, <i>J</i> = 7.3, 3.7 Hz, 1H), 6.85–6.92 (m, 1H), 6.99 (ddd, <i>J</i> = 11.4, 8.5, 3.0 Hz, 1H), 7.17 (td, <i>J</i> = 9.2, 5.6 Hz, 1H); ESI-MS calcd for C<sub>22</sub>H<sub>29</sub>F<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> = 417.2, found: 418.3.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Preparation of 2-(4-(2,4-Difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>6e</b>)</h4><div class="NLM_p last">In a 50 mL round-bottomed flask equipped with a stir bar, a solution of 2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine TFA salt (<b>6c</b>) (735.3 mg, 1.421 mmol) in DCM (14.2 mL) at 0 °C was treated with triethylamine (0.594 mL, 4.26 mmol), followed by addition of methanesulfonyl chloride (0.221 mL, 2.84 mmol). The reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by HPLC to give the title compound <b>6e</b> as an off-white solid (229.6 mg, 33.6%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.18 (d, <i>J</i> = 6.3 Hz, 6H), 1.88 (m, 2H), 2.07 (m, 2H), 2.75 (t, <i>J</i> = 5.9 Hz, 2H), 2.89 (m, 2H), 2.97 (s, 3H), 3.29 (m, 2H), 3.45 (t, <i>J</i> = 5.9 Hz, 2H), 4.09 (m, 1H), 4.16 (s, 2H), 4.52 (tt, <i>J</i> = 8.1, 3.9 Hz, 1H), 5.57 (d, <i>J</i> = 8.3 Hz, 1H), 7.01 (m, 1H), 7.30 (m, 2H); ESI-MS calcd for C<sub>22</sub>H<sub>29</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup> = 481.2, found: 481.90.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Preparation of Methyl 2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino)-7,8-dihydropyrido[3,4-<i>b</i>]pyrazine-6(5<i>H</i>)-carboxylate (<b>6f</b>)</h4><div class="NLM_p">To a solution of 2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>6c</b>) (45.6 mg, 0.113 mmol) and triethylamine (0.039 mL, 0.283 mmol) in DCM (0.75 mL) was added methyl carbonochloridate (0.013 mL, 0.170 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, warmed to 23 °C, and concentrated under reduced pressure. The resulting crude material was partitioned between EtOAc and H<sub>2</sub>O. The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, rinsed with EtOAc, and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (2% to 80% gradient eluant of EtOAc in heptane) to provide the title compound <b>4i</b> (48.7 mg, 93%) as a white foam. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.17–1.19 (m, 6H), 1.80–1.94 (m, 2H), 2.06 (ddd, <i>J</i> = 9.5, 5.9, 3.2 Hz, 2H), 2.64 (t, <i>J</i> = 5.9 Hz, 2H), 2.82–2.94 (m, 2H), 3.19–3.31 (m, 2H), 3.64 (s, 3H), 3.64–3.69 (m, 2H), 4.07–4.17 (m, 1H), 4.35 (br s, 2H), 4.51 (tt, <i>J</i> = 8.1, 3.9 Hz, 1H), 5.53 (d, <i>J</i> = 8.3 Hz, 1H), 7.01 (dddd, <i>J</i> = 9.3, 8.1, 3.2, 1.5 Hz, 1H), 7.26–7.35 (m, 2H); ESI-MS calcd for C<sub>23</sub>H<sub>29</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> = 461.2, found: 461.9.</div><div class="NLM_p">Preparation of 1-(3-(cyclopropylamino)-2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-7,8-dihydropyrido[3,4-<i>b</i>]pyrazin-6(5<i>H</i>)-yl)ethanone (<b>6g</b>) is similar to the synthesis of compound <b>6a</b> starting with <i>N</i>-cyclopropyl-2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>19a</b>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 0.46–0.56 (m, 2H) 0.78–0.87 (m, 2H) 1.87–1.96 (m, 2H) 2.05–2.14 (m, 2H) 2.18–2.22 (m, 3H) 2.72–2.94 (m, 5H) 3.27–3.37 (m, 2H) 3.70–3.77 (m, 1H) 3.86–3.92 (m, 1H) 4.28–4.36 (m, 1H) 4.56 (s, 1H) 4.70 (s, 1H) 5.05–5.15 (m, 1H) 6.76–6.82 (m, 1H) 6.84–6.90 (m, 1H) 6.96–7.03 (m, 1H); ESI-MS calcd for C<sub>23</sub>H<sub>27</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 443.2, found: 444.4.</div><div class="NLM_p">2-(4-(2,4-Difluorophenoxy)piperidin-1-yl)-<i>N</i>-isopropyl-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>6h</b>) was prepared in a manner similar to the synthesis of <b>6a</b> starting with <b>6c</b> and acetic anhydride. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, mixture of two rotamers) δ ppm 1.23 (d, <i>J</i> = 6.6 Hz, 3.3H), 1.24 (d, <i>J</i> = 6.6 Hz, 2.7H), 1.93 (m, 2H), 2.11 (m, 2H), 2.18 (s, 1.3H), 2.20 (s, 1.7H), 2.71 (t, <i>J</i> = 6.1 Hz, 0.9H), 2.80 (t, <i>J</i> = 6.1 Hz, 1.1H), 2.95 (m, 2H), 3.34 (m, 2H), 3.79 (t, <i>J</i> = 5.9 Hz, 1.1H), 3.84 (t, <i>J</i> = 6.1 Hz, 0.9H), 4.15 (m, 1H), 4.44 (tt, <i>J</i> = 7.5, 3.7 Hz, 1H), 4.53 (s, 0.9H), 4.54 (s, 1.1H), 6.86 (m, 1H), 6.97 (ddd, <i>J</i> = 11.2, 8.5, 3.2 Hz, 1H), 7.16 (td, <i>J</i> = 9.2, 5.6 Hz, 1H); ESI-MS calcd for C<sub>23</sub>H<sub>29</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 445.2, found: 446.0.</div><div class="NLM_p last">Preparation of (<i>R</i>)-1-(2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-((tetrahydrofuran-3-yl)amino)-7,8-dihydropyrido[3,4-<i>b</i>]pyrazin-6(5<i>H</i>)-yl)ethan-1-one (<b>6i</b>) is similar to the synthesis of compound <b>6a</b> starting with (<i>R</i>)-2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-<i>N</i>-(tetrahydrofuran-3-yl)pyrido[3,4-<i>b</i>]pyrazin-3-amine (<b>17c</b>). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, mixture of two rotamers) δ ppm 1.83–2.00 (m, 3H), 2.06 (dd, <i>J</i> = 6.83, 3.42 Hz, 2H), 2.09 (d, <i>J</i> = 3.42 Hz, 3H), 2.13–2.23 (m, 1H), 2.60 (t, <i>J</i> = 5.86 Hz, 1H), 2.72 (t, <i>J</i> = 5.86 Hz, 1H), 2.84–2.95 (m, 2H), 3.29 (br. s., 1H), 3.56 (dt, <i>J</i> = 8.79, 5.37 Hz, 1H), 3.68–3.75 (m, 3H), 3.82–3.88 (m, 1H), 3.90 (ddd, <i>J</i> = 8.79, 6.10, 2.68 Hz, 1 H), 4.35–4.41 (m, 1 H), 4.42 (s, 1H), 4.45 (s, 1H), 4.51 (tt, <i>J</i> = 8.12, 3.84 Hz, 1H), 5.90 (dd, <i>J</i> = 13.42, 6.10 Hz, 1H), 7.01 (dddd, <i>J</i> = 9.28, 8.05, 2.93, 1.71 Hz, 1H), 7.23–7.35 (m, 2H); SI-MS calcd for C<sub>24</sub>H<sub>29</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> = 473.2, found: 474.3.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> GPR6 cAMP TR-FRET Assay</h3><div class="NLM_p last">Cell-based GPR6 cAMP TR-FRET assays were used to quantify GPR6 receptor-dependent modulation of the cAMP level in CHO-K1 cells. The unusually high level of apparent constitutive activity of GPR6 in heterologous expression systems provided the opportunity to measure inhibition of GPR6 without agonist stimulation. T-REx-CHO-K1 cells (Invitrogen, USA) stably expressing tetracycline inducible human GPR6 were cultured in growth media (F12K medium [Gibco, Life Technologies], containing 10% tetracycline free fetal bovine serum FBS [HyClone, Fisher Scientific], 1% penicillin/streptomycin, and 200 μg/mL Hygromycin B). To induce GPR6 expression, cells were dissociated and plated in induction media (growth media plus 2.0 μg/mL doxycycline [Sigma D9891]) at a density of 250–500 cells per well in half area white solid bottom 96-well plates (Costar) and incubated (37 °C, 5% CO<sub>2</sub>) for 20 h. Following incubation, media was removed, and cells were washed with 50 μL of Krebs Ringer’s buffer (Sigma K4002). Source plates containing test compounds suspended in DMSO were diluted in Krebs Ringer’s buffer containing 0.5% fatty acid free BSA. Cells were incubated with compound for 45 min at 37 °C and 5% CO<sub>2</sub>, followed by Eu-cAMP tracer for 10 min and ULight-anti-cAMP antibody for 1 h at room temperature (PerkinElmer Lance Ultra cAMP assay (TRF0264)). TR-FRET signal was detected on an Envision plate reader (PerkinElmer). IC<sub>50</sub> curves were generated with a four-parameter logistic equation using GraphPad Prism 5.03.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> GPR6 Radioligand Binding Assay</h3><div class="NLM_p">RL-338 was synthesized in the chemistry laboratories of Envoy Therapeutics, Inc., FL. In vitro pharmacological profiling showed that RL-338 is a potent and highly selective GPR6 IAG, inhibiting GPR6 cAMP signaling in TR-FRET assays with a EC<sub>50</sub> = 16 nM and >100 fold selectivity against GPR3 and GPR12 (unpublished). RL-338 was radiolabeled with three tritium atoms by the Quotient Bioresearch (Cardiff, UK) and validated using standard in vitro pharmacology methods (<a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>). To study the binding characteristics of GPR6 IAG compounds, a competition binding assay using a filtration-based format was developed featuring membranes prepared from T-REx-CHO-GPR6 cells expressing human GPR6 cDNA driven by a doxycycline inducible promoter. First, assay-ready 96-well plates (651201, Greiner, USA) containing serial dilutions of test compounds (1 μL of test ligand/well) were prepared in DMSO using liquid handlers (5 μM, final assay top concentration). A total of 39 μL of assay buffer was added, and plates were mixed on a plate shaker for 10 min. Next, 40 μL of radioligand <sup>3</sup>H-RL-338 prepared in assay buffer (50 mM Tris, pH 7.4, 50 mM NaCl, 6 mM MgCl<sub>2,</sub> fatty acid free 0.1% BSA, proteinase inhibitor cocktail, Sigma USA) was added per well (2.4 nM final assay concentration). Binding reactions were initiated by adding 40 μL of total membranes obtained from cells expressing human GPR6 receptors. Membranes were prepared in assay buffer (50 mM Tris, pH 7.4, 50 mM NaCl, 6 mM MgCl<sub>2,</sub> fatty acid free 0.1% BSA, 1× proteinase inhibitor cocktail, Sigma USA) and added per well to 15 μg/well final assay concentration. Plates were sealed, mixed for 30 s at 300 rpm, and incubated for 2 h at room temperature. Reactions were filtered through filtermates (1450-421, filtermate A, PerkinElmer, USA), and washed five times for 5 s with 4 °C cold 50 mM Tris, pH 7.4, 50 mM NaCl, 6 mM MgCl<sub>2,</sub> fatty acid free 0.1% BSA using a Tomtec Harvester 96 instrument. Filters were dried in the microwave, scintillator sheet (1450-411, PerkinElmer, USA) melted on them and heat-sealed before CPM/wells were quantified in a Microbeta Trilux instrument (PerkinElmer, USA). Before use, filtermates were presoaked in 0.5% polyethylenimine solution for 3 h with gentle shaking, followed by air drying overnight.</div><div class="NLM_p last">The same protocol was used for saturation binding assays to determine radioligand <sup>3</sup>H-RL-338 affinity to GPR6. Different concentrations of radioligand <sup>3</sup>H-RL-338 ranging from 32 nM (high concentration) to 0.015 nM (low concentration) with 1:2 dilution steps were tested to generate saturation curves and obtain the equilibrium dissociation constant <i>K</i><sub>d</sub>. Nonspecific background binding of <sup>3</sup>H-RL-338 was determined using 10 mM of an unlabeled structurally diverse potent and selective GPR6 inverse agonists (data not shown). IC<sub>50</sub> and <i>K</i><sub>d</sub> values were calculated using nonlinear regression analysis in Prism (GraphPad, USA). Saturation curves were fitted to the Prism equation: one site - fit total and nonspecific binding without constraints. Dose-response curves were fitted to the four-parameter variable slope model without constraints in Prism to obtain IC<sub>50</sub>’s. <i>K</i><sub>i</sub> values were calculated using the Cheng–Prusoff equation (Cheng and Prusoff, 1973). CVN424 and other GPR6 IAG fully displaced <sup>3</sup>H-RL-338 from GPR6 and displayed binding properties that were consistent with a single binding site. Radioligand <sup>3</sup>H-RL-338 demonstrated high affinity for human GPR6 receptors stably expressed in T-REx-CHO-GPR6 cells (<i>K</i><sub>d</sub><sub>=</sub> 2.4 nM or 5 nM dependent on synthesized radioligand batch) in saturation binding assays.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Haloperidol-Induced Catalepsy</h3><div class="NLM_p last">Haloperidol-induced catalepsy in rodents is caused by blocking activity of striatal dopamine D2 receptors, resulting in elevated cAMP and overactivity of the indirect pathway of the striatum and decreased movement. Compounds <b>3e</b> was tested for reversal of haloperidol-induced catalepsy in male wild-type Sprague-Dawley rats (source: Harlan, Frederick (MD) USA), male C57BL/6N (source: wild-type mice (source: Jackson Laboratories, ME, USA) and GPR6 knock out mice using the bar test.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The cataleptic state was induced by the subcutaneous administration of the dopamine receptor antagonist haloperidol (0.3 mg/kg, sc rats and 1 mg/kg i.p. mice), 90 min before testing the animals. Front paws were placed on a horizontal metal bar raised 2’ (mice) or 6’ (rats) above a Plexiglas platform and time was recorded for up to 60 s. The test ended when the animal’s front paws returned to the platform or after 60 s. The test was repeated three times, and the average of the trials reported. Cataleptic animals treated with haloperidol will hold to the bar without moving for several minutes. Efficacy of compound <b>3e</b> to reverse haloperidol-induced catalepsy was tested 120 min post injection. The A2a antagonist KW6002 (Istradefylline) was dosed at 0.6 mg/kg i.p. as a positive control.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Bilateral 6-OHDA-Lesioned Parkinson’s Disease Rat Model</h3><div class="NLM_p last">Bilateral striatal 6-OHDA lesion in rats trigger degeneration of dopaminergic neurons, striatal dopamine depletion and show motor deficits, which mimics aspects of human PD pathology and symptomology. Early lead compound <b>6h</b> was tested for anti-parkinsonian efficacy in this model, administered as monotherapy (1 mg/kg, p.o.). Thirty minutes prior to surgery, animals (female Sprague-Dawley rats, Charles River Laboratories, Wilmington, MA USA) received pargyline (5 mg/kg; i.p.) and desipramine (10 mg/kg; i.p.) to optimize subsequent 6-hydroxydopamine (6-OHDA) availability and increase specificity for toxicity to dopaminergic neurons. Rats received bilateral injections of 6-OHDA (20 μg in 3 μL; 0.5 μL/min) into the striatum at coordinates AP: ML: DV, 1, ± 3, −5 mm relative to Bregma to introduce lesion. Open field activity of animals was recorded pre- and 28 days postsurgery for 3 h. Bilateral lesions induced a significant reduction in activity (40%) compared to prelesion. In addition, there was a 32% reduction of dopamine transporter expression in the striatum (not shown). Directly after dosing compound <b>6h</b> locomotor activity (defined as beam broken on the lower level) was assessed in open field arenas equipped with automatic activity monitors (Linton Instrumentation, U.K.).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02081" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72048" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72048" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02081?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02081</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Materials and Methods; preparation of key intermediates; characterization of lead compounds: <b>1</b>, <b>3e</b>, and <b>6h</b>; original pharmacology data for compound <b>3e</b> and lead compound <b>6h</b>; structure and validation data of radioligand [<sup>3</sup>H]-RL338; reference compound for cAMP TR-FRET assays: structure and in vitro pharmacology; compound <b>3e</b> in vitro pharmacology graphs (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02081/suppl_file/jm0c02081_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02081/suppl_file/jm0c02081_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02081/suppl_file/jm0c02081_si_001.pdf">jm0c02081_si_001.pdf (805.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02081/suppl_file/jm0c02081_si_002.csv">jm0c02081_si_002.csv (6.06 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02081" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huikai Sun</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4593-1306" title="Orcid link">https://orcid.org/0000-0002-4593-1306</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9bd3eef2f0faf2b5e8eef5dbeffaf0fefffab5f8f4f6"><span class="__cf_email__" data-cfemail="d098a5b9bbb1b9fea3a5be90a4b1bbb5b4b1feb3bfbd">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Holger Monenschein</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5d3532313a382f73301d293c3638393c733e3230"><span class="__cf_email__" data-cfemail="6f070003080a1d41022f1b0e040a0b0e410c0002">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hans H. Schiffer</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Holly A. Reichard</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shota Kikuchi</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Hopkins</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Todd K. Macklin</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Hitchcock</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Adams</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Green</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Brown</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sean T. Murphy</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nidhi Kaushal</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deanna R. Collia</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Moore</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William J. Ray</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole Marion English</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Beresford Lewis Carlton</span> - <span class="hlFld-Affiliation affiliation">Cerevance
Ltd, 418 Cambridge Science
Park, Cambridge, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicola L. Brice</span> - <span class="hlFld-Affiliation affiliation">Cerevance
Ltd, 418 Cambridge Science
Park, Cambridge, U.K.</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81570" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81570" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the following individuals for their contributions: Ron Chen, Padma Manam, Yang Song, and Paddi Ekhlassi for analytical chemistry and formulation support, Ron Steigerwalt for drug safety expertise, and our process chemistry colleagues Wolfgang Notz, Chunrong Ma, and Dave Provencal.</p></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77784" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77784" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This paper originally published ASAP on April 16, 2021. Co-author Nicole Marion English was added and a new version was reposted on July 8, 2021.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N,N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">Hz</td><td class="NLM_def"><p class="first last">hertz</p></td></tr><tr><td class="NLM_term">LC-MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">microwave</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01866" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01866" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poewe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seppi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliday, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brundin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrag, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A. E.</span></span> <span> </span><span class="NLM_article-title">Parkinson disease</span>. <i>Nat. Rev. Dis Primers</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">17013</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2017.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1038%2Fnrdp.2017.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=28332488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BC1cvgtFChsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=17013&author=W.+Poeweauthor=K.+Seppiauthor=C.+M.+Tannerauthor=G.+M.+Hallidayauthor=P.+Brundinauthor=J.+Volkmannauthor=A.+E.+Schragauthor=A.+E.+Lang&title=Parkinson+disease&doi=10.1038%2Fnrdp.2017.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson disease</span></div><div class="casAuthors">Poewe Werner; Seppi Klaus; Tanner Caroline M; Tanner Caroline M; Halliday Glenda M; Halliday Glenda M; Brundin Patrik; Volkmann Jens; Schrag Anette-Eleonore; Lang Anthony E</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17013</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkinson disease is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age.  Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease.  Multiple other cell types throughout the central and peripheral autonomic nervous system are also involved, probably from early disease onwards.  Although clinical diagnosis relies on the presence of bradykinesia and other cardinal motor features, Parkinson disease is associated with many non-motor symptoms that add to overall disability.  The underlying molecular pathogenesis involves multiple pathways and mechanisms: α-synuclein proteostasis, mitochondrial function, oxidative stress, calcium homeostasis, axonal transport and neuroinflammation.  Recent research into diagnostic biomarkers has taken advantage of neuroimaging in which several modalities, including PET, single-photon emission CT (SPECT) and novel MRI techniques, have been shown to aid early and differential diagnosis.  Treatment of Parkinson disease is anchored on pharmacological substitution of striatal dopamine, in addition to non-dopaminergic approaches to address both motor and non-motor symptoms and deep brain stimulation for those developing intractable L-DOPA-related motor complications.  Experimental therapies have tried to restore striatal dopamine by gene-based and cell-based approaches, and most recently, aggregation and cellular transport of α-synuclein have become therapeutic targets.  One of the greatest current challenges is to identify markers for prodromal disease stages, which would allow novel disease-modifying therapies to be started earlier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFPUR1uNNE1-98rul4nhSdfW6udTcc2ebH2Ps0PZmeDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvgtFChsA%253D%253D&md5=b624b37fee08b8b663ea88b83bc47865</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2017.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2017.13%26sid%3Dliteratum%253Aachs%26aulast%3DPoewe%26aufirst%3DW.%26aulast%3DSeppi%26aufirst%3DK.%26aulast%3DTanner%26aufirst%3DC.%2BM.%26aulast%3DHalliday%26aufirst%3DG.%2BM.%26aulast%3DBrundin%26aufirst%3DP.%26aulast%3DVolkmann%26aufirst%3DJ.%26aulast%3DSchrag%26aufirst%3DA.%2BE.%26aulast%3DLang%26aufirst%3DA.%2BE.%26atitle%3DParkinson%2520disease%26jtitle%3DNat.%2520Rev.%2520Dis%2520Primers%26date%3D2017%26volume%3D3%26spage%3D17013%26doi%3D10.1038%2Fnrdp.2017.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poewe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahlknecht, P.</span></span> <span> </span><span class="NLM_article-title">The clinical progression of Parkinson’s disease</span>. <i>Parkinsonism Relat Disord</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">Suppl 4</span>),  <span class="NLM_fpage">S28</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/S1353-8020(09)70831-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2FS1353-8020%2809%2970831-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=20123553" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=S28-32&issue=Suppl+4&author=W.+Poeweauthor=P.+Mahlknecht&title=The+clinical+progression+of+Parkinson%E2%80%99s+disease&doi=10.1016%2FS1353-8020%2809%2970831-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1353-8020%2809%2970831-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1353-8020%252809%252970831-4%26sid%3Dliteratum%253Aachs%26aulast%3DPoewe%26aufirst%3DW.%26aulast%3DMahlknecht%26aufirst%3DP.%26atitle%3DThe%2520clinical%2520progression%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DParkinsonism%2520Relat%2520Disord%26date%3D2009%26volume%3D15%26issue%3DSuppl%25204%26spage%3DS28%26epage%3D32%26doi%3D10.1016%2FS1353-8020%2809%2970831-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poewe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahlknecht, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankovic, J.</span></span> <span> </span><span class="NLM_article-title">Emerging therapies for Parkinson’s disease</span>. <i>Curr. Opin. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1097/WCO.0b013e3283542fde</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1097%2FWCO.0b013e3283542fde" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=22772874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWjs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=448-459&issue=4&author=W.+Poeweauthor=P.+Mahlknechtauthor=J.+Jankovic&title=Emerging+therapies+for+Parkinson%E2%80%99s+disease&doi=10.1097%2FWCO.0b013e3283542fde"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapies for Parkinson's disease</span></div><div class="casAuthors">Poewe, Werner; Mahlknecht, Philipp; Jankovic, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">448-459</span>CODEN:
                <span class="NLM_cas:coden">CONEEX</span>;
        ISSN:<span class="NLM_cas:issn">1350-7540</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The exptl. therapeutics of Parkinson's disease are reviewed, highlighting the current pipeline of emerging therapeutic approaches.  Recent findings: This review includes novel approaches to dopaminergic drug delivery such as intraintestinal infusions or new extended-release formulations of levodopa and also intrapulmonary delivery of apomorphine as well as novel dopaminergic agents like the monoamine oxidase-B inhibitor safinamide or novel catechol-O-Me transferase inhibitors.  An even greater no. of ongoing clin. trials assess the efficacy and safety of nondopaminergic approaches to enhance motor control or reduce motor complications like fluctuations and dyskinesias.  These include adenosine A2A antagonists, α-adrenergic and serotonergic agonists as well as drugs acting on the glutamatergic system.  Gene-based or cell-based intrastriatal delivery of therapeutic principles that enhance striatal dopaminergic transmission directly or via the stimulation of trophic activity has also reached phase II clin. development with encouraging results in some studies.  Finally, a wide spectrum of agents with a potential for slowing disease progression is currently tested.  Summary: A variety of medical and nonmedical interventions in different phases of clin. development provide an interesting and promising portfolio of emerging therapies for Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomNZpxzJjBtrVg90H21EOLACvtfcHk0lhZTuaswmyIAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWjs7zM&md5=421b6b0b289da7fcc8e817ae1808c15a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1097%2FWCO.0b013e3283542fde&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWCO.0b013e3283542fde%26sid%3Dliteratum%253Aachs%26aulast%3DPoewe%26aufirst%3DW.%26aulast%3DMahlknecht%26aufirst%3DP.%26aulast%3DJankovic%26aufirst%3DJ.%26atitle%3DEmerging%2520therapies%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Opin.%2520Neurol.%26date%3D2012%26volume%3D25%26issue%3D4%26spage%3D448%26epage%3D459%26doi%3D10.1097%2FWCO.0b013e3283542fde" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fearnley, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A. J.</span></span> <span> </span><span class="NLM_article-title">Ageing and Parkinson’s disease: substantia nigra regional selectivity</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2283</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi"> DOI: 10.1093/brain/114.5.2283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1093%2Fbrain%2F114.5.2283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1933245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADyaK38%252Fjtlyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1991&pages=2283-2301&issue=5&author=J.+M.+Fearnleyauthor=A.+J.+Lees&title=Ageing+and+Parkinson%E2%80%99s+disease%3A+substantia+nigra+regional+selectivity&doi=10.1093%2Fbrain%2F114.5.2283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Ageing and Parkinson's disease: substantia nigra regional selectivity</span></div><div class="casAuthors">Fearnley J M; Lees A J</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">114 ( Pt 5)</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2283-301</span>
        ISSN:<span class="NLM_cas:issn">0006-8950</span>.
    </div><div class="casAbstract">The micro-architecture of the substantia nigra was studied in control cases of varying age and patients with parkinsonism.  A single 7 mu section stained with haematoxylin and eosin was examined at a specific level within the caudal nigra using strict criteria.  The pars compacta was divided into a ventral and a dorsal tier, and each tier was further subdivided into 3 regions.  In 36 control cases there was a linear fallout of pigmented neurons with advancing age in the pars compacta of the caudal substantia nigra at a rate of 4.7% per decade.  Regionally, the lateral ventral tier was relatively spared (2.1% loss per decade) compared with the medial ventral tier (5.4%) and the dorsal tier (6.9%).  In 20 Parkinson's disease (PD) cases of varying disease duration there was an exponential loss of pigmented neurons with a 45% loss in the first decade.  Regionally, the pattern was opposite to ageing.  Loss was greatest in the lateral ventral tier (average loss 91%) followed by the medial ventral tier (71%) and the dorsal tier (56%).  The presymptomatic phase of PD from the onset of neuronal loss was estimated to be about 5 yrs.  This phase is represented by incidental Lewy body cases: individuals who die without clinical signs of PD or dementia, but who are found to have Lewy bodies at post-mortem.  In 7 cases cell loss was confined to the lateral ventral tier (average loss 52%) congruent with the lateral ventral selectivity of symptomatic PD.  It was calculated that at the onset of symptoms there was a 68% cell loss in the lateral ventral tier and a 48% loss in the caudal nigra as a whole.  The regional selectivity of PD is relatively specific.  In 15 cases of striatonigral degeneration the distribution of cell loss was similar, but the loss in the dorsal tier was greater than PD by 21%.  In 14 cases of Steele-Richardson-Olszewski syndrome (SRO) there was no predilection for the lateral ventral tier, but a tendency to involve the medial nigra and spare the lateral.  These findings suggest that age-related attrition of pigmented nigral cells is not an important factor in the pathogenesis of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxLysQt8EU6GGmni0r9GoKfW6udTcc2eYxBJ-4T6tuWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252Fjtlyisg%253D%253D&md5=1dc891e20a3b34168d18980c14b5189d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2F114.5.2283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252F114.5.2283%26sid%3Dliteratum%253Aachs%26aulast%3DFearnley%26aufirst%3DJ.%2BM.%26aulast%3DLees%26aufirst%3DA.%2BJ.%26atitle%3DAgeing%2520and%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520substantia%2520nigra%2520regional%2520selectivity%26jtitle%3DBrain%26date%3D1991%26volume%3D114%26issue%3D5%26spage%3D2283%26epage%3D2301%26doi%3D10.1093%2Fbrain%2F114.5.2283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duda, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duyckaerts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliday, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverenz, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Tredici, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wszolek, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litvan, I.</span></span> <span> </span><span class="NLM_article-title">Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1150</span>– <span class="NLM_lpage">1157</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(09)70238-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2FS1474-4422%2809%2970238-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=19909913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFymsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1150-1157&issue=12&author=D.+W.+Dicksonauthor=H.+Braakauthor=J.+E.+Dudaauthor=C.+Duyckaertsauthor=T.+Gasserauthor=G.+M.+Hallidayauthor=J.+Hardyauthor=J.+B.+Leverenzauthor=K.+Del+Trediciauthor=Z.+K.+Wszolekauthor=I.+Litvan&title=Neuropathological+assessment+of+Parkinson%E2%80%99s+disease%3A+refining+the+diagnostic+criteria&doi=10.1016%2FS1474-4422%2809%2970238-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria</span></div><div class="casAuthors">Dickson, Dennis W.; Braak, Heiko; Duda, John E.; Duyckaerts, Charles; Gasser, Thomas; Halliday, Glenda M.; Hardy, John; Leverenz, James B.; Del Tredici, Kelly; Wszolek, Zbigniew K.; Litvan, Irene</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1150-1157</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  To date, there have been few systematic attempts to provide a std. operating procedure for the neuropathol. diagnosis of Parkinson's disease (PD).  Pathol. examn. cannot classify the clin. syndrome with certainty; therefore, the neuropathol. diagnosis is, at best, a probability statement.  The neuropathol. diagnosis of parkinsonism has become increasingly based on fundamental mol. underpinnings, with recognition that the genetics of parkinsonism is heterogeneous and includes disorders that are assocd. with and without Lewy bodies.  The advent of α-synuclein immunohistochem. has substantially improved the ability to identify Lewy pathol., particularly cortical Lewy bodies and smaller aggregates within processes and the neuropil.  In this Review we discuss the diagnostic criteria for the neuropathol. assessment of PD.  These criteria are provisional and need to be validated through an iterative process that could help with their refinement.  Addnl., we suggest future directions for neuropathol. research on PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox88ZBP6oOOrVg90H21EOLACvtfcHk0ljDhvi8rmMd0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFymsbzP&md5=801a9a8cf892f136c062326bd3bf8a4c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2809%2970238-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252809%252970238-8%26sid%3Dliteratum%253Aachs%26aulast%3DDickson%26aufirst%3DD.%2BW.%26aulast%3DBraak%26aufirst%3DH.%26aulast%3DDuda%26aufirst%3DJ.%2BE.%26aulast%3DDuyckaerts%26aufirst%3DC.%26aulast%3DGasser%26aufirst%3DT.%26aulast%3DHalliday%26aufirst%3DG.%2BM.%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DLeverenz%26aufirst%3DJ.%2BB.%26aulast%3DDel%2BTredici%26aufirst%3DK.%26aulast%3DWszolek%26aufirst%3DZ.%2BK.%26aulast%3DLitvan%26aufirst%3DI.%26atitle%3DNeuropathological%2520assessment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520refining%2520the%2520diagnostic%2520criteria%26jtitle%3DLancet%2520Neurol.%26date%3D2009%26volume%3D8%26issue%3D12%26spage%3D1150%26epage%3D1157%26doi%3D10.1016%2FS1474-4422%2809%2970238-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A. B.</span></span> <span> </span><span class="NLM_article-title">Circuit Mechanisms of Parkinson’s Disease</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1042</span>– <span class="NLM_lpage">1056</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2019.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2Fj.neuron.2019.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=30897356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1entrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2019&pages=1042-1056&issue=6&author=M.+M.+McGregorauthor=A.+B.+Nelson&title=Circuit+Mechanisms+of+Parkinson%E2%80%99s+Disease&doi=10.1016%2Fj.neuron.2019.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Circuit Mechanisms of Parkinson's Disease</span></div><div class="casAuthors">McGregor, Matthew M.; Nelson, Alexandra B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1042-1056</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is a complex, multi-system neurodegenerative disorder.  The second most common neurodegenerative disorder after Alzheimer's disease, it affects approx. 1% of adults over age 60.  Diagnosis follows the development of one or more of the core motor features of the disease, including tremor, slowing of movement (bradykinesia), and rigidity.  However, there are numerous other motor and nonmotor disease manifestations.  Many PD symptoms result directly from neurodegeneration; others are driven by aberrant activity patterns in surviving neurons.  This latter phenomenon, PD circuit dysfunction, is an area of intense study, as it likely underlies our ability to treat many disease symptoms in the face of (currently) irreversible neurodegeneration.  This Review will discuss key clin. features of PD and their basis in neural circuit dysfunction.  We will first review important disease symptoms and some of the responsible neuropathol.  We will then describe the basal ganglia-thalamocortical circuit, the major locus of PD-related circuit dysfunction, and some of the models that have influenced its study.  We will review PD-related changes in network activity, subdividing findings into those that touch on the rate, rhythm, or synchronization of neurons.  Finally, we suggest some crit. remaining questions for the field and areas for new developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonseLGyLem0LVg90H21EOLACvtfcHk0ljDhvi8rmMd0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1entrk%253D&md5=2d2765077e28fcc5298a851c5a7ffb1e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2019.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2019.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DMcGregor%26aufirst%3DM.%2BM.%26aulast%3DNelson%26aufirst%3DA.%2BB.%26atitle%3DCircuit%2520Mechanisms%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DNeuron%26date%3D2019%26volume%3D101%26issue%3D6%26spage%3D1042%26epage%3D1056%26doi%3D10.1016%2Fj.neuron.2019.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, E.</span></span> <span> </span><span class="NLM_article-title">Levodopa in the treatment of Parkinson’s disease: current status and new developments</span>. <i>J. Parkinson's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.3233/JPD-130186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.3233%2FJPD-130186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=23948989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVekt73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=255-269&issue=3&author=D.+Salatauthor=E.+Tolosa&title=Levodopa+in+the+treatment+of+Parkinson%E2%80%99s+disease%3A+current+status+and+new+developments&doi=10.3233%2FJPD-130186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments</span></div><div class="casAuthors">Salat, David; Tolosa, Eduardo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Parkinson's Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-269</span>CODEN:
                <span class="NLM_cas:coden">JPDOAP</span>;
        ISSN:<span class="NLM_cas:issn">1877-7171</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease (PD).  Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor (DDCI), which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain.  Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, esp. when used in conjunction with a DDCI.  During early-stage PD, treatment will depend on the severity of symptoms; if greater symptomatic effect is required then levodopa or dopamine agonists are usually the drugs of choice.  The ability to remain employable or phys. active is an important goal in younger patients, therefore, in some instances levodopa initiation should be considered early on, either as a monotherapy or in combination with other drugs.  The clin. use of levodopa may eventually be limited by the development of various treatment-related complications, including response fluctuations, dyskinesia and psychiatric problems.  Motor complications are related to the intermittent delivery of dopamine-replacing drugs to the brain.  Triple combination of levodopa/carbidopa/entacapone available in a single tablet in multiple levodopa dose strengths offers flexibility and helps control response fluctuations.  Recent developments in treatment with levodopa try to obtain continuous delivery with levodopa and include duodenal infusion of a levodopa/carbidopa, transdermal levodopa patch, and oral pro-levodopa.  Levodopa remains the most potent dopaminergic therapy for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-aRJ0idEt4LVg90H21EOLACvtfcHk0ljDhvi8rmMd0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVekt73F&md5=1ab250a0d4602412128509287cf470cd</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3233%2FJPD-130186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJPD-130186%26sid%3Dliteratum%253Aachs%26aulast%3DSalat%26aufirst%3DD.%26aulast%3DTolosa%26aufirst%3DE.%26atitle%3DLevodopa%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520current%2520status%2520and%2520new%2520developments%26jtitle%3DJ.%2520Parkinson%2527s%2520Dis.%26date%3D2013%26volume%3D3%26issue%3D3%26spage%3D255%26epage%3D269%26doi%3D10.3233%2FJPD-130186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tambasco, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabresi, P.</span></span> <span> </span><span class="NLM_article-title">Levodopa in Parkinson’s Disease: Current Status and Future Developments</span>. <i>Curr. Neuropharmacol</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1239</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.2174/1570159X15666170510143821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.2174%2F1570159X15666170510143821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=28494719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OmsbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=1239-1252&issue=8&author=N.+Tambascoauthor=M.+Romoliauthor=P.+Calabresi&title=Levodopa+in+Parkinson%E2%80%99s+Disease%3A+Current+Status+and+Future+Developments&doi=10.2174%2F1570159X15666170510143821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa in Parkinson's Disease: Current Status and Future Developments</span></div><div class="casAuthors">Tambasco, Nicola; Romoli, Michele; Calabresi, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1239-1252</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Ever since the pioneering reports in the 60s, L-3,4-Dioxyphenylalanine (levodopa) has represented the gold std. for the treatment of Parkinson's Disease (PD).  However, long-term levodopa (LD) treatment is frequently assocd. with fluctuations in motor response with serious impact on patient quality of life.  The pharmacokinetic and pharmacodynamic properties of LD are pivotal to such motor fluctuations: discontinuous drug delivery, short half-life, poor bioavailability, and narrow therapeutic window are all crucial for such fluctuations.  During the last 60 years, several attempts have been made to improve LD treatment and avoid long-term complications.  Methods: Research and trials to improve the LD pharmacokinetic since 1960s are reviewed, summarizing the progressive improvements of LD treatment.  Results: Inhibitors of peripheral amino acid decarboxylase (AADC) have been introduced to achieve proper LD concn. in the central nervous system reducing systemic adverse events.  Inhibitors of catechol-O-methyltransferase (COMT) increased LD half-life and bioavailability.  Efforts are still being made to achieve a continuous dopaminergic stimulation, with the combination of oral LD with an AADC inhibitor and a COMT inhibitor, or the intra-duodenal water-based LD/ carbidopa gel.  Further approaches to enhance LD efficacy are focused on new non-oral administration routes, including nasal, intra-duodenal, intrapulmonary (CVT-301) and s.c. (ND0612), as well as on novel ER formulations, including IPX066, which recently concluded phase III trial.  Conclusion: New LD formulations, oral compds. as well as routes have been tested in the last years, with two main targets: achieve continuous dopaminergic stimulation and find an instant deliver route for LD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrak8NdNvrE_bVg90H21EOLACvtfcHk0lgukYoIpJD_HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OmsbnO&md5=5f1e88ebb1460250cf1cd7a19f555df7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F1570159X15666170510143821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X15666170510143821%26sid%3Dliteratum%253Aachs%26aulast%3DTambasco%26aufirst%3DN.%26aulast%3DRomoli%26aufirst%3DM.%26aulast%3DCalabresi%26aufirst%3DP.%26atitle%3DLevodopa%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520Current%2520Status%2520and%2520Future%2520Developments%26jtitle%3DCurr.%2520Neuropharmacol%26date%3D2018%26volume%3D16%26issue%3D8%26spage%3D1239%26epage%3D1252%26doi%3D10.2174%2F1570159X15666170510143821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tambasco, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcastro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrioto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabresi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A.</span></span> <span> </span><span class="NLM_article-title">Levodopa-induced breathing, cognitive and behavioral changes in Parkinson’s disease</span>. <i>J. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>258</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2296</span>– <span class="NLM_lpage">2299</span>, <span class="refDoi"> DOI: 10.1007/s00415-011-6119-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1007%2Fs00415-011-6119-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=21647729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FivFCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=2011&pages=2296-2299&issue=12&author=N.+Tambascoauthor=V.+Belcastroauthor=A.+Gallinaauthor=A.+Castriotoauthor=P.+Calabresiauthor=A.+Rossi&title=Levodopa-induced+breathing%2C+cognitive+and+behavioral+changes+in+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs00415-011-6119-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease</span></div><div class="casAuthors">Tambasco Nicola; Belcastro Vincenzo; Gallina Antongiulio; Castrioto Anna; Calabresi Paolo; Rossi Aroldo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">258</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2296-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjaDavY9o61xe4jJGKT5N0fW6udTcc2eYaGwK1jMQBnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FivFCgsw%253D%253D&md5=1208370eb04aebbf2353116072071249</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00415-011-6119-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00415-011-6119-5%26sid%3Dliteratum%253Aachs%26aulast%3DTambasco%26aufirst%3DN.%26aulast%3DBelcastro%26aufirst%3DV.%26aulast%3DGallina%26aufirst%3DA.%26aulast%3DCastrioto%26aufirst%3DA.%26aulast%3DCalabresi%26aufirst%3DP.%26aulast%3DRossi%26aufirst%3DA.%26atitle%3DLevodopa-induced%2520breathing%252C%2520cognitive%2520and%2520behavioral%2520changes%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurol.%26date%3D2011%26volume%3D258%26issue%3D12%26spage%3D2296%26epage%3D2299%26doi%3D10.1007%2Fs00415-011-6119-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabbrini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotchie, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, C. G.</span></span> <span> </span><span class="NLM_article-title">Levodopa-induced dyskinesias</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1379</span>– <span class="NLM_lpage">1389</span>, <span class="refDoi"> DOI: 10.1002/mds.21475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1002%2Fmds.21475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=17427940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BD2svjvFKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=1379-1389&issue=10&author=G.+Fabbriniauthor=J.+M.+Brotchieauthor=F.+Grandasauthor=M.+Nomotoauthor=C.+G.+Goetz&title=Levodopa-induced+dyskinesias&doi=10.1002%2Fmds.21475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa-induced dyskinesias</span></div><div class="casAuthors">Fabbrini Giovanni; Brotchie Jonathan M; Grandas Francisco; Nomoto Masahiro; Goetz Christopher G</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1379-1389</span>
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    </div><div class="casAbstract">Levodopa-induced dyskinesias (LID) are common and difficult to treat.  This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management.  The three primary clinical syndromes are OFF-period dystonia, peak-dose dyskinesia, and diphasic dyskinesia.  Several other forms also occur, making the evaluation and choice of treatment complicated.  A core component of the pathophysiology of LID is overactivity of the direct striatal output pathway.  This pathway provides a direct GABAergic connection by which the striatum inhibits the output regions of the basal ganglia, i.e., the internal globus pallidus and the substantia nigra pars reticulata.  Altering dopaminergic dosing and timing can abate dyskinesias, but usually impact the control of parkinsonism.  Putative therapies to reduce the problem of dyskinesias could focus on the glutamatergic, GABAergic, alpha2 adrenergic, serotonergic (5HT1A, 5HT2A), opioid, histamine H3, adenosine A2A receptors, the monoamine transport or cannabinoid CB1 receptors systems.  The only currently available drug with an evidence-based recommendation on efficacy for dyskinesia is amantadine.  Therapy goals include the prevention of dyskinesia and treatment of dyskinesias that are troublesome clinically.  New rating measures to assess severity and disability related to dyskinesia are in the process of development and clinimetric testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDoNA75wLjNdLIORRPd5lbfW6udTcc2eYaGwK1jMQBnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svjvFKhuw%253D%253D&md5=7eae8ac0714f373ce0db78ebf6769a2d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fmds.21475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.21475%26sid%3Dliteratum%253Aachs%26aulast%3DFabbrini%26aufirst%3DG.%26aulast%3DBrotchie%26aufirst%3DJ.%2BM.%26aulast%3DGrandas%26aufirst%3DF.%26aulast%3DNomoto%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DC.%2BG.%26atitle%3DLevodopa-induced%2520dyskinesias%26jtitle%3DMov.%2520Disord.%26date%3D2007%26volume%3D22%26issue%3D10%26spage%3D1379%26epage%3D1389%26doi%3D10.1002%2Fmds.21475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waters, C.</span></span> <span> </span><span class="NLM_article-title">Catechol-O-methyltransferase (COMT) inhibitors in Parkinson’s disease</span>. <i>J. Am. Geriatr. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1111/j.1532-5415.2000.tb04732.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1111%2Fj.1532-5415.2000.tb04732.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10855610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Sgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2000&pages=692-698&issue=6&author=C.+Waters&title=Catechol-O-methyltransferase+%28COMT%29+inhibitors+in+Parkinson%E2%80%99s+disease&doi=10.1111%2Fj.1532-5415.2000.tb04732.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease</span></div><div class="casAuthors">Waters, Cheryl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Geriatrics Society</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">692-698</span>CODEN:
                <span class="NLM_cas:coden">JAGSAF</span>;
        ISSN:<span class="NLM_cas:issn">0002-8614</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 29 refs.  Catechol-O-methyltransferase (COMT) inhibitors are a new therapeutic option in the treatment of patients with Parkinson's disease.  COMT inhibitors act by extending the duration of action of levodopa, thus improving the amt. of time a patient can experience benefit from levodopa.  COMT inhibitors are only used in conjunction with levodopa.  They do have a propensity to augment dopaminergic effects, such that levodopa doses might need to be adjusted downward.  Other side effects of COMT inhibitors include diarrhea and liver function abnormalities.  Due to the latter, recent guidelines have been developed to monitor patients on tolcapone for this rare side effect, and these guidelines will be discussed.  This article also provides representative case histories for the appropriate use of COMT inhibitors that illustrate how these drugs can be used to manage patients with a fluctuating response to levodopa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jhjugOBhm7Vg90H21EOLACvtfcHk0lgukYoIpJD_HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Sgtb0%253D&md5=c3ccd36f9dc74247306a9d2c773a8e5f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.1532-5415.2000.tb04732.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1532-5415.2000.tb04732.x%26sid%3Dliteratum%253Aachs%26aulast%3DWaters%26aufirst%3DC.%26atitle%3DCatechol-O-methyltransferase%2520%2528COMT%2529%2520inhibitors%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Am.%2520Geriatr.%2520Soc.%26date%3D2000%26volume%3D48%26issue%3D6%26spage%3D692%26epage%3D698%26doi%3D10.1111%2Fj.1532-5415.2000.tb04732.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, T.</span></span> <span> </span><span class="NLM_article-title">Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical-pharmacological aspects</span>. <i>J. Neural Transm (Vienna)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1757</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1876-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1007%2Fs00702-018-1876-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=29569037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BC1MnktV2ntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1751-1757&issue=11&author=P.+Riedererauthor=T.+Muller&title=Monoamine+oxidase-B+inhibitors+in+the+treatment+of+Parkinson%E2%80%99s+disease%3A+clinical-pharmacological+aspects&doi=10.1007%2Fs00702-018-1876-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects</span></div><div class="casAuthors">Riederer Peter; Muller Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission (Vienna, Austria : 1996)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1751-1757</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This invited narrative review emphasizes the role of MAO-B inhibition in the drug portfolio for dopamine substitution in patients with Parkinson's disease.  Neuronal and glial MAO-B inhibition contributes to more stable levels of dopamine and other biogenic amines in the synaptic cleft.  Accordingly, symptomatic effects of MAO-B inhibition for a limited amelioration of impaired motor behaviour and wearing-off phenomena in patients with Parkinson's disease are well proven, even when MAO-B inhibitors are only applied together with dopamine agonists.  Delay of disease progression by MAO-B inhibition is under debate despite positive experimental findings.  This discussion does not consider, that levodopa, respectively, dopamine agonists, are substrates, respectively, inhibitors of the ABCB1 (P-gp, MDR1, and CD243) transporter system.  It supports toxin efflux over the blood-brain barrier.  ABCB1 transporters have a limited capacity.  MAO-B inhibitors do not weaken it.  Treatment with MAO-B inhibitors is advantageous as it enables sparing of dopamine agonist and levodopa dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnpu8LyXFi1OdfST00W0BcfW6udTcc2eYdOkVsz-NmErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnktV2ntA%253D%253D&md5=cbfd1fe236ba9e73e6123e14e76086f9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1876-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1876-2%26sid%3Dliteratum%253Aachs%26aulast%3DRiederer%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DT.%26atitle%3DMonoamine%2520oxidase-B%2520inhibitors%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520clinical-pharmacological%2520aspects%26jtitle%3DJ.%2520Neural%2520Transm%2520%2528Vienna%2529%26date%3D2018%26volume%3D125%26issue%3D11%26spage%3D1751%26epage%3D1757%26doi%3D10.1007%2Fs00702-018-1876-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blandini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armentero, M. T.</span></span> <span> </span><span class="NLM_article-title">Dopamine receptor agonists for Parkinson’s disease</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1517/13543784.2014.869209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1517%2F13543784.2014.869209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=24313341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFymurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=387-410&issue=3&author=F.+Blandiniauthor=M.+T.+Armentero&title=Dopamine+receptor+agonists+for+Parkinson%E2%80%99s+disease&doi=10.1517%2F13543784.2014.869209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptor agonists for Parkinson's disease</span></div><div class="casAuthors">Blandini, Fabio; Armentero, Marie-Therese</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-410</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Prolonged administration of l-3,4-dihydroxyphenylalanine (l-DOPA) for Parkinson's disease (PD) is hampered by motor complications related to the progressive incapacity of residual nigrostriatal neurons to properly utilize the drug.  Direct stimulation of dopaminergic (DAergic) receptors with specific compds. (DA agonists) has, therefore, become an addnl. therapeutic tool for PD.  Areas covered: DA agonists have considerable anti-parkinsonian symptomatic efficacy, although they are less potent thanl-DOPA.  This review summarizes pre-clin. and clin. data on DA agonists and their role in treating PD.  Specific focus was put on second-generation, first-line non-ergolinic DA agonists and their motor, non-motor and putative neuroprotective effects.  The anti-parkinsonian potential of recently developed DA agonists that reached Phase II and III clin. trials was also addressed.  Expert opinion: DA agonists can be useful along the whole natural course of PD, as monotherapy in the initial phase or combined with l-DOPA in advanced PD.  Extended-release formulations have been developed for second-generation DA agonists, which are better appreciated by patients.  Neuroprotective properties have been proposed for DA agonists, based on pre-clin. studies, but never convincingly demonstrated in patients.  New DA agonists, with better symptomatic efficacy and devoid of the side effects that characterize current compds., are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot5J_MehLHQ7Vg90H21EOLACvtfcHk0ljjuA1704kxRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFymurY%253D&md5=0f50189a15c121715786298265c4bb39</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.869209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.869209%26sid%3Dliteratum%253Aachs%26aulast%3DBlandini%26aufirst%3DF.%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26atitle%3DDopamine%2520receptor%2520agonists%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26issue%3D3%26spage%3D387%26epage%3D410%26doi%3D10.1517%2F13543784.2014.869209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A. E.</span></span> <span> </span><span class="NLM_article-title">Pharmacological treatment of Parkinson disease: a review</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>311</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1683</span>, <span class="refDoi"> DOI: 10.1001/jama.2014.3654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1001%2Fjama.2014.3654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=24756517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFems7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2014&pages=1670-1683&issue=16&author=B.+S.+Connollyauthor=A.+E.+Lang&title=Pharmacological+treatment+of+Parkinson+disease%3A+a+review&doi=10.1001%2Fjama.2014.3654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment of Parkinson disease: a review</span></div><div class="casAuthors">Connolly, Barbara S.; Lang, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1670-1683, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">A review.  Importance: Parkinson disease is the second most common neurodegenerative disease worldwide.  Although no available therapies alter the underlying neurodegenerative process, symptomatic therapies can improve patient quality of life.  Objective: To provide an evidence-based review of the initial pharmacol. management of the classic motor symptoms of Parkinson disease; describe management of medication-related motor complications (such as motor fluctuations and dyskinesia), and other medication adverse effects (nausea, psychosis, and impulse control disorders and related behaviors); and discuss the management of selected nonmotor symptoms of Parkinson disease, including rapid eye movement sleep behavior disorder, cognitive impairment, depression, orthostatic hypotension, and sialorrhea.  Evidence Review: Refs. were identified using searches of PubMed between Jan. 1985 and Feb. 2014 for English-language human studies and the full database of the Cochrane Library.  The classification of studies by quality (classes I-IV) was assessed using the levels of evidence guidelines from the American Academy of Neurol. and the highest-quality data for each topic.  Results: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.  Motor fluctuations may be managed by modifying the levodopa dosing regimen or by adding several other medications, such as MAOBIs, catechol-O-methyltransferase inhibitors, or dopamine agonists.  Impulse control disorders are typically managed by reducing or withdrawing dopaminergic medication, particularly dopamine agonists.  Evidence-based management of some nonmotor symptoms is limited by a paucity of high-quality pos. studies.  Conclusions and Relevance: Strong evidence supports using levodopa and dopamine agonists for motor symptoms at all stages of Parkinson disease.  Dopamine agonists and drugs that block dopamine metab. are effective for motor fluctuations and clozapine is effective for hallucinations.  Cholinesterase inhibitors may improve symptoms of dementia and antidepressants and pramipexole may improve depression.  Evidence supporting other therapies for motor and nonmotor features is less well established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq4bHOyyI7XrVg90H21EOLACvtfcHk0ljjuA1704kxRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFems7rP&md5=a3faf879f5febdfc11a8992db89f2e67</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.3654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.3654%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DB.%2BS.%26aulast%3DLang%26aufirst%3DA.%2BE.%26atitle%3DPharmacological%2520treatment%2520of%2520Parkinson%2520disease%253A%2520a%2520review%26jtitle%3DJAMA%26date%3D2014%26volume%3D311%26issue%3D16%26spage%3D1670%26epage%3D1683%26doi%3D10.1001%2Fjama.2014.3654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. H.</span></span> <span> </span><span class="NLM_article-title">Non-dopaminergic treatments for motor control in Parkinson’s disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1405</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0105-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1007%2Fs40265-013-0105-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=23917951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1405-1415&issue=13&author=S.+H.+Fox&title=Non-dopaminergic+treatments+for+motor+control+in+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs40265-013-0105-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Non-dopaminergic Treatments for Motor Control in Parkinson's Disease</span></div><div class="casAuthors">Fox, Susan H.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1405-1415</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The pathol. processes underlying Parkinson's disease (PD) involve more than dopamine cell loss within the midbrain.  These non-dopaminergic neurotransmitters include noradrenergic, serotonergic, glutamatergic, and cholinergic systems within cortical, brainstem and basal ganglia regions.  Several non-dopaminergic treatments are now in clin. use to treat motor symptoms of PD, or are being evaluated as potential therapies.  Agents for symptomatic monotherapy and as adjunct to dopaminergic therapies for motor symptoms include adenosine A2A antagonists and the mixed monoamine-B inhibitor (MAO-BI) and glutamate release agent safinamide.  The largest area of potential use for non-dopaminergic drugs is as add-on therapy for motor fluctuations.  Thus adenosine A2A antagonists, safinamide, and the antiepileptic agent zonisamide can extend the duration of action of levodopa.  To reduce levodopa-induced dyskinesia, drugs that target overactive glutamatergic neurotransmission can be used, and include the non-selective N-Me d-aspartate antagonist amantadine.  More recently, selective metabotropic glutamate receptor (mGluR5) antagonists are being evaluated in phase II randomized controlled trials.  Serotonergic agents acting as 5-HT2A/2C antagonists, such as the atypical antipsychotic clozapine, may also reduce dyskinesia. 5-HT1A agonists theor. can reduce dyskinesia, but in practice, may also worsen PD motor symptoms, and so clin. applicability has not yet been shown.  Noradrenergic α2A antagonism using fipamezole can potentially reduce dyskinesia.  Several non-dopaminergic agents have also been investigated to reduce non-levodopa-responsive motor symptoms such as gait and tremor.  Thus the cholinesterase inhibitor donepezil showed mild benefit in gait, while the predominantly noradrenergic re-uptake inhibitor methylphenidate had conflicting results in advanced PD subjects.  Tremor in PD may respond to muscarinic M4 cholinergic antagonists (anticholinergics), but tolerability is often poor.  Alternatives include β-adrenergic antagonists such as propranolol.  Other options include 5-HT2A antagonists, and drugs that have mixed binding properties involving serotonin and acetylcholine, such as clozapine and the antidepressant mirtazapine, can be effective in reducing PD tremor.  Many other non-dopaminergic agents are in preclin. and phase I/II early stages of study, and the reader is directed to recent reviews.  While levodopa remains the most effective agent to treat motor symptoms in PD, the overall approach to using non-dopaminergic drugs in PD is to reduce reliance on levodopa and to target non-levodopa-responsive symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgKWj-lWItNbVg90H21EOLACvtfcHk0ljjuA1704kxRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurvK&md5=cb174b0eaa0565fe1f9803e288bc1500</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0105-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0105-4%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DS.%2BH.%26atitle%3DNon-dopaminergic%2520treatments%2520for%2520motor%2520control%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26issue%3D13%26spage%3D1405%26epage%3D1415%26doi%3D10.1007%2Fs40265-013-0105-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahoo, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span> <span> </span><span class="NLM_article-title">Istradefylline: a novel drug for ‘off’ episodes in Parkinson’s disease</span>. <i>Drugs & Therapy Perspectives</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1007/s40267-020-00718-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1007%2Fs40267-020-00718-w" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2020&pages=208-212&author=A.+K.+Sahooauthor=D.+Guptaauthor=A.+Singh&title=Istradefylline%3A+a+novel+drug+for+%E2%80%98off%E2%80%99+episodes+in+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs40267-020-00718-w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs40267-020-00718-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40267-020-00718-w%26sid%3Dliteratum%253Aachs%26aulast%3DSahoo%26aufirst%3DA.%2BK.%26aulast%3DGupta%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DA.%26atitle%3DIstradefylline%253A%2520a%2520novel%2520drug%2520for%2520%25E2%2580%2598off%25E2%2580%2599%2520episodes%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%2520%2526%2520Therapy%2520Perspectives%26date%3D2020%26volume%3D36%26spage%3D208%26epage%3D212%26doi%3D10.1007%2Fs40267-020-00718-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deuschl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agid, Y.</span></span> <span> </span><span class="NLM_article-title">Subthalamic neurostimulation for Parkinson’s disease with early fluctuations: balancing the risks and benefits</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1025</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(13)70151-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2FS1474-4422%2813%2970151-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=24050735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BC3sbpvVCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1025-1034&issue=10&author=G.+Deuschlauthor=Y.+Agid&title=Subthalamic+neurostimulation+for+Parkinson%E2%80%99s+disease+with+early+fluctuations%3A+balancing+the+risks+and+benefits&doi=10.1016%2FS1474-4422%2813%2970151-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits</span></div><div class="casAuthors">Deuschl Gunther; Agid Yves</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1025-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Electrical stimulation of the subthalamic nucleus is an established treatment for patients with advanced Parkinson's disease with pharmacologically unresponsive fluctuations.  Compared with pharmacological treatment, subthalamic neurostimulation significantly improves motor symptoms, particularly during the phases of poor response to drug treatment, and reduces the severity of dyskinesias.  Importantly, it also significantly improves quality of life and other integral measures of disease severity.  The treatment response can last for more than 10 years, although there is no evidence that levodopa-resistant symptoms are delayed by subthalamic neurostimulation.  At present, the mean disease duration for patients at the time of implantation is 12 years.  In a recent study (EARLYSTIM) in patients with a disease duration of 7·5 years and fluctuations for 1·5 years, similar improvements in clinical outcomes were reported.  These findings suggest that neurostimulation of the subthalamic nucleus could be used earlier in the disease course for carefully selected patients if the benefits of the treatment are weighed against the surgical risks and the lifelong need for specialised care by an experienced team.  As mobility is consistently improved during the times with poor mobility by reducing fluctuations and delaying levodopa-sensitive complications, we propose that this treatment changes the disease course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6Pfmykbu9PWK_SFaaT9INfW6udTcc2eZhVEW4Cxjjmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbpvVCqtw%253D%253D&md5=22059826fe4311e5e8de9587ffc4a180</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2813%2970151-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252813%252970151-0%26sid%3Dliteratum%253Aachs%26aulast%3DDeuschl%26aufirst%3DG.%26aulast%3DAgid%26aufirst%3DY.%26atitle%3DSubthalamic%2520neurostimulation%2520for%2520Parkinson%25E2%2580%2599s%2520disease%2520with%2520early%2520fluctuations%253A%2520balancing%2520the%2520risks%2520and%2520benefits%26jtitle%3DLancet%2520Neurol.%26date%3D2013%26volume%3D12%26issue%3D10%26spage%3D1025%26epage%3D1034%26doi%3D10.1016%2FS1474-4422%2813%2970151-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uhlenbrock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gassenhuber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1016/S0898-6568(02)00041-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2FS0898-6568%2802%2900041-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=12220620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvVCku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2002&pages=941-953&issue=11&author=K.+Uhlenbrockauthor=H.+Gassenhuberauthor=E.+Kostenis&title=Sphingosine+1-phosphate+is+a+ligand+of+the+human+gpr3%2C+gpr6+and+gpr12+family+of+constitutively+active+G+protein-coupled+receptors&doi=10.1016%2FS0898-6568%2802%2900041-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors</span></div><div class="casAuthors">Uhlenbrock, Kirsten; Gassenhuber, Hans; Kostenis, Evi</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">941-953</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Five G protein-coupled receptors (GPCRs) for the lysophospholipid sphingosine 1-phosphate (S1P) have been cloned and characterized so far.  We report here about the identification of gpr3, gpr6 and gpr12 as addnl. members of the S1P-GPCR family.  When expressed transiently in HEK293 cells, gpr3, gpr6 and gpr12 confer constitutive activation of adenylate cyclase (AC) similar in amplitude to that seen with fully activated Gαs-coupled receptors.  Culturing the transfected cells in medium with charcoal-stripped serum (devoid of lipids) significantly reduces cyclic adenosine monophosphate (cAMP) levels, suggesting a lipid-like ligand.  A library contg. 200 bioactive lipids was applied in functional assays recording intracellular Ca2+ mobilization.  S1P and dihydrosphingosine 1-phosphate (DHS1P) were identified as functional activators exhibiting nanomolar EC50 values.  In the presence of the S1P and LPA receptor antagonist suramin, gpr3-, gpr6- and gpr12-mediated intracellular Ca2+ mobilization via S1P is enhanced.  Besides constitutive activation of Gαs type of G proteins, all three receptors are capable of constitutively activating inhibitory Gαi/o proteins: (i) in the presence of pertussis toxin, gpr3-, gpr6- and gpr12-mediated stimulation of AC is enhanced; and (ii) overexpression of Gαi significantly reduces the stimulatory action on intracellular cAMP levels.  Agonist (S1P)-mediated internalization can be visualized in intact HEK293 cells using a gpr6 green fluorescent protein (GFP) fusion protein.  In summary, our data suggest that gpr3, gpr6 and gpr12 are a family of constitutively active receptors with dual coupling to Gαs and Gαi type of G proteins.  Constitutive activation of AC and mobilization of [Ca2+]i can be modulated by the sphingophospholipids S1P and DHS1P, adding three addnl. members to the family of S1P receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzCtPQR1FNB7Vg90H21EOLACvtfcHk0lj-QyxABPGPgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvVCku7w%253D&md5=df3874623040fcee0239858dd1ba22fb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0898-6568%2802%2900041-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0898-6568%252802%252900041-4%26sid%3Dliteratum%253Aachs%26aulast%3DUhlenbrock%26aufirst%3DK.%26aulast%3DGassenhuber%26aufirst%3DH.%26aulast%3DKostenis%26aufirst%3DE.%26atitle%3DSphingosine%25201-phosphate%2520is%2520a%2520ligand%2520of%2520the%2520human%2520gpr3%252C%2520gpr6%2520and%2520gpr12%2520family%2520of%2520constitutively%2520active%2520G%2520protein-coupled%2520receptors%26jtitle%3DCell.%2520Signalling%26date%3D2002%26volume%3D14%26issue%3D11%26spage%3D941%26epage%3D953%26doi%3D10.1016%2FS0898-6568%2802%2900041-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ignatov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lintzel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreienkamp, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, H. C.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular Ca2+ release by activating the sphingosine-kinase pathway</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>311</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2003.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2Fj.bbrc.2003.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=14592418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFSntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2003&pages=329-336&issue=2&author=A.+Ignatovauthor=J.+Lintzelauthor=H.+J.+Kreienkampauthor=H.+C.+Schaller&title=Sphingosine-1-phosphate+is+a+high-affinity+ligand+for+the+G+protein-coupled+receptor+GPR6+from+mouse+and+induces+intracellular+Ca2%2B+release+by+activating+the+sphingosine-kinase+pathway&doi=10.1016%2Fj.bbrc.2003.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular Ca2+ release by activating the sphingosine-kinase pathway</span></div><div class="casAuthors">Ignatov, Atanas; Lintzel, Julia; Kreienkamp, Hans-Juergen; Schaller, H. Chica</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">We identified and cloned the mouse ortholog of human GPR6 as a new member of the lysophospholipid-receptor family.  Sphingosine-1-phosphate (S1P) activated GPR6, transiently expressed in frog oocytes or in Chinese hamster ovary (CHO) cells, with high specificity and nanomolar affinity.  The GPR6 gene was found to be located on chromosome 10B1 and a single exon coded for the entire open-reading frame.  Signal transduction of S1P was inhibited by pertussis toxin, suggesting a coupling of GPR6 to an inhibitory G protein.  In CHO cells transfected with GPR6, the sphingosine-kinase pathway mediated Ca2+ mobilization from internal stores.  Apoptotic cell death was induced by serum deprivation or H2O2 treatment and was prevented by S1P in GPR6-, but not in vector-transfected CHO cells.  The antiapoptotic effect of S1P required activation of sphingosine kinase and was accompanied by an increase in MAP-kinase phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiEQm99d_1W7Vg90H21EOLACvtfcHk0lh_c4C6R1eu0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFSntL8%253D&md5=c6a2bae377401b1cad2c99c177b5b66c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2003.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2003.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DIgnatov%26aufirst%3DA.%26aulast%3DLintzel%26aufirst%3DJ.%26aulast%3DKreienkamp%26aufirst%3DH.%2BJ.%26aulast%3DSchaller%26aufirst%3DH.%2BC.%26atitle%3DSphingosine-1-phosphate%2520is%2520a%2520high-affinity%2520ligand%2520for%2520the%2520G%2520protein-coupled%2520receptor%2520GPR6%2520from%2520mouse%2520and%2520induces%2520intracellular%2520Ca2%252B%2520release%2520by%2520activating%2520the%2520sphingosine-kinase%2520pathway%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D311%26issue%3D2%26spage%3D329%26epage%3D336%26doi%3D10.1016%2Fj.bbrc.2003.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronstam, R. S.</span></span> <span> </span><span class="NLM_article-title">Constitutive Activity among Orphan Class-A G Protein Coupled Receptors</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>), <span class="NLM_elocation-id">e0138463</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0138463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1371%2Fjournal.pone.0138463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=26384023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&issue=9&author=A.+L.+Martinauthor=M.+A.+Steurerauthor=R.+S.+Aronstam&title=Constitutive+Activity+among+Orphan+Class-A+G+Protein+Coupled+Receptors&doi=10.1371%2Fjournal.pone.0138463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activity among orphan class-A G protein coupled receptors</span></div><div class="casAuthors">Martin, Adam L.; Steurer, Michael A.; Aronstam, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0138463/1-e0138463/12</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The purpose of this study was to evaluate the extent of constitutive activity among orphan class-A G protein coupled receptors within the cAMP signaling pathway.  Constitutive signaling was revealed by changes in gene expression under control of the cAMP response element.  Gene expression was measured in Chinese hamster ovary cells transiently cotransfected with plasmids contg. a luciferase reporter and orphan receptor.  Criteria adopted for defining constitutive activation were: (1) 200% elevation over baseline reporter gene expression; (2) 40% inhibition of baseline expression; and (3) 40% inhibition of expression stimulated by 3 μM forskolin.  Five patterns of activity were noted: (1) inhibition under both baseline and forskolin stimulated expression (GPR15, GPR17, GPR18, GPR20, GPR25, GPR27, GPR31, GPR32, GPR45, GPR57, GPR68, GPR83, GPR84, GPR132, GPR150, GPR176); (2) no effect on baseline expression, but inhibition of forskolin stimulated expression (GPR4, GPR26, GPR61, GPR62, GPR78, GPR101, GPR119); (3) elevation of baseline signaling coupled with inhibition of forskolin stimulated expression (GPR6, GPR12); (4) elevation of baseline signaling without inhibition of forskolin stimulated expression (GPR3, GPR21, GPR52, GPR65); and (5) no effect on expression (GPR1, GPR19, GPR22, GPR34, GPR35, GPR39, GPR63, GPR82, GPR85, GPR87).  Constitutive activity was obsd. in 75% of the orphan class-A receptors examd. (30 of 40).  This constitutive signaling cannot be explained by simple overexpression of the receptor.  Inhibition of cAMP mediated expression was far more common (65%) than stimulation of expression (15%).  Orphan receptors that were closely related based on amino acid homol. tended to have similar effects on gene expression.  These results suggest that identification of inverse agonists may be a fruitful approach for categorizing these orphan receptors and targeting them for pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAzoFrN1fJO7Vg90H21EOLACvtfcHk0lh_c4C6R1eu0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFCjtw%253D%253D&md5=94482d03b35bec1f4c2967b8d88d5ef0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0138463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0138463%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DA.%2BL.%26aulast%3DSteurer%26aufirst%3DM.%2BA.%26aulast%3DAronstam%26aufirst%3DR.%2BS.%26atitle%3DConstitutive%2520Activity%2520among%2520Orphan%2520Class-A%2520G%2520Protein%2520Coupled%2520Receptors%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D9%26doi%3D10.1371%2Fjournal.pone.0138463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heiman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bupp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doughty, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heintz, N.</span></span> <span> </span><span class="NLM_article-title">Application of a translational profiling approach for the comparative analysis of CNS cell types</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>135</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2008.10.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2Fj.cell.2008.10.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=19013282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCls7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2008&pages=749-762&issue=4&author=J.+P.+Doyleauthor=J.+D.+Doughertyauthor=M.+Heimanauthor=E.+F.+Schmidtauthor=T.+R.+Stevensauthor=G.+Maauthor=S.+Buppauthor=P.+Shresthaauthor=R.+D.+Shahauthor=M.+L.+Doughtyauthor=S.+Gongauthor=P.+Greengardauthor=N.+Heintz&title=Application+of+a+translational+profiling+approach+for+the+comparative+analysis+of+CNS+cell+types&doi=10.1016%2Fj.cell.2008.10.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Application of a translational profiling approach for the comparative analysis of CNS cell types</span></div><div class="casAuthors">Doyle, Joseph P.; Dougherty, Joseph D.; Heiman, Myriam; Schmidt, Eric F.; Stevens, Tanya R.; Ma, Guojun; Bupp, Sujata; Shrestha, Prerana; Shah, Rajiv D.; Doughty, Martin L.; Gong, Shiaoching; Greengard, Paul; Heintz, Nathaniel</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">749-762</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Comparative anal. can provide important insights into complex biol. systems.  As demonstrated in the accompanying paper (Heiman, M., et al., ibid. 738-748), translating ribosome affinity purifn. (TRAP) permits comprehensive studies of translated mRNAs in genetically defined cell populations after physiol. perturbations.  To establish the generality of this approach, the authors present translational profiles for 24 CNS cell populations and identify known cell-specific and enriched transcripts for each population.  The authors report thousands of cell-specific mRNAs that were not detected in whole-tissue microarray studies and provide examples that demonstrate the benefits deriving from comparative anal.  To provide a foundation for further biol. and in silico studies, the authors provide a resource of 16 transgenic mouse lines, their corresponding anat. characterization, and translational profiles for cell types from a variety of central nervous system structures.  This resource will enable a wide spectrum of mol. and mechanistic studies of both well-known and previously uncharacterized neural cell populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyQelg8GOu0rVg90H21EOLACvtfcHk0lgdfVRJj7qdiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCls7vL&md5=8293abc5461aec91c516d58af5496803</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.10.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.10.029%26sid%3Dliteratum%253Aachs%26aulast%3DDoyle%26aufirst%3DJ.%2BP.%26aulast%3DDougherty%26aufirst%3DJ.%2BD.%26aulast%3DHeiman%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DE.%2BF.%26aulast%3DStevens%26aufirst%3DT.%2BR.%26aulast%3DMa%26aufirst%3DG.%26aulast%3DBupp%26aufirst%3DS.%26aulast%3DShrestha%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DR.%2BD.%26aulast%3DDoughty%26aufirst%3DM.%2BL.%26aulast%3DGong%26aufirst%3DS.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DHeintz%26aufirst%3DN.%26atitle%3DApplication%2520of%2520a%2520translational%2520profiling%2520approach%2520for%2520the%2520comparative%2520analysis%2520of%2520CNS%2520cell%2520types%26jtitle%3DCell%26date%3D2008%26volume%3D135%26issue%3D4%26spage%3D749%26epage%3D762%26doi%3D10.1016%2Fj.cell.2008.10.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostlund, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balleine, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. W.</span></span> <span> </span><span class="NLM_article-title">Genetic control of instrumental conditioning by striatopallidal neuron-specific S1P receptor Gpr6</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1395</span>– <span class="NLM_lpage">1397</span>, <span class="refDoi"> DOI: 10.1038/nn1987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1038%2Fnn1987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=17934457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ajtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=1395-1397&issue=11&author=M.+K.+Loboauthor=Y.+Cuiauthor=S.+B.+Ostlundauthor=B.+W.+Balleineauthor=X.+W.+Yang&title=Genetic+control+of+instrumental+conditioning+by+striatopallidal+neuron-specific+S1P+receptor+Gpr6&doi=10.1038%2Fnn1987"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic control of instrumental conditioning by striatopallidal neuron-specific S1P receptor Gpr6</span></div><div class="casAuthors">Lobo, Mary Kay; Cui, Yijun; Ostlund, Sean B.; Balleine, Bernard W.; Yang, X. William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1395-1397</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Instrumental conditioning allows animals to learn about the consequences of their own actions, but the underpinning mol. mechanisms remain elusive.  Here, we show that the sphingosine-1-phosphate (S1P) receptor Gpr6 is selectively expressed in the striatopallidal neurons in the striatum.  Gpr6-deficient mice showed reduced striatal cAMP prodn. in vitro and selective alterations in instrumental conditioning in vivo.  Thus, Gpr6 is the first striatopallidal neuron-specific genetic regulator of instrumental conditioning in a mammal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocnUk4GBkOirVg90H21EOLACvtfcHk0lgdfVRJj7qdiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ajtr7L&md5=d75a9d6b12200e10d610c924d4357cb7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnn1987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1987%26sid%3Dliteratum%253Aachs%26aulast%3DLobo%26aufirst%3DM.%2BK.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DOstlund%26aufirst%3DS.%2BB.%26aulast%3DBalleine%26aufirst%3DB.%2BW.%26aulast%3DYang%26aufirst%3DX.%2BW.%26atitle%3DGenetic%2520control%2520of%2520instrumental%2520conditioning%2520by%2520striatopallidal%2520neuron-specific%2520S1P%2520receptor%2520Gpr6%26jtitle%3DNat.%2520Neurosci.%26date%3D2007%26volume%3D10%26issue%3D11%26spage%3D1395%26epage%3D1397%26doi%3D10.1038%2Fnn1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oeckl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengerer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferger, B.</span></span> <span> </span><span class="NLM_article-title">G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson’s disease</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2014.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2Fj.expneurol.2014.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=24747358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=2014&pages=1-9&author=P.+Oecklauthor=B.+Hengererauthor=B.+Ferger&title=G-protein+coupled+receptor+6+deficiency+alters+striatal+dopamine+and+cAMP+concentrations+and+reduces+dyskinesia+in+a+mouse+model+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.expneurol.2014.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease</span></div><div class="casAuthors">Oeckl, Patrick; Hengerer, Bastian; Ferger, Boris</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The orphan G-protein coupled receptor 6 (GPR6) is a constitutively active receptor which is pos. coupled to the formation of cyclic adenosine-3',5'-monophosphate (cAMP).  GPR6 is predominantly expressed in striatopallidal neurons.  Here, we investigated neurochem. and behavioral effects of Gpr6 deficiency in mice.  Gpr6 depletion decreased in vivo cAMP tissue concns. (20%) in the striatum.  An increase of striatal tissue dopamine concns. (10%) was found in Gpr6-/- mice, whereas basal extracellular dopamine levels were not changed compared with Gpr6+/+ mice, as shown by in vivo microdialysis.  Western blot analyses revealed no alteration in the expression and subcellular localization of the dopamine D2 receptor in the striatum of Gpr6-/- mice, and the no. of tyrosine hydroxylase pos. neurons in the substantia nigra was unchanged.  DARPP-32 (dopamine and cAMP-regulated phosphoprotein of 32 kDa) expression in the striatum of Gpr6-/- mice was not altered, however, a twofold increase in the phosphorylation of DARPP-32 at Thr34 was detected in Gpr6-/- compared with Gpr6+/+ mice.  Gpr6-/- mice showed higher locomotor activity in the open field, which persisted after treatment with the dopamine D2 receptor antagonist haloperidol.  They also displayed reduced abnormal involuntary movements after apomorphine and quinpirole treatment in the mouse dyskinesia model of Parkinson's disease.  In conclusion, the depletion of Gpr6 reduces cAMP concns. in the striatum and alters the striatal dopaminergic system.  Gpr6 deficiency causes an interesting behavioral phenotype in the form of enhanced motor activity combined with reduced abnormal involuntary movements.  These findings could offer an opportunity for the treatment of Parkinson's disease beyond dopamine replacement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzy8OHbJ-worVg90H21EOLACvtfcHk0lgdfVRJj7qdiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemur7O&md5=cb72b4c9546dee4ae3399558995c8b61</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2014.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2014.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DOeckl%26aufirst%3DP.%26aulast%3DHengerer%26aufirst%3DB.%26aulast%3DFerger%26aufirst%3DB.%26atitle%3DG-protein%2520coupled%2520receptor%25206%2520deficiency%2520alters%2520striatal%2520dopamine%2520and%2520cAMP%2520concentrations%2520and%2520reduces%2520dyskinesia%2520in%2520a%2520mouse%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExp.%2520Neurol.%26date%3D2014%26volume%3D257%26spage%3D1%26epage%3D9%26doi%3D10.1016%2Fj.expneurol.2014.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinoza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span> <span> </span><span class="NLM_article-title">Dopamine receptors - IUPHAR Review 13</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1111/bph.12906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1111%2Fbph.12906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=25671228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1-23&issue=1&author=J.+M.+Beaulieuauthor=S.+Espinozaauthor=R.+R.+Gainetdinov&title=Dopamine+receptors+-+IUPHAR+Review+13&doi=10.1111%2Fbph.12906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptors - IUPHAR Review 13</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Espinoza, Stefano; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-23</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The variety of physiol. functions controlled by dopamine in the brain and periphery is mediated by the D1, D2, D3, D4 and D5 dopamine GPCRs.  Drugs acting on dopamine receptors are significant tools for the management of several neuropsychiatric disorders including schizophrenia, bipolar disorder, depression and Parkinson's disease.  Recent investigations of dopamine receptor signalling have shown that dopamine receptors, apart from their canonical action on cAMP-mediated signalling, can regulate a myriad of cellular responses to fine-tune the expression of dopamine-assocd. behaviors and functions.  Such signalling mechanisms may involve alternate G protein coupling or non-G protein mechanisms involving ion channels, receptor tyrosine kinases or proteins such as β-arrestins that are classically involved in GPCR desensitization.  Another level of complexity is the growing appreciation of the physiol. roles played by dopamine receptor heteromers.  Applications of new in vivo techniques have significantly furthered the understanding of the physiol. functions played by dopamine receptors.  Here we provide an update of the current knowledge regarding the complex biol., signalling, physiol. and pharmacol. of dopamine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1fpdKAWrR5rVg90H21EOLACvtfcHk0lj8Z4W3StIjtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ&md5=7f15533abc8fb6aa76a4ec41072b6219</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fbph.12906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12906%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DEspinoza%26aufirst%3DS.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DDopamine%2520receptors%2520-%2520IUPHAR%2520Review%252013%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26issue%3D1%26spage%3D1%26epage%3D23%26doi%3D10.1111%2Fbph.12906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quik, M.</span></span> <span> </span><span class="NLM_article-title">Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1002/mds.26955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1002%2Fmds.26955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=28256010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt12rsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=538-548&issue=4&author=X.+A.+Perezauthor=D.+Zhangauthor=T.+Bordiaauthor=M.+Quik&title=Striatal+D1+medium+spiny+neuron+activation+induces+dyskinesias+in+parkinsonian+mice&doi=10.1002%2Fmds.26955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice</span></div><div class="casAuthors">Perez, Xiomara A.; Zhang, Danhui; Bordia, Tanuja; Quik, Maryka</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">538-548</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Dyskinesias are a disabling motor complication that arises with prolonged L-dopa treatment.  Studies using D1 receptor drugs and genetically modified mice suggest that medium spiny neurons expressing D1 receptors play a primary role in L-dopa-induced dyskinesias.  However, the specific role of these neurons in dyskinesias is not fully understood.  Methods : We used optogenetics, which allows for precise modulation of select neurons in vivo, to investigate whether striatal D1-expressing medium spiny neuron activity regulates abnormal involuntary movements or dyskinesia in parkinsonian mice.  D1-cre mice unilaterally lesioned with 6-hydroxydopamine received striatal injections of cre-dependent channelrhodopsin2 virus or control virus.  After stable virus expression, the effect of optical stimulation on dyskinesia was tested in L-dopa-naive and L-dopa-primed mice.  Results : Single-pulse and burst-optical stimulation of D1-expressing medium spiny neurons induced dyskinesias in L-dopa-naive channelrhodopsin2 mice.  In stably dyskinetic mice, L-dopa injection induced dyskinesia to a similar or somewhat greater extent than optical stimulation.  Combined L-dopa administration and stimulation resulted in an additive increase in dyskinesias, indicating that other mechanisms also contribute.  Mol. studies indicate that changes in extracellular signal-regulated kinase phosphorylation in D1-expressing medium spiny neurons are involved.  Optical stimulation did not ameliorate parkinsonism in L-dopa-naive mice.  However, it improved parkinsonism in L-dopa-primed mice to a similar extent as L-dopa administration.  None of the stimulation paradigms enhanced dyskinesia or modified parkinsonism in L-dopa-naive or L-dopa-primed control virus mice.  Conclusion : The data provide direct evidence that striatal D1-expressing medium spiny neuron stimulation is sufficient to induce dyskinesias and contributes to the regulation of motor control. © 2017 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9M6dsbCKup7Vg90H21EOLACvtfcHk0lj8Z4W3StIjtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt12rsbg%253D&md5=052babde146b4c9d33bd951e103af5d2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fmds.26955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.26955%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DX.%2BA.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DBordia%26aufirst%3DT.%26aulast%3DQuik%26aufirst%3DM.%26atitle%3DStriatal%2520D1%2520medium%2520spiny%2520neuron%2520activation%2520induces%2520dyskinesias%2520in%2520parkinsonian%2520mice%26jtitle%3DMov.%2520Disord.%26date%3D2017%26volume%3D32%26issue%3D4%26spage%3D538%26epage%3D548%26doi%3D10.1002%2Fmds.26955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, M. A.</span></span> <span> </span><span class="NLM_article-title">Presynaptic Mechanisms of <span class="smallcaps smallerCapital">l</span>-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications</span>. <i>Front Neurol</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">242</span>, <span class="refDoi"> DOI: 10.3389/fneur.2014.00242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.3389%2Ffneur.2014.00242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=25566170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BC2MvksVyqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=242&author=M.+A.+Cenci&title=Presynaptic+Mechanisms+of+l-DOPA-Induced+Dyskinesia%3A+The+Findings%2C+the+Debate%2C+and+the+Therapeutic+Implications&doi=10.3389%2Ffneur.2014.00242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications</span></div><div class="casAuthors">Cenci M Angela</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">242</span>
        ISSN:<span class="NLM_cas:issn">1664-2295</span>.
    </div><div class="casAbstract">The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson's disease (PD) for over 40 years.  However, the response to this treatment changes with disease progression, and most patients develop dyskinesias (abnormal involuntary movements) and motor fluctuations within a few years of l-DOPA therapy.  There is wide consensus that these motor complications depend on both pre- and post-synaptic disturbances of nigrostriatal DA transmission.  Several presynaptic mechanisms converge to generate large DA swings in the brain concomitant with the peaks-and-troughs of plasma l-DOPA levels, while post-synaptic changes engender abnormal functional responses in dopaminoceptive neurons.  While this general picture is well-accepted, the relative contribution of different factors remains a matter of debate.  A particularly animated debate has been growing around putative players on the presynaptic side of the cascade.  To what extent do presynaptic disturbances in DA transmission depend on deficiency/dysfunction of the DA transporter, aberrant release of DA from serotonin neurons, or gliovascular mechanisms? And does noradrenaline (which is synthetized from DA) play a role? This review article will summarize key findings, controversies, and pending questions regarding the presynaptic mechanisms of l-DOPA-induced dyskinesia.  Intriguingly, the debate around these mechanisms has spurred research into previously unexplored facets of brain plasticity that have far-reaching implications to the treatment of neuropsychiatric disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTh-dX8oZYnsM25P7XSLhESfW6udTcc2eYNTqS0vVNe1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvksVyqsQ%253D%253D&md5=48e8771d387e7d57b350867494e8c42e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2014.00242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2014.00242%26sid%3Dliteratum%253Aachs%26aulast%3DCenci%26aufirst%3DM.%2BA.%26atitle%3DPresynaptic%2520Mechanisms%2520of%2520l-DOPA-Induced%2520Dyskinesia%253A%2520The%2520Findings%252C%2520the%2520Debate%252C%2520and%2520the%2520Therapeutic%2520Implications%26jtitle%3DFront%2520Neurol%26date%3D2014%26volume%3D5%26spage%3D242%26doi%3D10.3389%2Ffneur.2014.00242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2091</span>– <span class="NLM_lpage">2113</span>, <span class="refDoi"> DOI: 10.1021/jm5019093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2091-2113&issue=5&author=J.+L.+Dahlinauthor=J.+W.+Nissinkauthor=J.+M.+Strasserauthor=S.+Francisauthor=L.+Higginsauthor=H.+Zhouauthor=Z.+Zhangauthor=M.+A.+Walters&title=PAINS+in+the+assay%3A+chemical+mechanisms+of+assay+interference+and+promiscuous+enzymatic+inhibition+observed+during+a+sulfhydryl-scavenging+HTS.&doi=10.1021%2Fjm5019093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span></div><div class="casAuthors">Dahlin, Jayme L.; Nissink, J. Willem M.; Strasser, Jessica M.; Francis, Subhashree; Higgins, LeeAnn; Zhou, Hui; Zhang, Zhiguo; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2091-2113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant resources in early drug discovery are spent unknowingly pursuing artifacts and promiscuous bioactive compds., while understanding the chem. basis for these adverse behaviors often goes unexplored in pursuit of lead compds.  Nearly all the hits from our recent sulfhydryl-scavenging high-throughput screen (HTS) targeting the histone acetyltransferase Rtt109 were such compds.  Herein, we characterize the chem. basis for assay interference and promiscuous enzymic inhibition for several prominent chemotypes identified by this HTS, including some pan-assay interference compds. (PAINS).  Protein mass spectrometry and ALARM NMR confirmed these compds. react covalently with cysteines on multiple proteins.  Unfortunately, compds. contg. these chemotypes have been published as screening actives in reputable journals and even touted as chem. probes or preclin. candidates.  Our detailed characterization and identification of such thiol-reactive chemotypes should accelerate triage of nuisance compds., guide screening library design, and prevent follow-up on undesirable chem. matter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4XTJapoezkrVg90H21EOLACvtfcHk0limrDt9m2KFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D&md5=3f77702544cea2ec4c8184b60dd38b8a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm5019093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019093%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%26aulast%3DStrasser%26aufirst%3DJ.%2BM.%26aulast%3DFrancis%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DPAINS%2520in%2520the%2520assay%253A%2520chemical%2520mechanisms%2520of%2520assay%2520interference%2520and%2520promiscuous%2520enzymatic%2520inhibition%2520observed%2520during%2520a%2520sulfhydryl-scavenging%2520HTS.%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D5%26spage%3D2091%26epage%3D2113%26doi%3D10.1021%2Fjm5019093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R.</span></span> <span> </span><span class="NLM_article-title">Time-dependent CYP inhibition</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1517/17425255.3.1.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1517%2F17425255.3.1.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=17269894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=51-66&issue=1&author=R.+J.+Rileyauthor=K.+Grimeauthor=R.+Weaver&title=Time-dependent+CYP+inhibition&doi=10.1517%2F17425255.3.1.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Time-dependent CYP inhibition</span></div><div class="casAuthors">Riley, Robert J.; Grime, Ken; Weaver, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-66</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Time-dependent inhibition (TDI) of CYP refers to a change in potency during an in vitro incubation or dosing period in vivo.  Potential mechanisms include the formation of inhibitory metabolites and mechanism-based inhibition (MBI).  In vitro expts. are configured to assess TDI and MBI is inferred, at least initially.  MBI is more profound after multiple-dosing and the recovery period is independent of continued drug exposure.  Advances in in vitro-in vivo extrapolations for competitive inhibition and the potential relationship between MBI and reactive metabolite-mediated toxicity, have redirected emphasis to CYP TDI.  In contrast, with reversible inhibition, strategies for projecting the risks from TDI are less developed and the traditional I/Ki model often yields a dramatic underprediction.  This review explores the contribution of TDI to drug-drug interactions and idiosyncratic drug toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY8w1eAZ9QULVg90H21EOLACvtfcHk0limrDt9m2KFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGlurY%253D&md5=184636ac0768f51d65f407a0655233e4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F17425255.3.1.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.3.1.51%26sid%3Dliteratum%253Aachs%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26aulast%3DGrime%26aufirst%3DK.%26aulast%3DWeaver%26aufirst%3DR.%26atitle%3DTime-dependent%2520CYP%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2007%26volume%3D3%26issue%3D1%26spage%3D51%26epage%3D66%26doi%3D10.1517%2F17425255.3.1.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zirvi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">burka, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guengerich, F. P.</span></span> <span> </span><span class="NLM_article-title">Mechanism of cytochrome P450 inhibition by cyclopropylamines</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">2050</span>– <span class="NLM_lpage">2052</span>, <span class="refDoi"> DOI: 10.1021/ja00371a056</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00371a056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADyaL38Xhtlykt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1982&pages=2050-2052&author=T.+L.+Macdonaldauthor=K.+Zirviauthor=L.+T.+burkaauthor=P.+Peymanauthor=F.+P.+Guengerich&title=Mechanism+of+cytochrome+P450+inhibition+by+cyclopropylamines&doi=10.1021%2Fja00371a056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of cytochrome P-450 inhibition by cyclopropylamines</span></div><div class="casAuthors">Macdonald, Timothy L.; Zirvi, Karimullah; Burka, Leo T.; Peyman, Pamela; Guengerich, F. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2050-2</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The cytochrome P-450 monooxygenases are subject to mechanism-based or suicide inhibition by numerous substrates as a function of the metab. of uniquely positioned olefinic, acetylenic, or cyclopropyl amine moieties.  Cyclopropylamines are also suicide inhibitors of mitochondrial monoamine oxidase and of plasma amine oxidase.  The mechanism-based inhibition of these distinct enzyme classes by cyclopropylamines has been postulated to be a consequence of α-hydroxylation to form a cyclopropylcarbinolamine, which reacts with enzyme-bound nucleophiles via a highly reactive iminium ion.  Apparently, an alternative mechanism, postulated to involve initial amine N oxidn. to a radical cation, is operative for the suicide inactivation of cytochrome P-450 by cyclopropylamines.  The inhibition of benzphetamine and aminopyrine N-demethylases was examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojGZ5OOi00QLVg90H21EOLACvtfcHk0limrDt9m2KFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xhtlykt70%253D&md5=5b6d5069752bf9ebd3f59fe3963329af</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fja00371a056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00371a056%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26aulast%3DZirvi%26aufirst%3DK.%26aulast%3Dburka%26aufirst%3DL.%2BT.%26aulast%3DPeyman%26aufirst%3DP.%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DMechanism%2520of%2520cytochrome%2520P450%2520inhibition%2520by%2520cyclopropylamines%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1982%26volume%3D104%26spage%3D2050%26epage%3D2052%26doi%3D10.1021%2Fja00371a056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alavi, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamsizadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azhdari-Zarmehri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roohbakhsh, A.</span></span> <span> </span><span class="NLM_article-title">Orphan G protein-coupled receptors: The role in CNS disorders</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2017.12.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2Fj.biopha.2017.12.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=29268243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVelur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2018&pages=222-232&author=M.+S.+Alaviauthor=A.+Shamsizadehauthor=H.+Azhdari-Zarmehriauthor=A.+Roohbakhsh&title=Orphan+G+protein-coupled+receptors%3A+The+role+in+CNS+disorders&doi=10.1016%2Fj.biopha.2017.12.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Orphan G protein-coupled receptors: The role in CNS disorders</span></div><div class="casAuthors">Alavi, Mohaddeseh Sadat; Shamsizadeh, Ali; Azhdari-Zarmehri, Hassan; Roohbakhsh, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">222-232</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">There are various types of receptors in the central nervous system (CNS).  G protein-coupled receptors (GPCRs) have the highest expression with a wide range of physiol. functions.  A newer sub group of these receptors namely orphan GPCRs have been discovered.  GPR3, GPR6, GPR17, GPR26, GPR37, GPR39, GPR40, GPR50, GPR52, GPR54, GPR55, GPR85, GPR88, GPR103, and GPR139 are the selected orphan GPCRs for this article.  Their roles in the central nervous system have not been understood well so far.  However, recent studies show that they may have very important functions in the CNS.  Hence, in the present study, we reviewed most recent findings regarding the physiol. roles of the selected orphan GPCRs in the CNS.  After a brief presentation of each receptor, considering the results from genetic and pharmacol. manipulation of the receptors, their roles in the pathophysiol. of different diseases and disorders including anxiety, depression, schizophrenia, epilepsy, Alzheimer's disease, Parkinson's disease, and substance abuse will be discussed.  At present, our knowledge regarding the role of GPCRs in the brain is very limited.  However, previous limited studies show that orphan GPCRs have an important place in psychopharmacol. and these receptors are potential new targets for the treatment of major CNS diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSHrLncYbdvLVg90H21EOLACvtfcHk0liBbkLy2A0oCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVelur%252FP&md5=b3391b2988fac093bb66e376f88b5e1b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2017.12.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2017.12.056%26sid%3Dliteratum%253Aachs%26aulast%3DAlavi%26aufirst%3DM.%2BS.%26aulast%3DShamsizadeh%26aufirst%3DA.%26aulast%3DAzhdari-Zarmehri%26aufirst%3DH.%26aulast%3DRoohbakhsh%26aufirst%3DA.%26atitle%3DOrphan%2520G%2520protein-coupled%2520receptors%253A%2520The%2520role%2520in%2520CNS%2520disorders%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2018%26volume%3D98%26spage%3D222%26epage%3D232%26doi%3D10.1016%2Fj.biopha.2017.12.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isawi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span> <span> </span><span class="NLM_article-title">Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1080/03602532.2018.1428616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1080%2F03602532.2018.1428616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=29390908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1aiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=74-93&issue=1&author=P.+Moralesauthor=I.+Isawiauthor=P.+H.+Reggio&title=Towards+a+better+understanding+of+the+cannabinoid-related+orphan+receptors+GPR3%2C+GPR6%2C+and+GPR12&doi=10.1080%2F03602532.2018.1428616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12</span></div><div class="casAuthors">Morales, Paula; Isawi, Israa; Reggio, Patricia H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-93</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  GPR3, GPR6, and GPR12 are three orphan receptors that belong to the Class A family of G-protein-coupled receptors (GPCRs).  These GPCRs share over 60% of sequence similarity among them.  Because of their close phylogenetic relationship, GPR3, GPR6, and GPR12 share a high percentage of homol. with other lipid receptors such as the lysophospholipid and the cannabinoid receptors.  On the basis of sequence similarities at key structural motifs, these orphan receptors have been related to the cannabinoid family.  However, further exptl. data are required to confirm this assocn.  GPR3, GPR6, and GPR12 are predominantly expressed in mammalian brain.  Their high constitutive activation of adenylyl cyclase triggers increases in cAMP levels similar in amplitude to fully activated GPCRs.  This feature defines their physiol. role under certain pathol. conditions.  In this review, we aim to summarize the knowledge attained so far on the understanding of these receptors.  Expression patterns, pharmacol., physiopathol. relevance, and mols. targeting GPR3, GPR6, and GPR12 will be analyzed herein.  Interestingly, certain cannabinoid ligands have been reported to modulate these orphan receptors.  The current debate about sphingolipids as putative endogenous ligands will also be addressed.  A special focus will be on their potential role in the brain, particularly under neurol. conditions such as Parkinson or Alzheimer's disease.  Reported physiol. roles outside the central nervous system will also be covered.  This crit. overview may contribute to a further comprehension of the physiopathol. role of these orphan GPCRs, hopefully attracting more research towards a future therapeutic exploitation of these promising targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCCO33SWKr9LVg90H21EOLACvtfcHk0liBbkLy2A0oCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1aiurw%253D&md5=8b586a7c398475b5347fb9abe7e40e09</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1080%2F03602532.2018.1428616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602532.2018.1428616%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DIsawi%26aufirst%3DI.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26atitle%3DTowards%2520a%2520better%2520understanding%2520of%2520the%2520cannabinoid-related%2520orphan%2520receptors%2520GPR3%252C%2520GPR6%252C%2520and%2520GPR12%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2018%26volume%3D50%26issue%3D1%26spage%3D74%26epage%3D93%26doi%3D10.1080%2F03602532.2018.1428616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, T. I.</span></span> <span> </span><span class="NLM_article-title">Molecular cloning and chromosomal localization of human genes encoding three closely related G protein-coupled receptors</span>. <i>Genomics</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1006/geno.1995.1154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1006%2Fgeno.1995.1154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=8530049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADyaK2MXnsVOnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1995&pages=347-349&issue=2&author=Z.+H.+Songauthor=W.+Modiauthor=T.+I.+Bonner&title=Molecular+cloning+and+chromosomal+localization+of+human+genes+encoding+three+closely+related+G+protein-coupled+receptors&doi=10.1006%2Fgeno.1995.1154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning and chromosomal localization of human genes encoding three closely related G protein-coupled receptors</span></div><div class="casAuthors">Song, Zhao-Hu; Modi, William; Bonner, Tom I.</div><div class="citationInfo"><span class="NLM_cas:title">Genomics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-9</span>CODEN:
                <span class="NLM_cas:coden">GNMCEP</span>;
        ISSN:<span class="NLM_cas:issn">0888-7543</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Cosmids contg. human genes for three orphan G protein-coupled receptors, GPR12, GPR6, and GPR3, were isolated using their rat homologs as probes.  Previous studies of the mouse and rat cDNAs have shown the receptors to be expressed primarily in brain but have failed to identify their ligands.  The three receptor proteins of 334, 363, and 330 amino acids, resp., are encoded by a single exon in each gene.  Excluding the divergent sequences preceding the first transmembrane domain, they have ∼60% amino acid identity with each other.  Fluorescence in situ hybridization of GPR12, GPR6, and GPR3 localized these three genes to human chromosomal regions 13q12, 6q21, and 1p34.4-p36.1, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAUji7jcKar7Vg90H21EOLACvtfcHk0liBbkLy2A0oCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnsVOnurk%253D&md5=1801935467f79d6536ea83f60ee225ac</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1006%2Fgeno.1995.1154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fgeno.1995.1154%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%2BH.%26aulast%3DModi%26aufirst%3DW.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26atitle%3DMolecular%2520cloning%2520and%2520chromosomal%2520localization%2520of%2520human%2520genes%2520encoding%2520three%2520closely%2520related%2520G%2520protein-coupled%2520receptors%26jtitle%3DGenomics%26date%3D1995%26volume%3D28%26issue%3D2%26spage%3D347%26epage%3D349%26doi%3D10.1006%2Fgeno.1995.1154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0limC-x2teedng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span> <span> </span><span class="NLM_article-title">Escape from Flatland 2: complexity and promiscuity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">515</span>, <span class="refDoi"> DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515&issue=3&author=F.+Lovering&title=Escape+from+Flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0limC-x2teedng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520Flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D3%26spage%3D515%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedregal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Grau, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudra, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, V. N.</span></span> <span> </span><span class="NLM_article-title">Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4955</span>– <span class="NLM_lpage">4967</span>, <span class="refDoi"> DOI: 10.1021/jm201629q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201629q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4955-4967&issue=11&author=C.+Pedregalauthor=E.+M.+Joshiauthor=M.+A.+Toledoauthor=C.+Lafuenteauthor=N.+Diazauthor=M.+A.+Martinez-Grauauthor=A.+Jimenezauthor=A.+Benitoauthor=A.+Navarroauthor=Z.+Chenauthor=D.+R.+Mudraauthor=S.+D.+Kahlauthor=K.+S.+Rashauthor=M.+A.+Statnickauthor=V.+N.+Barth&title=Development+of+LC-MS%2FMS-based+receptor+occupancy+tracers+and+positron+emission+tomography+radioligands+for+the+nociceptin%2Forphanin+FQ+%28NOP%29+receptor&doi=10.1021%2Fjm201629q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Development of LC-MS/MS-Based Receptor Occupancy Tracers and Positron Emission Tomography Radioligands for the Nociceptin/Orphanin FQ (NOP) Receptor</span></div><div class="casAuthors">Pedregal, Concepcion; Joshi, Elizabeth M.; Toledo, Miguel A.; Lafuente, Celia; Diaz, Nuria; Martinez-Grau, Maria A.; Jimenez, Alma; Benito, Ana; Navarro, Antonio; Chen, Zhaogen; Mudra, Daniel R.; Kahl, Steven D.; Rash, Karen S.; Statnick, Michael A.; Barth, Vanessa N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4955-4967</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Currently, a lack of sufficient tools has limited the understanding of the relation between neuropsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor.  Herein, we describe the discovery and development of an antagonist NOP receptor occupancy (RO) tracer and a novel positron emission tomog. (PET) radioligand suitable to probe the NOP receptor in human clin. studies.  A thorough structure-activity relation (SAR) around the high-affinity 3-(2'-fluoro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)-2-(2-halobenzyl)-N-alkylpropanamide scaffold identified a series of subnanomolar, highly selective NOP antagonists.  Subsequently, these unlabeled NOP ligands were evaluated in vivo by liq. chromatog.-tandem mass spectrometry (LC-MS/MS) in rat to det. brain uptake, kinetics and specific binding.  Three compds. were selected for evaluation in nonhuman primates as PET tracers.  Carbon-11 labeling yielded [11C]I, which exhibited minimal generation of central nervous system (CNS) penetrant radiometabolites, improved brain uptake, and was an excellent PET radioligand in both rat and monkey.  Currently [11C]I is being evaluated as a PET radiotracer for the NOP receptor in human subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9BUDm4qd1VrVg90H21EOLACvtfcHk0limC-x2teedng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqu7c%253D&md5=37ba5b3497d5300a487c179a668a9055</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm201629q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201629q%26sid%3Dliteratum%253Aachs%26aulast%3DPedregal%26aufirst%3DC.%26aulast%3DJoshi%26aufirst%3DE.%2BM.%26aulast%3DToledo%26aufirst%3DM.%2BA.%26aulast%3DLafuente%26aufirst%3DC.%26aulast%3DDiaz%26aufirst%3DN.%26aulast%3DMartinez-Grau%26aufirst%3DM.%2BA.%26aulast%3DJimenez%26aufirst%3DA.%26aulast%3DBenito%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMudra%26aufirst%3DD.%2BR.%26aulast%3DKahl%26aufirst%3DS.%2BD.%26aulast%3DRash%26aufirst%3DK.%2BS.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DBarth%26aufirst%3DV.%2BN.%26atitle%3DDevelopment%2520of%2520LC-MS%252FMS-based%2520receptor%2520occupancy%2520tracers%2520and%2520positron%2520emission%2520tomography%2520radioligands%2520for%2520the%2520nociceptin%252Forphanin%2520FQ%2520%2528NOP%2529%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D11%26spage%3D4955%26epage%3D4967%26doi%3D10.1021%2Fjm201629q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jesudason, C. D.</span>; <span class="NLM_string-name">DuBois, S.</span>; <span class="NLM_string-name">Johnson, M.</span>; <span class="NLM_string-name">Barth, V. N.</span>; <span class="NLM_string-name">Need, A. B.</span></span>, et al. In Vivo Receptor Occupancy in Rodents by LC-MS/MS. <a href="https://www.ncbi.nlm.nih.gov/books/NBK424998/" class="extLink">https://www.ncbi.nlm.nih.gov/books/NBK424998/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jesudason%2C+C.+D.%3B+DuBois%2C+S.%3B+Johnson%2C+M.%3B+Barth%2C+V.+N.%3B+Need%2C+A.+B.%2C+et+al.+In+Vivo+Receptor+Occupancy+in+Rodents+by+LC-MS%2FMS.+https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK424998%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DJesudason%26aufirst%3DC.%2BD." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuhara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kameda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, I.</span></span> <span> </span><span class="NLM_article-title">Animal Models for Parkinson’s Disease Research: Trends in the 2000s</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">5402</span>, <span class="refDoi"> DOI: 10.3390/ijms20215402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.3390%2Fijms20215402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFShtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=5402&issue=21&author=K.+Kinauthor=T.+Yasuharaauthor=M.+Kamedaauthor=I.+Date&title=Animal+Models+for+Parkinson%E2%80%99s+Disease+Research%3A+Trends+in+the+2000s&doi=10.3390%2Fijms20215402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models for Parkinson's disease research: trends in the 2000s</span></div><div class="casAuthors">Kin, Kyohei; Yasuhara, Takao; Kameda, Masahiro; Date, Isao</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5402</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is a chronic and progressive movement disorder and the second most common neurodegenerative disease.  Although many studies have been conducted, there is an unmet clin. need to develop new treatments because, currently, only symptomatic therapies are available.  To achieve this goal, clarification of the pathol. is required.  Attempts have been made to emulate human PD and various animal models have been developed over the decades.  Neurotoxin models have been commonly used for PD research.  Recently, advances in transgenic technol. have enabled the development of genetic models that help to identify new approaches in PD research.  However, PD animal model trends have not been investigated.  Revealing the trends for PD research will be valuable for increasing our understanding of the pos. and neg. aspects of each model.  In this article, we clarified the trends for animal models that were used to research PD in the 2000s, and we discussed each model based on these trends.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxq4Xfy28Z7rVg90H21EOLACvtfcHk0lhoHd3GFbWatQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFShtrg%253D&md5=e6be7b2028ee3c2dce42cb87f3f2b040</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3390%2Fijms20215402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20215402%26sid%3Dliteratum%253Aachs%26aulast%3DKin%26aufirst%3DK.%26aulast%3DYasuhara%26aufirst%3DT.%26aulast%3DKameda%26aufirst%3DM.%26aulast%3DDate%26aufirst%3DI.%26atitle%3DAnimal%2520Models%2520for%2520Parkinson%25E2%2580%2599s%2520Disease%2520Research%253A%2520Trends%2520in%2520the%25202000s%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26issue%3D21%26spage%3D5402%26doi%3D10.3390%2Fijms20215402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brice, N. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffer, H. H</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monenschein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, V. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burley, J R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheardown, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartkowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosea, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, L. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. H</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlton, M. B</span></span> <span> </span><span class="NLM_article-title">Development of CVN<sub>424</sub>: a selective and novel GPR6 inverse agonist effective in models of Parkinson’s Disease</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, <span class="refDoi"> DOI: 10.1124/jpet.120.000438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1124%2Fjpet.120.000438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=33795395" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=N.+L+Briceauthor=H.+H+Schifferauthor=H.+Monenscheinauthor=V.+J+Mulliganauthor=K.+Pageauthor=J.+Powellauthor=X.+Xuauthor=T.+Cheungauthor=J+R.+Burleyauthor=H.+Sunauthor=L.+Dicksonauthor=S.+T+Murphyauthor=N.+Kaushalauthor=S.+Sheardownauthor=J.+Lawrenceauthor=Y.+Chenauthor=D.+Bartkowskiauthor=A.+Kantaauthor=J.+Russoauthor=N.+Hoseaauthor=L.+A+Dawsonauthor=S.+H+Hitchcockauthor=M.+B+Carlton&title=Development+of+CVN424%3A+a+selective+and+novel+GPR6+inverse+agonist+effective+in+models+of+Parkinson%E2%80%99s+Disease&doi=10.1124%2Fjpet.120.000438"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fjpet.120.000438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.120.000438%26sid%3Dliteratum%253Aachs%26aulast%3DBrice%26aufirst%3DN.%2BL%26aulast%3DSchiffer%26aufirst%3DH.%2BH%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DMulligan%26aufirst%3DV.%2BJ%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DCheung%26aufirst%3DT.%26aulast%3DBurley%26aufirst%3DJ%2BR.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DDickson%26aufirst%3DL.%26aulast%3DMurphy%26aufirst%3DS.%2BT%26aulast%3DKaushal%26aufirst%3DN.%26aulast%3DSheardown%26aufirst%3DS.%26aulast%3DLawrence%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBartkowski%26aufirst%3DD.%26aulast%3DKanta%26aufirst%3DA.%26aulast%3DRusso%26aufirst%3DJ.%26aulast%3DHosea%26aufirst%3DN.%26aulast%3DDawson%26aufirst%3DL.%2BA%26aulast%3DHitchcock%26aufirst%3DS.%2BH%26aulast%3DCarlton%26aufirst%3DM.%2BB%26atitle%3DDevelopment%2520of%2520CVN424%253A%2520a%2520selective%2520and%2520novel%2520GPR6%2520inverse%2520agonist%2520effective%2520in%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2021%26doi%3D10.1124%2Fjpet.120.000438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Studies on compound <b>3e</b> in a haloperidol-induced catalepsy model. (a) Compound <b>3e</b> reverses haloperidol-induced catalepsy in male rats. Haloperidol-induced catalepsy was measured 120 min after dosing Sprague-Dawley rats (<i>n</i> = 9–10 per group) at the same time with haloperidol (1 mg/kg, ip) and either vehicle (10% DMSO, 0.5% methylcellulose) or compound <b>3e</b> (0.1, 1, 10, and 30 mg/kg sc) or positive control compound KW6002 (0.6 mg/kg ip; adenosine A2A antagonist) treatments. (b) Compound <b>3e</b> reverses catalepsy in wild-type (WT) but not in male GPR6 knock out (KO) mice. Haloperidol-induced catalepsy was measured in wild-type (C57BL/6J) and GPR6 knock out mice 120 min after dosing animals at the same time (<i>n</i> = 6 per group) with haloperidol (1 mg/kg, ip) and vehicle (10% DMSO, 0.5% methylcellulose) or after dosing at the same time with haloperidol and either compound <b>3e</b> (30 mg/kg sc) or positive control compound KW6002 (0.3 mg/kg ip; adenosine A2A antagonist). Applied statistics: one-way ANOVA using Dunnett’s post hoc tests, significant effect of genotype difference or treatment as indicated: *<i>p</i> < 0.05 and **<i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vivo label-free LC-MS/MS-based GPR6 receptor occupancy (RO) of lead compound <b>6h</b> in male Sprague-Dawley rats. (a) GPR6 IAG tracer compound RL-338 (0.04 μg/kg, i.v.) accumulates nine-fold in the rat striatum (STR), a brain region expressing a high level of GPR6, in comparison to the cerebellum (CB), a brain region without GPR6 expression (90 min post dosing). Compound <b>6h</b> (0.03, 0.3,3 and 30 mg/kg, p.o.) dose-dependently reduced striatal enrichment of tracer RL-338 compared to vehicle (Tween-80, 0.5% methylcellulose) 90 min post dosing—an in vivo measure of isotope-free GPR6 receptor occupancy. (b) Correlation of compound <b>6h</b> plasma exposure and striatal receptor occupancy using <i>in vivo</i> label-free RO method (compound <b>6h</b> Occ<sub>50</sub> (plasma) = 2.8 ng/mL). Data are mean ± s.e.m. (<i>n</i> = 5 per group) after 90 min postinjection of <b>6h</b>; *<i>P</i> < 0.05, ****<i>P</i> < 0.0001 vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>6h</b> shows anti-Parkinsonian efficacy in the bilateral 6-OHDA-lesioned rat model of Parkinson’s disease. 6-OHDA-lesioned female animals are dosed with vehicle (0.5% methylcellulose) or compound <b>6h</b> (1 mg/kg, p.o.). Animals are placed in automated activity monitors for 3 h post dosing to assess mobility. The pen field activity of unperturbed study animals before the introduction of a bilateral 6-OHDA lesion is shown as control. Collected data are mean ± s.e.m. (<i>n</i> = 10 per group) of total counts over 3 h. *<i>P</i> < 0.05 vs vehicle; repeated measures one-way ANOVA followed by Newman-Keuls test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>2a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH(OAc)<sub>3</sub>, DCE, rt; (b) HCl, dioxane, rt; (c) (i) cyclopropylamine, DIPEA, DCM, 0 °C; (ii) 1-(3-methylbenzyl)piperazine, DIPEA, rt. (d) (i) cyclopropylamine, dioxane, 80 °C; (ii) 1-(3-methylbenzyl)piperazine or <b>8a</b>, dioxane, 150 °C; for <b>2a</b>–<b>e</b> and <b>2g</b>; (e) (i) <b>8a</b>, DIPEA DCM, rt; (ii) cyclopropylamine, DIPEA, dioxane, 100 °C, for <b>2f</b>; (f) (i) <b>2g</b>, KOH, MeOH, rt; (ii) Me<sub>2</sub>NH, HATU, DIPEA, DMF.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>3a</b>–<b>h</b> and <b>4a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>8a</b> or 4-(2,4-difluorophenoxy)piperidine, DIPEA, DCM, 0 °C; (b) cyclopropylamine or isopropylamine, DIPEA, dioxane, 110 °C in a sealed tube; (c) cyclopropylamine or isopropylamine, DIPEA dioxane or DCM, 0 °C; (d) <b>8a</b>, <b>8b</b>, <b>8c</b>, <b>8d</b>, or 4-(2,4-difluorophenoxy)piperidine, DIPEA, dioxane, 80 °C; (e) <b>4f</b>, 1,1′-bis(diphenylphosphino) ferrocene, Pd<sub>2</sub>(dba)<sub>3</sub>, Zn(CN)<sub>2</sub>, NMP, 120 °C.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>5a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (a) <b>8d</b>, DIPEA, DCM, 0 °C; (b) isopropylamine, DIPEA, dioxane, 100 °C in a sealed tube; (c) Ac<sub>2</sub>O, H<sub>2</sub>, 10% Pd/C, acetone/dioxane, 45 °C; (d) NaOH, MeOH, 65 °C; (e) propionic anhydride or MeSO<sub>2</sub>Cl, DIPEA, DCM, 0 °C.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/medium/jm0c02081_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0007.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>6a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.0c02081/20210716/images/large/jm0c02081_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02081&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i). BnBr, MeCN, 80 °C; (ii). NaBH(OAc)<sub>3</sub>, DCM, rt; (iii). H<sub>2</sub>, Pd/C, MeOH, rt; (b) <b>18a</b> or <b>18b</b>, Ac<sub>2</sub>O, DIPEA, DCM, 0 °C to rt; (c) <b>19a</b> or <b>6c</b>, MeSO<sub>2</sub>Cl or Ac<sub>2</sub>O or MeO<sub>2</sub>CCl, DIPEA, DCM, 0 °C to rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64364" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64364" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poewe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seppi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliday, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brundin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrag, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A. E.</span></span> <span> </span><span class="NLM_article-title">Parkinson disease</span>. <i>Nat. Rev. Dis Primers</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">17013</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2017.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1038%2Fnrdp.2017.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=28332488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BC1cvgtFChsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=17013&author=W.+Poeweauthor=K.+Seppiauthor=C.+M.+Tannerauthor=G.+M.+Hallidayauthor=P.+Brundinauthor=J.+Volkmannauthor=A.+E.+Schragauthor=A.+E.+Lang&title=Parkinson+disease&doi=10.1038%2Fnrdp.2017.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson disease</span></div><div class="casAuthors">Poewe Werner; Seppi Klaus; Tanner Caroline M; Tanner Caroline M; Halliday Glenda M; Halliday Glenda M; Brundin Patrik; Volkmann Jens; Schrag Anette-Eleonore; Lang Anthony E</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17013</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkinson disease is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age.  Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease.  Multiple other cell types throughout the central and peripheral autonomic nervous system are also involved, probably from early disease onwards.  Although clinical diagnosis relies on the presence of bradykinesia and other cardinal motor features, Parkinson disease is associated with many non-motor symptoms that add to overall disability.  The underlying molecular pathogenesis involves multiple pathways and mechanisms: α-synuclein proteostasis, mitochondrial function, oxidative stress, calcium homeostasis, axonal transport and neuroinflammation.  Recent research into diagnostic biomarkers has taken advantage of neuroimaging in which several modalities, including PET, single-photon emission CT (SPECT) and novel MRI techniques, have been shown to aid early and differential diagnosis.  Treatment of Parkinson disease is anchored on pharmacological substitution of striatal dopamine, in addition to non-dopaminergic approaches to address both motor and non-motor symptoms and deep brain stimulation for those developing intractable L-DOPA-related motor complications.  Experimental therapies have tried to restore striatal dopamine by gene-based and cell-based approaches, and most recently, aggregation and cellular transport of α-synuclein have become therapeutic targets.  One of the greatest current challenges is to identify markers for prodromal disease stages, which would allow novel disease-modifying therapies to be started earlier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFPUR1uNNE1-98rul4nhSdfW6udTcc2eZ0oAUEomQoSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvgtFChsA%253D%253D&md5=b624b37fee08b8b663ea88b83bc47865</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2017.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2017.13%26sid%3Dliteratum%253Aachs%26aulast%3DPoewe%26aufirst%3DW.%26aulast%3DSeppi%26aufirst%3DK.%26aulast%3DTanner%26aufirst%3DC.%2BM.%26aulast%3DHalliday%26aufirst%3DG.%2BM.%26aulast%3DBrundin%26aufirst%3DP.%26aulast%3DVolkmann%26aufirst%3DJ.%26aulast%3DSchrag%26aufirst%3DA.%2BE.%26aulast%3DLang%26aufirst%3DA.%2BE.%26atitle%3DParkinson%2520disease%26jtitle%3DNat.%2520Rev.%2520Dis%2520Primers%26date%3D2017%26volume%3D3%26spage%3D17013%26doi%3D10.1038%2Fnrdp.2017.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poewe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahlknecht, P.</span></span> <span> </span><span class="NLM_article-title">The clinical progression of Parkinson’s disease</span>. <i>Parkinsonism Relat Disord</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">Suppl 4</span>),  <span class="NLM_fpage">S28</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/S1353-8020(09)70831-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2FS1353-8020%2809%2970831-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=20123553" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=S28-32&issue=Suppl+4&author=W.+Poeweauthor=P.+Mahlknecht&title=The+clinical+progression+of+Parkinson%E2%80%99s+disease&doi=10.1016%2FS1353-8020%2809%2970831-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1353-8020%2809%2970831-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1353-8020%252809%252970831-4%26sid%3Dliteratum%253Aachs%26aulast%3DPoewe%26aufirst%3DW.%26aulast%3DMahlknecht%26aufirst%3DP.%26atitle%3DThe%2520clinical%2520progression%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DParkinsonism%2520Relat%2520Disord%26date%3D2009%26volume%3D15%26issue%3DSuppl%25204%26spage%3DS28%26epage%3D32%26doi%3D10.1016%2FS1353-8020%2809%2970831-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poewe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahlknecht, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankovic, J.</span></span> <span> </span><span class="NLM_article-title">Emerging therapies for Parkinson’s disease</span>. <i>Curr. Opin. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1097/WCO.0b013e3283542fde</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1097%2FWCO.0b013e3283542fde" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=22772874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWjs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=448-459&issue=4&author=W.+Poeweauthor=P.+Mahlknechtauthor=J.+Jankovic&title=Emerging+therapies+for+Parkinson%E2%80%99s+disease&doi=10.1097%2FWCO.0b013e3283542fde"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapies for Parkinson's disease</span></div><div class="casAuthors">Poewe, Werner; Mahlknecht, Philipp; Jankovic, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">448-459</span>CODEN:
                <span class="NLM_cas:coden">CONEEX</span>;
        ISSN:<span class="NLM_cas:issn">1350-7540</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The exptl. therapeutics of Parkinson's disease are reviewed, highlighting the current pipeline of emerging therapeutic approaches.  Recent findings: This review includes novel approaches to dopaminergic drug delivery such as intraintestinal infusions or new extended-release formulations of levodopa and also intrapulmonary delivery of apomorphine as well as novel dopaminergic agents like the monoamine oxidase-B inhibitor safinamide or novel catechol-O-Me transferase inhibitors.  An even greater no. of ongoing clin. trials assess the efficacy and safety of nondopaminergic approaches to enhance motor control or reduce motor complications like fluctuations and dyskinesias.  These include adenosine A2A antagonists, α-adrenergic and serotonergic agonists as well as drugs acting on the glutamatergic system.  Gene-based or cell-based intrastriatal delivery of therapeutic principles that enhance striatal dopaminergic transmission directly or via the stimulation of trophic activity has also reached phase II clin. development with encouraging results in some studies.  Finally, a wide spectrum of agents with a potential for slowing disease progression is currently tested.  Summary: A variety of medical and nonmedical interventions in different phases of clin. development provide an interesting and promising portfolio of emerging therapies for Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomNZpxzJjBtrVg90H21EOLACvtfcHk0lgmX-M-9z3ceA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWjs7zM&md5=421b6b0b289da7fcc8e817ae1808c15a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1097%2FWCO.0b013e3283542fde&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWCO.0b013e3283542fde%26sid%3Dliteratum%253Aachs%26aulast%3DPoewe%26aufirst%3DW.%26aulast%3DMahlknecht%26aufirst%3DP.%26aulast%3DJankovic%26aufirst%3DJ.%26atitle%3DEmerging%2520therapies%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Opin.%2520Neurol.%26date%3D2012%26volume%3D25%26issue%3D4%26spage%3D448%26epage%3D459%26doi%3D10.1097%2FWCO.0b013e3283542fde" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fearnley, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A. J.</span></span> <span> </span><span class="NLM_article-title">Ageing and Parkinson’s disease: substantia nigra regional selectivity</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2283</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi"> DOI: 10.1093/brain/114.5.2283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1093%2Fbrain%2F114.5.2283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1933245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADyaK38%252Fjtlyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1991&pages=2283-2301&issue=5&author=J.+M.+Fearnleyauthor=A.+J.+Lees&title=Ageing+and+Parkinson%E2%80%99s+disease%3A+substantia+nigra+regional+selectivity&doi=10.1093%2Fbrain%2F114.5.2283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Ageing and Parkinson's disease: substantia nigra regional selectivity</span></div><div class="casAuthors">Fearnley J M; Lees A J</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">114 ( Pt 5)</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2283-301</span>
        ISSN:<span class="NLM_cas:issn">0006-8950</span>.
    </div><div class="casAbstract">The micro-architecture of the substantia nigra was studied in control cases of varying age and patients with parkinsonism.  A single 7 mu section stained with haematoxylin and eosin was examined at a specific level within the caudal nigra using strict criteria.  The pars compacta was divided into a ventral and a dorsal tier, and each tier was further subdivided into 3 regions.  In 36 control cases there was a linear fallout of pigmented neurons with advancing age in the pars compacta of the caudal substantia nigra at a rate of 4.7% per decade.  Regionally, the lateral ventral tier was relatively spared (2.1% loss per decade) compared with the medial ventral tier (5.4%) and the dorsal tier (6.9%).  In 20 Parkinson's disease (PD) cases of varying disease duration there was an exponential loss of pigmented neurons with a 45% loss in the first decade.  Regionally, the pattern was opposite to ageing.  Loss was greatest in the lateral ventral tier (average loss 91%) followed by the medial ventral tier (71%) and the dorsal tier (56%).  The presymptomatic phase of PD from the onset of neuronal loss was estimated to be about 5 yrs.  This phase is represented by incidental Lewy body cases: individuals who die without clinical signs of PD or dementia, but who are found to have Lewy bodies at post-mortem.  In 7 cases cell loss was confined to the lateral ventral tier (average loss 52%) congruent with the lateral ventral selectivity of symptomatic PD.  It was calculated that at the onset of symptoms there was a 68% cell loss in the lateral ventral tier and a 48% loss in the caudal nigra as a whole.  The regional selectivity of PD is relatively specific.  In 15 cases of striatonigral degeneration the distribution of cell loss was similar, but the loss in the dorsal tier was greater than PD by 21%.  In 14 cases of Steele-Richardson-Olszewski syndrome (SRO) there was no predilection for the lateral ventral tier, but a tendency to involve the medial nigra and spare the lateral.  These findings suggest that age-related attrition of pigmented nigral cells is not an important factor in the pathogenesis of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxLysQt8EU6GGmni0r9GoKfW6udTcc2ebLLlJ3z9dhtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252Fjtlyisg%253D%253D&md5=1dc891e20a3b34168d18980c14b5189d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2F114.5.2283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252F114.5.2283%26sid%3Dliteratum%253Aachs%26aulast%3DFearnley%26aufirst%3DJ.%2BM.%26aulast%3DLees%26aufirst%3DA.%2BJ.%26atitle%3DAgeing%2520and%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520substantia%2520nigra%2520regional%2520selectivity%26jtitle%3DBrain%26date%3D1991%26volume%3D114%26issue%3D5%26spage%3D2283%26epage%3D2301%26doi%3D10.1093%2Fbrain%2F114.5.2283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duda, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duyckaerts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliday, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverenz, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Tredici, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wszolek, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litvan, I.</span></span> <span> </span><span class="NLM_article-title">Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1150</span>– <span class="NLM_lpage">1157</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(09)70238-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2FS1474-4422%2809%2970238-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=19909913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFymsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1150-1157&issue=12&author=D.+W.+Dicksonauthor=H.+Braakauthor=J.+E.+Dudaauthor=C.+Duyckaertsauthor=T.+Gasserauthor=G.+M.+Hallidayauthor=J.+Hardyauthor=J.+B.+Leverenzauthor=K.+Del+Trediciauthor=Z.+K.+Wszolekauthor=I.+Litvan&title=Neuropathological+assessment+of+Parkinson%E2%80%99s+disease%3A+refining+the+diagnostic+criteria&doi=10.1016%2FS1474-4422%2809%2970238-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria</span></div><div class="casAuthors">Dickson, Dennis W.; Braak, Heiko; Duda, John E.; Duyckaerts, Charles; Gasser, Thomas; Halliday, Glenda M.; Hardy, John; Leverenz, James B.; Del Tredici, Kelly; Wszolek, Zbigniew K.; Litvan, Irene</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1150-1157</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  To date, there have been few systematic attempts to provide a std. operating procedure for the neuropathol. diagnosis of Parkinson's disease (PD).  Pathol. examn. cannot classify the clin. syndrome with certainty; therefore, the neuropathol. diagnosis is, at best, a probability statement.  The neuropathol. diagnosis of parkinsonism has become increasingly based on fundamental mol. underpinnings, with recognition that the genetics of parkinsonism is heterogeneous and includes disorders that are assocd. with and without Lewy bodies.  The advent of α-synuclein immunohistochem. has substantially improved the ability to identify Lewy pathol., particularly cortical Lewy bodies and smaller aggregates within processes and the neuropil.  In this Review we discuss the diagnostic criteria for the neuropathol. assessment of PD.  These criteria are provisional and need to be validated through an iterative process that could help with their refinement.  Addnl., we suggest future directions for neuropathol. research on PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox88ZBP6oOOrVg90H21EOLACvtfcHk0lgmX-M-9z3ceA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFymsbzP&md5=801a9a8cf892f136c062326bd3bf8a4c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2809%2970238-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252809%252970238-8%26sid%3Dliteratum%253Aachs%26aulast%3DDickson%26aufirst%3DD.%2BW.%26aulast%3DBraak%26aufirst%3DH.%26aulast%3DDuda%26aufirst%3DJ.%2BE.%26aulast%3DDuyckaerts%26aufirst%3DC.%26aulast%3DGasser%26aufirst%3DT.%26aulast%3DHalliday%26aufirst%3DG.%2BM.%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DLeverenz%26aufirst%3DJ.%2BB.%26aulast%3DDel%2BTredici%26aufirst%3DK.%26aulast%3DWszolek%26aufirst%3DZ.%2BK.%26aulast%3DLitvan%26aufirst%3DI.%26atitle%3DNeuropathological%2520assessment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520refining%2520the%2520diagnostic%2520criteria%26jtitle%3DLancet%2520Neurol.%26date%3D2009%26volume%3D8%26issue%3D12%26spage%3D1150%26epage%3D1157%26doi%3D10.1016%2FS1474-4422%2809%2970238-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A. B.</span></span> <span> </span><span class="NLM_article-title">Circuit Mechanisms of Parkinson’s Disease</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1042</span>– <span class="NLM_lpage">1056</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2019.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2Fj.neuron.2019.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=30897356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1entrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2019&pages=1042-1056&issue=6&author=M.+M.+McGregorauthor=A.+B.+Nelson&title=Circuit+Mechanisms+of+Parkinson%E2%80%99s+Disease&doi=10.1016%2Fj.neuron.2019.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Circuit Mechanisms of Parkinson's Disease</span></div><div class="casAuthors">McGregor, Matthew M.; Nelson, Alexandra B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1042-1056</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is a complex, multi-system neurodegenerative disorder.  The second most common neurodegenerative disorder after Alzheimer's disease, it affects approx. 1% of adults over age 60.  Diagnosis follows the development of one or more of the core motor features of the disease, including tremor, slowing of movement (bradykinesia), and rigidity.  However, there are numerous other motor and nonmotor disease manifestations.  Many PD symptoms result directly from neurodegeneration; others are driven by aberrant activity patterns in surviving neurons.  This latter phenomenon, PD circuit dysfunction, is an area of intense study, as it likely underlies our ability to treat many disease symptoms in the face of (currently) irreversible neurodegeneration.  This Review will discuss key clin. features of PD and their basis in neural circuit dysfunction.  We will first review important disease symptoms and some of the responsible neuropathol.  We will then describe the basal ganglia-thalamocortical circuit, the major locus of PD-related circuit dysfunction, and some of the models that have influenced its study.  We will review PD-related changes in network activity, subdividing findings into those that touch on the rate, rhythm, or synchronization of neurons.  Finally, we suggest some crit. remaining questions for the field and areas for new developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonseLGyLem0LVg90H21EOLACvtfcHk0ljbPd9V01HesA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1entrk%253D&md5=2d2765077e28fcc5298a851c5a7ffb1e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2019.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2019.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DMcGregor%26aufirst%3DM.%2BM.%26aulast%3DNelson%26aufirst%3DA.%2BB.%26atitle%3DCircuit%2520Mechanisms%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DNeuron%26date%3D2019%26volume%3D101%26issue%3D6%26spage%3D1042%26epage%3D1056%26doi%3D10.1016%2Fj.neuron.2019.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, E.</span></span> <span> </span><span class="NLM_article-title">Levodopa in the treatment of Parkinson’s disease: current status and new developments</span>. <i>J. Parkinson's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.3233/JPD-130186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.3233%2FJPD-130186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=23948989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVekt73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=255-269&issue=3&author=D.+Salatauthor=E.+Tolosa&title=Levodopa+in+the+treatment+of+Parkinson%E2%80%99s+disease%3A+current+status+and+new+developments&doi=10.3233%2FJPD-130186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments</span></div><div class="casAuthors">Salat, David; Tolosa, Eduardo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Parkinson's Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-269</span>CODEN:
                <span class="NLM_cas:coden">JPDOAP</span>;
        ISSN:<span class="NLM_cas:issn">1877-7171</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease (PD).  Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor (DDCI), which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain.  Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, esp. when used in conjunction with a DDCI.  During early-stage PD, treatment will depend on the severity of symptoms; if greater symptomatic effect is required then levodopa or dopamine agonists are usually the drugs of choice.  The ability to remain employable or phys. active is an important goal in younger patients, therefore, in some instances levodopa initiation should be considered early on, either as a monotherapy or in combination with other drugs.  The clin. use of levodopa may eventually be limited by the development of various treatment-related complications, including response fluctuations, dyskinesia and psychiatric problems.  Motor complications are related to the intermittent delivery of dopamine-replacing drugs to the brain.  Triple combination of levodopa/carbidopa/entacapone available in a single tablet in multiple levodopa dose strengths offers flexibility and helps control response fluctuations.  Recent developments in treatment with levodopa try to obtain continuous delivery with levodopa and include duodenal infusion of a levodopa/carbidopa, transdermal levodopa patch, and oral pro-levodopa.  Levodopa remains the most potent dopaminergic therapy for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-aRJ0idEt4LVg90H21EOLACvtfcHk0ljbPd9V01HesA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVekt73F&md5=1ab250a0d4602412128509287cf470cd</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3233%2FJPD-130186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJPD-130186%26sid%3Dliteratum%253Aachs%26aulast%3DSalat%26aufirst%3DD.%26aulast%3DTolosa%26aufirst%3DE.%26atitle%3DLevodopa%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520current%2520status%2520and%2520new%2520developments%26jtitle%3DJ.%2520Parkinson%2527s%2520Dis.%26date%3D2013%26volume%3D3%26issue%3D3%26spage%3D255%26epage%3D269%26doi%3D10.3233%2FJPD-130186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tambasco, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabresi, P.</span></span> <span> </span><span class="NLM_article-title">Levodopa in Parkinson’s Disease: Current Status and Future Developments</span>. <i>Curr. Neuropharmacol</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1239</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.2174/1570159X15666170510143821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.2174%2F1570159X15666170510143821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=28494719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OmsbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=1239-1252&issue=8&author=N.+Tambascoauthor=M.+Romoliauthor=P.+Calabresi&title=Levodopa+in+Parkinson%E2%80%99s+Disease%3A+Current+Status+and+Future+Developments&doi=10.2174%2F1570159X15666170510143821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa in Parkinson's Disease: Current Status and Future Developments</span></div><div class="casAuthors">Tambasco, Nicola; Romoli, Michele; Calabresi, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1239-1252</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Ever since the pioneering reports in the 60s, L-3,4-Dioxyphenylalanine (levodopa) has represented the gold std. for the treatment of Parkinson's Disease (PD).  However, long-term levodopa (LD) treatment is frequently assocd. with fluctuations in motor response with serious impact on patient quality of life.  The pharmacokinetic and pharmacodynamic properties of LD are pivotal to such motor fluctuations: discontinuous drug delivery, short half-life, poor bioavailability, and narrow therapeutic window are all crucial for such fluctuations.  During the last 60 years, several attempts have been made to improve LD treatment and avoid long-term complications.  Methods: Research and trials to improve the LD pharmacokinetic since 1960s are reviewed, summarizing the progressive improvements of LD treatment.  Results: Inhibitors of peripheral amino acid decarboxylase (AADC) have been introduced to achieve proper LD concn. in the central nervous system reducing systemic adverse events.  Inhibitors of catechol-O-methyltransferase (COMT) increased LD half-life and bioavailability.  Efforts are still being made to achieve a continuous dopaminergic stimulation, with the combination of oral LD with an AADC inhibitor and a COMT inhibitor, or the intra-duodenal water-based LD/ carbidopa gel.  Further approaches to enhance LD efficacy are focused on new non-oral administration routes, including nasal, intra-duodenal, intrapulmonary (CVT-301) and s.c. (ND0612), as well as on novel ER formulations, including IPX066, which recently concluded phase III trial.  Conclusion: New LD formulations, oral compds. as well as routes have been tested in the last years, with two main targets: achieve continuous dopaminergic stimulation and find an instant deliver route for LD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrak8NdNvrE_bVg90H21EOLACvtfcHk0ljbPd9V01HesA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OmsbnO&md5=5f1e88ebb1460250cf1cd7a19f555df7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F1570159X15666170510143821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X15666170510143821%26sid%3Dliteratum%253Aachs%26aulast%3DTambasco%26aufirst%3DN.%26aulast%3DRomoli%26aufirst%3DM.%26aulast%3DCalabresi%26aufirst%3DP.%26atitle%3DLevodopa%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520Current%2520Status%2520and%2520Future%2520Developments%26jtitle%3DCurr.%2520Neuropharmacol%26date%3D2018%26volume%3D16%26issue%3D8%26spage%3D1239%26epage%3D1252%26doi%3D10.2174%2F1570159X15666170510143821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tambasco, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcastro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrioto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabresi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A.</span></span> <span> </span><span class="NLM_article-title">Levodopa-induced breathing, cognitive and behavioral changes in Parkinson’s disease</span>. <i>J. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>258</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2296</span>– <span class="NLM_lpage">2299</span>, <span class="refDoi"> DOI: 10.1007/s00415-011-6119-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1007%2Fs00415-011-6119-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=21647729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FivFCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=2011&pages=2296-2299&issue=12&author=N.+Tambascoauthor=V.+Belcastroauthor=A.+Gallinaauthor=A.+Castriotoauthor=P.+Calabresiauthor=A.+Rossi&title=Levodopa-induced+breathing%2C+cognitive+and+behavioral+changes+in+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs00415-011-6119-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease</span></div><div class="casAuthors">Tambasco Nicola; Belcastro Vincenzo; Gallina Antongiulio; Castrioto Anna; Calabresi Paolo; Rossi Aroldo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">258</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2296-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjaDavY9o61xe4jJGKT5N0fW6udTcc2eYePpEAplJQubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FivFCgsw%253D%253D&md5=1208370eb04aebbf2353116072071249</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00415-011-6119-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00415-011-6119-5%26sid%3Dliteratum%253Aachs%26aulast%3DTambasco%26aufirst%3DN.%26aulast%3DBelcastro%26aufirst%3DV.%26aulast%3DGallina%26aufirst%3DA.%26aulast%3DCastrioto%26aufirst%3DA.%26aulast%3DCalabresi%26aufirst%3DP.%26aulast%3DRossi%26aufirst%3DA.%26atitle%3DLevodopa-induced%2520breathing%252C%2520cognitive%2520and%2520behavioral%2520changes%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurol.%26date%3D2011%26volume%3D258%26issue%3D12%26spage%3D2296%26epage%3D2299%26doi%3D10.1007%2Fs00415-011-6119-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabbrini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotchie, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, C. G.</span></span> <span> </span><span class="NLM_article-title">Levodopa-induced dyskinesias</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1379</span>– <span class="NLM_lpage">1389</span>, <span class="refDoi"> DOI: 10.1002/mds.21475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1002%2Fmds.21475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=17427940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BD2svjvFKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=1379-1389&issue=10&author=G.+Fabbriniauthor=J.+M.+Brotchieauthor=F.+Grandasauthor=M.+Nomotoauthor=C.+G.+Goetz&title=Levodopa-induced+dyskinesias&doi=10.1002%2Fmds.21475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa-induced dyskinesias</span></div><div class="casAuthors">Fabbrini Giovanni; Brotchie Jonathan M; Grandas Francisco; Nomoto Masahiro; Goetz Christopher G</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1379-1389</span>
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    </div><div class="casAbstract">Levodopa-induced dyskinesias (LID) are common and difficult to treat.  This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management.  The three primary clinical syndromes are OFF-period dystonia, peak-dose dyskinesia, and diphasic dyskinesia.  Several other forms also occur, making the evaluation and choice of treatment complicated.  A core component of the pathophysiology of LID is overactivity of the direct striatal output pathway.  This pathway provides a direct GABAergic connection by which the striatum inhibits the output regions of the basal ganglia, i.e., the internal globus pallidus and the substantia nigra pars reticulata.  Altering dopaminergic dosing and timing can abate dyskinesias, but usually impact the control of parkinsonism.  Putative therapies to reduce the problem of dyskinesias could focus on the glutamatergic, GABAergic, alpha2 adrenergic, serotonergic (5HT1A, 5HT2A), opioid, histamine H3, adenosine A2A receptors, the monoamine transport or cannabinoid CB1 receptors systems.  The only currently available drug with an evidence-based recommendation on efficacy for dyskinesia is amantadine.  Therapy goals include the prevention of dyskinesia and treatment of dyskinesias that are troublesome clinically.  New rating measures to assess severity and disability related to dyskinesia are in the process of development and clinimetric testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDoNA75wLjNdLIORRPd5lbfW6udTcc2eYePpEAplJQubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svjvFKhuw%253D%253D&md5=7eae8ac0714f373ce0db78ebf6769a2d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fmds.21475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.21475%26sid%3Dliteratum%253Aachs%26aulast%3DFabbrini%26aufirst%3DG.%26aulast%3DBrotchie%26aufirst%3DJ.%2BM.%26aulast%3DGrandas%26aufirst%3DF.%26aulast%3DNomoto%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DC.%2BG.%26atitle%3DLevodopa-induced%2520dyskinesias%26jtitle%3DMov.%2520Disord.%26date%3D2007%26volume%3D22%26issue%3D10%26spage%3D1379%26epage%3D1389%26doi%3D10.1002%2Fmds.21475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waters, C.</span></span> <span> </span><span class="NLM_article-title">Catechol-O-methyltransferase (COMT) inhibitors in Parkinson’s disease</span>. <i>J. Am. Geriatr. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1111/j.1532-5415.2000.tb04732.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1111%2Fj.1532-5415.2000.tb04732.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10855610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Sgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2000&pages=692-698&issue=6&author=C.+Waters&title=Catechol-O-methyltransferase+%28COMT%29+inhibitors+in+Parkinson%E2%80%99s+disease&doi=10.1111%2Fj.1532-5415.2000.tb04732.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease</span></div><div class="casAuthors">Waters, Cheryl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Geriatrics Society</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">692-698</span>CODEN:
                <span class="NLM_cas:coden">JAGSAF</span>;
        ISSN:<span class="NLM_cas:issn">0002-8614</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 29 refs.  Catechol-O-methyltransferase (COMT) inhibitors are a new therapeutic option in the treatment of patients with Parkinson's disease.  COMT inhibitors act by extending the duration of action of levodopa, thus improving the amt. of time a patient can experience benefit from levodopa.  COMT inhibitors are only used in conjunction with levodopa.  They do have a propensity to augment dopaminergic effects, such that levodopa doses might need to be adjusted downward.  Other side effects of COMT inhibitors include diarrhea and liver function abnormalities.  Due to the latter, recent guidelines have been developed to monitor patients on tolcapone for this rare side effect, and these guidelines will be discussed.  This article also provides representative case histories for the appropriate use of COMT inhibitors that illustrate how these drugs can be used to manage patients with a fluctuating response to levodopa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jhjugOBhm7Vg90H21EOLACvtfcHk0lhXwQIn_lPNyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Sgtb0%253D&md5=c3ccd36f9dc74247306a9d2c773a8e5f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.1532-5415.2000.tb04732.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1532-5415.2000.tb04732.x%26sid%3Dliteratum%253Aachs%26aulast%3DWaters%26aufirst%3DC.%26atitle%3DCatechol-O-methyltransferase%2520%2528COMT%2529%2520inhibitors%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Am.%2520Geriatr.%2520Soc.%26date%3D2000%26volume%3D48%26issue%3D6%26spage%3D692%26epage%3D698%26doi%3D10.1111%2Fj.1532-5415.2000.tb04732.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, T.</span></span> <span> </span><span class="NLM_article-title">Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical-pharmacological aspects</span>. <i>J. Neural Transm (Vienna)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1757</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1876-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1007%2Fs00702-018-1876-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=29569037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BC1MnktV2ntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1751-1757&issue=11&author=P.+Riedererauthor=T.+Muller&title=Monoamine+oxidase-B+inhibitors+in+the+treatment+of+Parkinson%E2%80%99s+disease%3A+clinical-pharmacological+aspects&doi=10.1007%2Fs00702-018-1876-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects</span></div><div class="casAuthors">Riederer Peter; Muller Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission (Vienna, Austria : 1996)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1751-1757</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This invited narrative review emphasizes the role of MAO-B inhibition in the drug portfolio for dopamine substitution in patients with Parkinson's disease.  Neuronal and glial MAO-B inhibition contributes to more stable levels of dopamine and other biogenic amines in the synaptic cleft.  Accordingly, symptomatic effects of MAO-B inhibition for a limited amelioration of impaired motor behaviour and wearing-off phenomena in patients with Parkinson's disease are well proven, even when MAO-B inhibitors are only applied together with dopamine agonists.  Delay of disease progression by MAO-B inhibition is under debate despite positive experimental findings.  This discussion does not consider, that levodopa, respectively, dopamine agonists, are substrates, respectively, inhibitors of the ABCB1 (P-gp, MDR1, and CD243) transporter system.  It supports toxin efflux over the blood-brain barrier.  ABCB1 transporters have a limited capacity.  MAO-B inhibitors do not weaken it.  Treatment with MAO-B inhibitors is advantageous as it enables sparing of dopamine agonist and levodopa dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnpu8LyXFi1OdfST00W0BcfW6udTcc2eYePpEAplJQubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnktV2ntA%253D%253D&md5=cbfd1fe236ba9e73e6123e14e76086f9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1876-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1876-2%26sid%3Dliteratum%253Aachs%26aulast%3DRiederer%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DT.%26atitle%3DMonoamine%2520oxidase-B%2520inhibitors%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520clinical-pharmacological%2520aspects%26jtitle%3DJ.%2520Neural%2520Transm%2520%2528Vienna%2529%26date%3D2018%26volume%3D125%26issue%3D11%26spage%3D1751%26epage%3D1757%26doi%3D10.1007%2Fs00702-018-1876-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blandini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armentero, M. T.</span></span> <span> </span><span class="NLM_article-title">Dopamine receptor agonists for Parkinson’s disease</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1517/13543784.2014.869209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1517%2F13543784.2014.869209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=24313341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFymurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=387-410&issue=3&author=F.+Blandiniauthor=M.+T.+Armentero&title=Dopamine+receptor+agonists+for+Parkinson%E2%80%99s+disease&doi=10.1517%2F13543784.2014.869209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptor agonists for Parkinson's disease</span></div><div class="casAuthors">Blandini, Fabio; Armentero, Marie-Therese</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-410</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Prolonged administration of l-3,4-dihydroxyphenylalanine (l-DOPA) for Parkinson's disease (PD) is hampered by motor complications related to the progressive incapacity of residual nigrostriatal neurons to properly utilize the drug.  Direct stimulation of dopaminergic (DAergic) receptors with specific compds. (DA agonists) has, therefore, become an addnl. therapeutic tool for PD.  Areas covered: DA agonists have considerable anti-parkinsonian symptomatic efficacy, although they are less potent thanl-DOPA.  This review summarizes pre-clin. and clin. data on DA agonists and their role in treating PD.  Specific focus was put on second-generation, first-line non-ergolinic DA agonists and their motor, non-motor and putative neuroprotective effects.  The anti-parkinsonian potential of recently developed DA agonists that reached Phase II and III clin. trials was also addressed.  Expert opinion: DA agonists can be useful along the whole natural course of PD, as monotherapy in the initial phase or combined with l-DOPA in advanced PD.  Extended-release formulations have been developed for second-generation DA agonists, which are better appreciated by patients.  Neuroprotective properties have been proposed for DA agonists, based on pre-clin. studies, but never convincingly demonstrated in patients.  New DA agonists, with better symptomatic efficacy and devoid of the side effects that characterize current compds., are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot5J_MehLHQ7Vg90H21EOLACvtfcHk0lgENveaHGx3xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFymurY%253D&md5=0f50189a15c121715786298265c4bb39</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.869209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.869209%26sid%3Dliteratum%253Aachs%26aulast%3DBlandini%26aufirst%3DF.%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26atitle%3DDopamine%2520receptor%2520agonists%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26issue%3D3%26spage%3D387%26epage%3D410%26doi%3D10.1517%2F13543784.2014.869209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A. E.</span></span> <span> </span><span class="NLM_article-title">Pharmacological treatment of Parkinson disease: a review</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>311</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1683</span>, <span class="refDoi"> DOI: 10.1001/jama.2014.3654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1001%2Fjama.2014.3654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=24756517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFems7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2014&pages=1670-1683&issue=16&author=B.+S.+Connollyauthor=A.+E.+Lang&title=Pharmacological+treatment+of+Parkinson+disease%3A+a+review&doi=10.1001%2Fjama.2014.3654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment of Parkinson disease: a review</span></div><div class="casAuthors">Connolly, Barbara S.; Lang, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1670-1683, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">A review.  Importance: Parkinson disease is the second most common neurodegenerative disease worldwide.  Although no available therapies alter the underlying neurodegenerative process, symptomatic therapies can improve patient quality of life.  Objective: To provide an evidence-based review of the initial pharmacol. management of the classic motor symptoms of Parkinson disease; describe management of medication-related motor complications (such as motor fluctuations and dyskinesia), and other medication adverse effects (nausea, psychosis, and impulse control disorders and related behaviors); and discuss the management of selected nonmotor symptoms of Parkinson disease, including rapid eye movement sleep behavior disorder, cognitive impairment, depression, orthostatic hypotension, and sialorrhea.  Evidence Review: Refs. were identified using searches of PubMed between Jan. 1985 and Feb. 2014 for English-language human studies and the full database of the Cochrane Library.  The classification of studies by quality (classes I-IV) was assessed using the levels of evidence guidelines from the American Academy of Neurol. and the highest-quality data for each topic.  Results: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.  Motor fluctuations may be managed by modifying the levodopa dosing regimen or by adding several other medications, such as MAOBIs, catechol-O-methyltransferase inhibitors, or dopamine agonists.  Impulse control disorders are typically managed by reducing or withdrawing dopaminergic medication, particularly dopamine agonists.  Evidence-based management of some nonmotor symptoms is limited by a paucity of high-quality pos. studies.  Conclusions and Relevance: Strong evidence supports using levodopa and dopamine agonists for motor symptoms at all stages of Parkinson disease.  Dopamine agonists and drugs that block dopamine metab. are effective for motor fluctuations and clozapine is effective for hallucinations.  Cholinesterase inhibitors may improve symptoms of dementia and antidepressants and pramipexole may improve depression.  Evidence supporting other therapies for motor and nonmotor features is less well established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq4bHOyyI7XrVg90H21EOLACvtfcHk0lgENveaHGx3xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFems7rP&md5=a3faf879f5febdfc11a8992db89f2e67</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.3654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.3654%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DB.%2BS.%26aulast%3DLang%26aufirst%3DA.%2BE.%26atitle%3DPharmacological%2520treatment%2520of%2520Parkinson%2520disease%253A%2520a%2520review%26jtitle%3DJAMA%26date%3D2014%26volume%3D311%26issue%3D16%26spage%3D1670%26epage%3D1683%26doi%3D10.1001%2Fjama.2014.3654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. H.</span></span> <span> </span><span class="NLM_article-title">Non-dopaminergic treatments for motor control in Parkinson’s disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1405</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0105-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1007%2Fs40265-013-0105-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=23917951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1405-1415&issue=13&author=S.+H.+Fox&title=Non-dopaminergic+treatments+for+motor+control+in+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs40265-013-0105-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Non-dopaminergic Treatments for Motor Control in Parkinson's Disease</span></div><div class="casAuthors">Fox, Susan H.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1405-1415</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The pathol. processes underlying Parkinson's disease (PD) involve more than dopamine cell loss within the midbrain.  These non-dopaminergic neurotransmitters include noradrenergic, serotonergic, glutamatergic, and cholinergic systems within cortical, brainstem and basal ganglia regions.  Several non-dopaminergic treatments are now in clin. use to treat motor symptoms of PD, or are being evaluated as potential therapies.  Agents for symptomatic monotherapy and as adjunct to dopaminergic therapies for motor symptoms include adenosine A2A antagonists and the mixed monoamine-B inhibitor (MAO-BI) and glutamate release agent safinamide.  The largest area of potential use for non-dopaminergic drugs is as add-on therapy for motor fluctuations.  Thus adenosine A2A antagonists, safinamide, and the antiepileptic agent zonisamide can extend the duration of action of levodopa.  To reduce levodopa-induced dyskinesia, drugs that target overactive glutamatergic neurotransmission can be used, and include the non-selective N-Me d-aspartate antagonist amantadine.  More recently, selective metabotropic glutamate receptor (mGluR5) antagonists are being evaluated in phase II randomized controlled trials.  Serotonergic agents acting as 5-HT2A/2C antagonists, such as the atypical antipsychotic clozapine, may also reduce dyskinesia. 5-HT1A agonists theor. can reduce dyskinesia, but in practice, may also worsen PD motor symptoms, and so clin. applicability has not yet been shown.  Noradrenergic α2A antagonism using fipamezole can potentially reduce dyskinesia.  Several non-dopaminergic agents have also been investigated to reduce non-levodopa-responsive motor symptoms such as gait and tremor.  Thus the cholinesterase inhibitor donepezil showed mild benefit in gait, while the predominantly noradrenergic re-uptake inhibitor methylphenidate had conflicting results in advanced PD subjects.  Tremor in PD may respond to muscarinic M4 cholinergic antagonists (anticholinergics), but tolerability is often poor.  Alternatives include β-adrenergic antagonists such as propranolol.  Other options include 5-HT2A antagonists, and drugs that have mixed binding properties involving serotonin and acetylcholine, such as clozapine and the antidepressant mirtazapine, can be effective in reducing PD tremor.  Many other non-dopaminergic agents are in preclin. and phase I/II early stages of study, and the reader is directed to recent reviews.  While levodopa remains the most effective agent to treat motor symptoms in PD, the overall approach to using non-dopaminergic drugs in PD is to reduce reliance on levodopa and to target non-levodopa-responsive symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgKWj-lWItNbVg90H21EOLACvtfcHk0lgENveaHGx3xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurvK&md5=cb174b0eaa0565fe1f9803e288bc1500</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0105-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0105-4%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DS.%2BH.%26atitle%3DNon-dopaminergic%2520treatments%2520for%2520motor%2520control%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26issue%3D13%26spage%3D1405%26epage%3D1415%26doi%3D10.1007%2Fs40265-013-0105-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahoo, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span> <span> </span><span class="NLM_article-title">Istradefylline: a novel drug for ‘off’ episodes in Parkinson’s disease</span>. <i>Drugs & Therapy Perspectives</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1007/s40267-020-00718-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1007%2Fs40267-020-00718-w" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2020&pages=208-212&author=A.+K.+Sahooauthor=D.+Guptaauthor=A.+Singh&title=Istradefylline%3A+a+novel+drug+for+%E2%80%98off%E2%80%99+episodes+in+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs40267-020-00718-w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs40267-020-00718-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40267-020-00718-w%26sid%3Dliteratum%253Aachs%26aulast%3DSahoo%26aufirst%3DA.%2BK.%26aulast%3DGupta%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DA.%26atitle%3DIstradefylline%253A%2520a%2520novel%2520drug%2520for%2520%25E2%2580%2598off%25E2%2580%2599%2520episodes%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%2520%2526%2520Therapy%2520Perspectives%26date%3D2020%26volume%3D36%26spage%3D208%26epage%3D212%26doi%3D10.1007%2Fs40267-020-00718-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deuschl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agid, Y.</span></span> <span> </span><span class="NLM_article-title">Subthalamic neurostimulation for Parkinson’s disease with early fluctuations: balancing the risks and benefits</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1025</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(13)70151-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2FS1474-4422%2813%2970151-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=24050735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BC3sbpvVCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1025-1034&issue=10&author=G.+Deuschlauthor=Y.+Agid&title=Subthalamic+neurostimulation+for+Parkinson%E2%80%99s+disease+with+early+fluctuations%3A+balancing+the+risks+and+benefits&doi=10.1016%2FS1474-4422%2813%2970151-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits</span></div><div class="casAuthors">Deuschl Gunther; Agid Yves</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1025-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Electrical stimulation of the subthalamic nucleus is an established treatment for patients with advanced Parkinson's disease with pharmacologically unresponsive fluctuations.  Compared with pharmacological treatment, subthalamic neurostimulation significantly improves motor symptoms, particularly during the phases of poor response to drug treatment, and reduces the severity of dyskinesias.  Importantly, it also significantly improves quality of life and other integral measures of disease severity.  The treatment response can last for more than 10 years, although there is no evidence that levodopa-resistant symptoms are delayed by subthalamic neurostimulation.  At present, the mean disease duration for patients at the time of implantation is 12 years.  In a recent study (EARLYSTIM) in patients with a disease duration of 7·5 years and fluctuations for 1·5 years, similar improvements in clinical outcomes were reported.  These findings suggest that neurostimulation of the subthalamic nucleus could be used earlier in the disease course for carefully selected patients if the benefits of the treatment are weighed against the surgical risks and the lifelong need for specialised care by an experienced team.  As mobility is consistently improved during the times with poor mobility by reducing fluctuations and delaying levodopa-sensitive complications, we propose that this treatment changes the disease course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6Pfmykbu9PWK_SFaaT9INfW6udTcc2eaR3rC2H4fgHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbpvVCqtw%253D%253D&md5=22059826fe4311e5e8de9587ffc4a180</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2813%2970151-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252813%252970151-0%26sid%3Dliteratum%253Aachs%26aulast%3DDeuschl%26aufirst%3DG.%26aulast%3DAgid%26aufirst%3DY.%26atitle%3DSubthalamic%2520neurostimulation%2520for%2520Parkinson%25E2%2580%2599s%2520disease%2520with%2520early%2520fluctuations%253A%2520balancing%2520the%2520risks%2520and%2520benefits%26jtitle%3DLancet%2520Neurol.%26date%3D2013%26volume%3D12%26issue%3D10%26spage%3D1025%26epage%3D1034%26doi%3D10.1016%2FS1474-4422%2813%2970151-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uhlenbrock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gassenhuber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1016/S0898-6568(02)00041-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2FS0898-6568%2802%2900041-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=12220620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvVCku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2002&pages=941-953&issue=11&author=K.+Uhlenbrockauthor=H.+Gassenhuberauthor=E.+Kostenis&title=Sphingosine+1-phosphate+is+a+ligand+of+the+human+gpr3%2C+gpr6+and+gpr12+family+of+constitutively+active+G+protein-coupled+receptors&doi=10.1016%2FS0898-6568%2802%2900041-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors</span></div><div class="casAuthors">Uhlenbrock, Kirsten; Gassenhuber, Hans; Kostenis, Evi</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">941-953</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Five G protein-coupled receptors (GPCRs) for the lysophospholipid sphingosine 1-phosphate (S1P) have been cloned and characterized so far.  We report here about the identification of gpr3, gpr6 and gpr12 as addnl. members of the S1P-GPCR family.  When expressed transiently in HEK293 cells, gpr3, gpr6 and gpr12 confer constitutive activation of adenylate cyclase (AC) similar in amplitude to that seen with fully activated Gαs-coupled receptors.  Culturing the transfected cells in medium with charcoal-stripped serum (devoid of lipids) significantly reduces cyclic adenosine monophosphate (cAMP) levels, suggesting a lipid-like ligand.  A library contg. 200 bioactive lipids was applied in functional assays recording intracellular Ca2+ mobilization.  S1P and dihydrosphingosine 1-phosphate (DHS1P) were identified as functional activators exhibiting nanomolar EC50 values.  In the presence of the S1P and LPA receptor antagonist suramin, gpr3-, gpr6- and gpr12-mediated intracellular Ca2+ mobilization via S1P is enhanced.  Besides constitutive activation of Gαs type of G proteins, all three receptors are capable of constitutively activating inhibitory Gαi/o proteins: (i) in the presence of pertussis toxin, gpr3-, gpr6- and gpr12-mediated stimulation of AC is enhanced; and (ii) overexpression of Gαi significantly reduces the stimulatory action on intracellular cAMP levels.  Agonist (S1P)-mediated internalization can be visualized in intact HEK293 cells using a gpr6 green fluorescent protein (GFP) fusion protein.  In summary, our data suggest that gpr3, gpr6 and gpr12 are a family of constitutively active receptors with dual coupling to Gαs and Gαi type of G proteins.  Constitutive activation of AC and mobilization of [Ca2+]i can be modulated by the sphingophospholipids S1P and DHS1P, adding three addnl. members to the family of S1P receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzCtPQR1FNB7Vg90H21EOLACvtfcHk0lg40g-RpBmOWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvVCku7w%253D&md5=df3874623040fcee0239858dd1ba22fb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0898-6568%2802%2900041-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0898-6568%252802%252900041-4%26sid%3Dliteratum%253Aachs%26aulast%3DUhlenbrock%26aufirst%3DK.%26aulast%3DGassenhuber%26aufirst%3DH.%26aulast%3DKostenis%26aufirst%3DE.%26atitle%3DSphingosine%25201-phosphate%2520is%2520a%2520ligand%2520of%2520the%2520human%2520gpr3%252C%2520gpr6%2520and%2520gpr12%2520family%2520of%2520constitutively%2520active%2520G%2520protein-coupled%2520receptors%26jtitle%3DCell.%2520Signalling%26date%3D2002%26volume%3D14%26issue%3D11%26spage%3D941%26epage%3D953%26doi%3D10.1016%2FS0898-6568%2802%2900041-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ignatov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lintzel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreienkamp, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, H. C.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular Ca2+ release by activating the sphingosine-kinase pathway</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>311</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2003.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2Fj.bbrc.2003.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=14592418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFSntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2003&pages=329-336&issue=2&author=A.+Ignatovauthor=J.+Lintzelauthor=H.+J.+Kreienkampauthor=H.+C.+Schaller&title=Sphingosine-1-phosphate+is+a+high-affinity+ligand+for+the+G+protein-coupled+receptor+GPR6+from+mouse+and+induces+intracellular+Ca2%2B+release+by+activating+the+sphingosine-kinase+pathway&doi=10.1016%2Fj.bbrc.2003.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular Ca2+ release by activating the sphingosine-kinase pathway</span></div><div class="casAuthors">Ignatov, Atanas; Lintzel, Julia; Kreienkamp, Hans-Juergen; Schaller, H. Chica</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">We identified and cloned the mouse ortholog of human GPR6 as a new member of the lysophospholipid-receptor family.  Sphingosine-1-phosphate (S1P) activated GPR6, transiently expressed in frog oocytes or in Chinese hamster ovary (CHO) cells, with high specificity and nanomolar affinity.  The GPR6 gene was found to be located on chromosome 10B1 and a single exon coded for the entire open-reading frame.  Signal transduction of S1P was inhibited by pertussis toxin, suggesting a coupling of GPR6 to an inhibitory G protein.  In CHO cells transfected with GPR6, the sphingosine-kinase pathway mediated Ca2+ mobilization from internal stores.  Apoptotic cell death was induced by serum deprivation or H2O2 treatment and was prevented by S1P in GPR6-, but not in vector-transfected CHO cells.  The antiapoptotic effect of S1P required activation of sphingosine kinase and was accompanied by an increase in MAP-kinase phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiEQm99d_1W7Vg90H21EOLACvtfcHk0lg40g-RpBmOWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFSntL8%253D&md5=c6a2bae377401b1cad2c99c177b5b66c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2003.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2003.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DIgnatov%26aufirst%3DA.%26aulast%3DLintzel%26aufirst%3DJ.%26aulast%3DKreienkamp%26aufirst%3DH.%2BJ.%26aulast%3DSchaller%26aufirst%3DH.%2BC.%26atitle%3DSphingosine-1-phosphate%2520is%2520a%2520high-affinity%2520ligand%2520for%2520the%2520G%2520protein-coupled%2520receptor%2520GPR6%2520from%2520mouse%2520and%2520induces%2520intracellular%2520Ca2%252B%2520release%2520by%2520activating%2520the%2520sphingosine-kinase%2520pathway%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D311%26issue%3D2%26spage%3D329%26epage%3D336%26doi%3D10.1016%2Fj.bbrc.2003.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronstam, R. S.</span></span> <span> </span><span class="NLM_article-title">Constitutive Activity among Orphan Class-A G Protein Coupled Receptors</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>), <span class="NLM_elocation-id">e0138463</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0138463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1371%2Fjournal.pone.0138463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=26384023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&issue=9&author=A.+L.+Martinauthor=M.+A.+Steurerauthor=R.+S.+Aronstam&title=Constitutive+Activity+among+Orphan+Class-A+G+Protein+Coupled+Receptors&doi=10.1371%2Fjournal.pone.0138463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activity among orphan class-A G protein coupled receptors</span></div><div class="casAuthors">Martin, Adam L.; Steurer, Michael A.; Aronstam, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0138463/1-e0138463/12</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The purpose of this study was to evaluate the extent of constitutive activity among orphan class-A G protein coupled receptors within the cAMP signaling pathway.  Constitutive signaling was revealed by changes in gene expression under control of the cAMP response element.  Gene expression was measured in Chinese hamster ovary cells transiently cotransfected with plasmids contg. a luciferase reporter and orphan receptor.  Criteria adopted for defining constitutive activation were: (1) 200% elevation over baseline reporter gene expression; (2) 40% inhibition of baseline expression; and (3) 40% inhibition of expression stimulated by 3 μM forskolin.  Five patterns of activity were noted: (1) inhibition under both baseline and forskolin stimulated expression (GPR15, GPR17, GPR18, GPR20, GPR25, GPR27, GPR31, GPR32, GPR45, GPR57, GPR68, GPR83, GPR84, GPR132, GPR150, GPR176); (2) no effect on baseline expression, but inhibition of forskolin stimulated expression (GPR4, GPR26, GPR61, GPR62, GPR78, GPR101, GPR119); (3) elevation of baseline signaling coupled with inhibition of forskolin stimulated expression (GPR6, GPR12); (4) elevation of baseline signaling without inhibition of forskolin stimulated expression (GPR3, GPR21, GPR52, GPR65); and (5) no effect on expression (GPR1, GPR19, GPR22, GPR34, GPR35, GPR39, GPR63, GPR82, GPR85, GPR87).  Constitutive activity was obsd. in 75% of the orphan class-A receptors examd. (30 of 40).  This constitutive signaling cannot be explained by simple overexpression of the receptor.  Inhibition of cAMP mediated expression was far more common (65%) than stimulation of expression (15%).  Orphan receptors that were closely related based on amino acid homol. tended to have similar effects on gene expression.  These results suggest that identification of inverse agonists may be a fruitful approach for categorizing these orphan receptors and targeting them for pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAzoFrN1fJO7Vg90H21EOLACvtfcHk0lhT1b8_SApHPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFCjtw%253D%253D&md5=94482d03b35bec1f4c2967b8d88d5ef0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0138463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0138463%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DA.%2BL.%26aulast%3DSteurer%26aufirst%3DM.%2BA.%26aulast%3DAronstam%26aufirst%3DR.%2BS.%26atitle%3DConstitutive%2520Activity%2520among%2520Orphan%2520Class-A%2520G%2520Protein%2520Coupled%2520Receptors%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D9%26doi%3D10.1371%2Fjournal.pone.0138463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heiman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bupp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doughty, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heintz, N.</span></span> <span> </span><span class="NLM_article-title">Application of a translational profiling approach for the comparative analysis of CNS cell types</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>135</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2008.10.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2Fj.cell.2008.10.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=19013282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCls7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2008&pages=749-762&issue=4&author=J.+P.+Doyleauthor=J.+D.+Doughertyauthor=M.+Heimanauthor=E.+F.+Schmidtauthor=T.+R.+Stevensauthor=G.+Maauthor=S.+Buppauthor=P.+Shresthaauthor=R.+D.+Shahauthor=M.+L.+Doughtyauthor=S.+Gongauthor=P.+Greengardauthor=N.+Heintz&title=Application+of+a+translational+profiling+approach+for+the+comparative+analysis+of+CNS+cell+types&doi=10.1016%2Fj.cell.2008.10.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Application of a translational profiling approach for the comparative analysis of CNS cell types</span></div><div class="casAuthors">Doyle, Joseph P.; Dougherty, Joseph D.; Heiman, Myriam; Schmidt, Eric F.; Stevens, Tanya R.; Ma, Guojun; Bupp, Sujata; Shrestha, Prerana; Shah, Rajiv D.; Doughty, Martin L.; Gong, Shiaoching; Greengard, Paul; Heintz, Nathaniel</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">749-762</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Comparative anal. can provide important insights into complex biol. systems.  As demonstrated in the accompanying paper (Heiman, M., et al., ibid. 738-748), translating ribosome affinity purifn. (TRAP) permits comprehensive studies of translated mRNAs in genetically defined cell populations after physiol. perturbations.  To establish the generality of this approach, the authors present translational profiles for 24 CNS cell populations and identify known cell-specific and enriched transcripts for each population.  The authors report thousands of cell-specific mRNAs that were not detected in whole-tissue microarray studies and provide examples that demonstrate the benefits deriving from comparative anal.  To provide a foundation for further biol. and in silico studies, the authors provide a resource of 16 transgenic mouse lines, their corresponding anat. characterization, and translational profiles for cell types from a variety of central nervous system structures.  This resource will enable a wide spectrum of mol. and mechanistic studies of both well-known and previously uncharacterized neural cell populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyQelg8GOu0rVg90H21EOLACvtfcHk0lhT1b8_SApHPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCls7vL&md5=8293abc5461aec91c516d58af5496803</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.10.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.10.029%26sid%3Dliteratum%253Aachs%26aulast%3DDoyle%26aufirst%3DJ.%2BP.%26aulast%3DDougherty%26aufirst%3DJ.%2BD.%26aulast%3DHeiman%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DE.%2BF.%26aulast%3DStevens%26aufirst%3DT.%2BR.%26aulast%3DMa%26aufirst%3DG.%26aulast%3DBupp%26aufirst%3DS.%26aulast%3DShrestha%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DR.%2BD.%26aulast%3DDoughty%26aufirst%3DM.%2BL.%26aulast%3DGong%26aufirst%3DS.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DHeintz%26aufirst%3DN.%26atitle%3DApplication%2520of%2520a%2520translational%2520profiling%2520approach%2520for%2520the%2520comparative%2520analysis%2520of%2520CNS%2520cell%2520types%26jtitle%3DCell%26date%3D2008%26volume%3D135%26issue%3D4%26spage%3D749%26epage%3D762%26doi%3D10.1016%2Fj.cell.2008.10.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostlund, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balleine, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. W.</span></span> <span> </span><span class="NLM_article-title">Genetic control of instrumental conditioning by striatopallidal neuron-specific S1P receptor Gpr6</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1395</span>– <span class="NLM_lpage">1397</span>, <span class="refDoi"> DOI: 10.1038/nn1987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1038%2Fnn1987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=17934457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ajtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=1395-1397&issue=11&author=M.+K.+Loboauthor=Y.+Cuiauthor=S.+B.+Ostlundauthor=B.+W.+Balleineauthor=X.+W.+Yang&title=Genetic+control+of+instrumental+conditioning+by+striatopallidal+neuron-specific+S1P+receptor+Gpr6&doi=10.1038%2Fnn1987"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic control of instrumental conditioning by striatopallidal neuron-specific S1P receptor Gpr6</span></div><div class="casAuthors">Lobo, Mary Kay; Cui, Yijun; Ostlund, Sean B.; Balleine, Bernard W.; Yang, X. William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1395-1397</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Instrumental conditioning allows animals to learn about the consequences of their own actions, but the underpinning mol. mechanisms remain elusive.  Here, we show that the sphingosine-1-phosphate (S1P) receptor Gpr6 is selectively expressed in the striatopallidal neurons in the striatum.  Gpr6-deficient mice showed reduced striatal cAMP prodn. in vitro and selective alterations in instrumental conditioning in vivo.  Thus, Gpr6 is the first striatopallidal neuron-specific genetic regulator of instrumental conditioning in a mammal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocnUk4GBkOirVg90H21EOLACvtfcHk0lhT1b8_SApHPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ajtr7L&md5=d75a9d6b12200e10d610c924d4357cb7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnn1987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1987%26sid%3Dliteratum%253Aachs%26aulast%3DLobo%26aufirst%3DM.%2BK.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DOstlund%26aufirst%3DS.%2BB.%26aulast%3DBalleine%26aufirst%3DB.%2BW.%26aulast%3DYang%26aufirst%3DX.%2BW.%26atitle%3DGenetic%2520control%2520of%2520instrumental%2520conditioning%2520by%2520striatopallidal%2520neuron-specific%2520S1P%2520receptor%2520Gpr6%26jtitle%3DNat.%2520Neurosci.%26date%3D2007%26volume%3D10%26issue%3D11%26spage%3D1395%26epage%3D1397%26doi%3D10.1038%2Fnn1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oeckl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengerer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferger, B.</span></span> <span> </span><span class="NLM_article-title">G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson’s disease</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2014.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2Fj.expneurol.2014.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=24747358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=2014&pages=1-9&author=P.+Oecklauthor=B.+Hengererauthor=B.+Ferger&title=G-protein+coupled+receptor+6+deficiency+alters+striatal+dopamine+and+cAMP+concentrations+and+reduces+dyskinesia+in+a+mouse+model+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.expneurol.2014.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease</span></div><div class="casAuthors">Oeckl, Patrick; Hengerer, Bastian; Ferger, Boris</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The orphan G-protein coupled receptor 6 (GPR6) is a constitutively active receptor which is pos. coupled to the formation of cyclic adenosine-3',5'-monophosphate (cAMP).  GPR6 is predominantly expressed in striatopallidal neurons.  Here, we investigated neurochem. and behavioral effects of Gpr6 deficiency in mice.  Gpr6 depletion decreased in vivo cAMP tissue concns. (20%) in the striatum.  An increase of striatal tissue dopamine concns. (10%) was found in Gpr6-/- mice, whereas basal extracellular dopamine levels were not changed compared with Gpr6+/+ mice, as shown by in vivo microdialysis.  Western blot analyses revealed no alteration in the expression and subcellular localization of the dopamine D2 receptor in the striatum of Gpr6-/- mice, and the no. of tyrosine hydroxylase pos. neurons in the substantia nigra was unchanged.  DARPP-32 (dopamine and cAMP-regulated phosphoprotein of 32 kDa) expression in the striatum of Gpr6-/- mice was not altered, however, a twofold increase in the phosphorylation of DARPP-32 at Thr34 was detected in Gpr6-/- compared with Gpr6+/+ mice.  Gpr6-/- mice showed higher locomotor activity in the open field, which persisted after treatment with the dopamine D2 receptor antagonist haloperidol.  They also displayed reduced abnormal involuntary movements after apomorphine and quinpirole treatment in the mouse dyskinesia model of Parkinson's disease.  In conclusion, the depletion of Gpr6 reduces cAMP concns. in the striatum and alters the striatal dopaminergic system.  Gpr6 deficiency causes an interesting behavioral phenotype in the form of enhanced motor activity combined with reduced abnormal involuntary movements.  These findings could offer an opportunity for the treatment of Parkinson's disease beyond dopamine replacement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzy8OHbJ-worVg90H21EOLACvtfcHk0lhD70-zSn9kdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemur7O&md5=cb72b4c9546dee4ae3399558995c8b61</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2014.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2014.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DOeckl%26aufirst%3DP.%26aulast%3DHengerer%26aufirst%3DB.%26aulast%3DFerger%26aufirst%3DB.%26atitle%3DG-protein%2520coupled%2520receptor%25206%2520deficiency%2520alters%2520striatal%2520dopamine%2520and%2520cAMP%2520concentrations%2520and%2520reduces%2520dyskinesia%2520in%2520a%2520mouse%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExp.%2520Neurol.%26date%3D2014%26volume%3D257%26spage%3D1%26epage%3D9%26doi%3D10.1016%2Fj.expneurol.2014.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinoza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span> <span> </span><span class="NLM_article-title">Dopamine receptors - IUPHAR Review 13</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1111/bph.12906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1111%2Fbph.12906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=25671228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1-23&issue=1&author=J.+M.+Beaulieuauthor=S.+Espinozaauthor=R.+R.+Gainetdinov&title=Dopamine+receptors+-+IUPHAR+Review+13&doi=10.1111%2Fbph.12906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptors - IUPHAR Review 13</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Espinoza, Stefano; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-23</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The variety of physiol. functions controlled by dopamine in the brain and periphery is mediated by the D1, D2, D3, D4 and D5 dopamine GPCRs.  Drugs acting on dopamine receptors are significant tools for the management of several neuropsychiatric disorders including schizophrenia, bipolar disorder, depression and Parkinson's disease.  Recent investigations of dopamine receptor signalling have shown that dopamine receptors, apart from their canonical action on cAMP-mediated signalling, can regulate a myriad of cellular responses to fine-tune the expression of dopamine-assocd. behaviors and functions.  Such signalling mechanisms may involve alternate G protein coupling or non-G protein mechanisms involving ion channels, receptor tyrosine kinases or proteins such as β-arrestins that are classically involved in GPCR desensitization.  Another level of complexity is the growing appreciation of the physiol. roles played by dopamine receptor heteromers.  Applications of new in vivo techniques have significantly furthered the understanding of the physiol. functions played by dopamine receptors.  Here we provide an update of the current knowledge regarding the complex biol., signalling, physiol. and pharmacol. of dopamine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1fpdKAWrR5rVg90H21EOLACvtfcHk0lhD70-zSn9kdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ&md5=7f15533abc8fb6aa76a4ec41072b6219</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fbph.12906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12906%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DEspinoza%26aufirst%3DS.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DDopamine%2520receptors%2520-%2520IUPHAR%2520Review%252013%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26issue%3D1%26spage%3D1%26epage%3D23%26doi%3D10.1111%2Fbph.12906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quik, M.</span></span> <span> </span><span class="NLM_article-title">Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1002/mds.26955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1002%2Fmds.26955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=28256010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt12rsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=538-548&issue=4&author=X.+A.+Perezauthor=D.+Zhangauthor=T.+Bordiaauthor=M.+Quik&title=Striatal+D1+medium+spiny+neuron+activation+induces+dyskinesias+in+parkinsonian+mice&doi=10.1002%2Fmds.26955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice</span></div><div class="casAuthors">Perez, Xiomara A.; Zhang, Danhui; Bordia, Tanuja; Quik, Maryka</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">538-548</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Dyskinesias are a disabling motor complication that arises with prolonged L-dopa treatment.  Studies using D1 receptor drugs and genetically modified mice suggest that medium spiny neurons expressing D1 receptors play a primary role in L-dopa-induced dyskinesias.  However, the specific role of these neurons in dyskinesias is not fully understood.  Methods : We used optogenetics, which allows for precise modulation of select neurons in vivo, to investigate whether striatal D1-expressing medium spiny neuron activity regulates abnormal involuntary movements or dyskinesia in parkinsonian mice.  D1-cre mice unilaterally lesioned with 6-hydroxydopamine received striatal injections of cre-dependent channelrhodopsin2 virus or control virus.  After stable virus expression, the effect of optical stimulation on dyskinesia was tested in L-dopa-naive and L-dopa-primed mice.  Results : Single-pulse and burst-optical stimulation of D1-expressing medium spiny neurons induced dyskinesias in L-dopa-naive channelrhodopsin2 mice.  In stably dyskinetic mice, L-dopa injection induced dyskinesia to a similar or somewhat greater extent than optical stimulation.  Combined L-dopa administration and stimulation resulted in an additive increase in dyskinesias, indicating that other mechanisms also contribute.  Mol. studies indicate that changes in extracellular signal-regulated kinase phosphorylation in D1-expressing medium spiny neurons are involved.  Optical stimulation did not ameliorate parkinsonism in L-dopa-naive mice.  However, it improved parkinsonism in L-dopa-primed mice to a similar extent as L-dopa administration.  None of the stimulation paradigms enhanced dyskinesia or modified parkinsonism in L-dopa-naive or L-dopa-primed control virus mice.  Conclusion : The data provide direct evidence that striatal D1-expressing medium spiny neuron stimulation is sufficient to induce dyskinesias and contributes to the regulation of motor control. © 2017 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9M6dsbCKup7Vg90H21EOLACvtfcHk0lhD70-zSn9kdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt12rsbg%253D&md5=052babde146b4c9d33bd951e103af5d2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fmds.26955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.26955%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DX.%2BA.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DBordia%26aufirst%3DT.%26aulast%3DQuik%26aufirst%3DM.%26atitle%3DStriatal%2520D1%2520medium%2520spiny%2520neuron%2520activation%2520induces%2520dyskinesias%2520in%2520parkinsonian%2520mice%26jtitle%3DMov.%2520Disord.%26date%3D2017%26volume%3D32%26issue%3D4%26spage%3D538%26epage%3D548%26doi%3D10.1002%2Fmds.26955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, M. A.</span></span> <span> </span><span class="NLM_article-title">Presynaptic Mechanisms of <span class="smallcaps smallerCapital">l</span>-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications</span>. <i>Front Neurol</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">242</span>, <span class="refDoi"> DOI: 10.3389/fneur.2014.00242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.3389%2Ffneur.2014.00242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=25566170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A280%3ADC%252BC2MvksVyqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=242&author=M.+A.+Cenci&title=Presynaptic+Mechanisms+of+l-DOPA-Induced+Dyskinesia%3A+The+Findings%2C+the+Debate%2C+and+the+Therapeutic+Implications&doi=10.3389%2Ffneur.2014.00242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications</span></div><div class="casAuthors">Cenci M Angela</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">242</span>
        ISSN:<span class="NLM_cas:issn">1664-2295</span>.
    </div><div class="casAbstract">The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson's disease (PD) for over 40 years.  However, the response to this treatment changes with disease progression, and most patients develop dyskinesias (abnormal involuntary movements) and motor fluctuations within a few years of l-DOPA therapy.  There is wide consensus that these motor complications depend on both pre- and post-synaptic disturbances of nigrostriatal DA transmission.  Several presynaptic mechanisms converge to generate large DA swings in the brain concomitant with the peaks-and-troughs of plasma l-DOPA levels, while post-synaptic changes engender abnormal functional responses in dopaminoceptive neurons.  While this general picture is well-accepted, the relative contribution of different factors remains a matter of debate.  A particularly animated debate has been growing around putative players on the presynaptic side of the cascade.  To what extent do presynaptic disturbances in DA transmission depend on deficiency/dysfunction of the DA transporter, aberrant release of DA from serotonin neurons, or gliovascular mechanisms? And does noradrenaline (which is synthetized from DA) play a role? This review article will summarize key findings, controversies, and pending questions regarding the presynaptic mechanisms of l-DOPA-induced dyskinesia.  Intriguingly, the debate around these mechanisms has spurred research into previously unexplored facets of brain plasticity that have far-reaching implications to the treatment of neuropsychiatric disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTh-dX8oZYnsM25P7XSLhESfW6udTcc2ebVzKLbFWHFD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvksVyqsQ%253D%253D&md5=48e8771d387e7d57b350867494e8c42e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2014.00242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2014.00242%26sid%3Dliteratum%253Aachs%26aulast%3DCenci%26aufirst%3DM.%2BA.%26atitle%3DPresynaptic%2520Mechanisms%2520of%2520l-DOPA-Induced%2520Dyskinesia%253A%2520The%2520Findings%252C%2520the%2520Debate%252C%2520and%2520the%2520Therapeutic%2520Implications%26jtitle%3DFront%2520Neurol%26date%3D2014%26volume%3D5%26spage%3D242%26doi%3D10.3389%2Ffneur.2014.00242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2091</span>– <span class="NLM_lpage">2113</span>, <span class="refDoi"> DOI: 10.1021/jm5019093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2091-2113&issue=5&author=J.+L.+Dahlinauthor=J.+W.+Nissinkauthor=J.+M.+Strasserauthor=S.+Francisauthor=L.+Higginsauthor=H.+Zhouauthor=Z.+Zhangauthor=M.+A.+Walters&title=PAINS+in+the+assay%3A+chemical+mechanisms+of+assay+interference+and+promiscuous+enzymatic+inhibition+observed+during+a+sulfhydryl-scavenging+HTS.&doi=10.1021%2Fjm5019093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span></div><div class="casAuthors">Dahlin, Jayme L.; Nissink, J. Willem M.; Strasser, Jessica M.; Francis, Subhashree; Higgins, LeeAnn; Zhou, Hui; Zhang, Zhiguo; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2091-2113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant resources in early drug discovery are spent unknowingly pursuing artifacts and promiscuous bioactive compds., while understanding the chem. basis for these adverse behaviors often goes unexplored in pursuit of lead compds.  Nearly all the hits from our recent sulfhydryl-scavenging high-throughput screen (HTS) targeting the histone acetyltransferase Rtt109 were such compds.  Herein, we characterize the chem. basis for assay interference and promiscuous enzymic inhibition for several prominent chemotypes identified by this HTS, including some pan-assay interference compds. (PAINS).  Protein mass spectrometry and ALARM NMR confirmed these compds. react covalently with cysteines on multiple proteins.  Unfortunately, compds. contg. these chemotypes have been published as screening actives in reputable journals and even touted as chem. probes or preclin. candidates.  Our detailed characterization and identification of such thiol-reactive chemotypes should accelerate triage of nuisance compds., guide screening library design, and prevent follow-up on undesirable chem. matter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4XTJapoezkrVg90H21EOLACvtfcHk0lhUGSYoqH-Uuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D&md5=3f77702544cea2ec4c8184b60dd38b8a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm5019093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019093%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%26aulast%3DStrasser%26aufirst%3DJ.%2BM.%26aulast%3DFrancis%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DPAINS%2520in%2520the%2520assay%253A%2520chemical%2520mechanisms%2520of%2520assay%2520interference%2520and%2520promiscuous%2520enzymatic%2520inhibition%2520observed%2520during%2520a%2520sulfhydryl-scavenging%2520HTS.%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D5%26spage%3D2091%26epage%3D2113%26doi%3D10.1021%2Fjm5019093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R.</span></span> <span> </span><span class="NLM_article-title">Time-dependent CYP inhibition</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1517/17425255.3.1.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1517%2F17425255.3.1.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=17269894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=51-66&issue=1&author=R.+J.+Rileyauthor=K.+Grimeauthor=R.+Weaver&title=Time-dependent+CYP+inhibition&doi=10.1517%2F17425255.3.1.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Time-dependent CYP inhibition</span></div><div class="casAuthors">Riley, Robert J.; Grime, Ken; Weaver, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-66</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Time-dependent inhibition (TDI) of CYP refers to a change in potency during an in vitro incubation or dosing period in vivo.  Potential mechanisms include the formation of inhibitory metabolites and mechanism-based inhibition (MBI).  In vitro expts. are configured to assess TDI and MBI is inferred, at least initially.  MBI is more profound after multiple-dosing and the recovery period is independent of continued drug exposure.  Advances in in vitro-in vivo extrapolations for competitive inhibition and the potential relationship between MBI and reactive metabolite-mediated toxicity, have redirected emphasis to CYP TDI.  In contrast, with reversible inhibition, strategies for projecting the risks from TDI are less developed and the traditional I/Ki model often yields a dramatic underprediction.  This review explores the contribution of TDI to drug-drug interactions and idiosyncratic drug toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY8w1eAZ9QULVg90H21EOLACvtfcHk0lhUGSYoqH-Uuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGlurY%253D&md5=184636ac0768f51d65f407a0655233e4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F17425255.3.1.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.3.1.51%26sid%3Dliteratum%253Aachs%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26aulast%3DGrime%26aufirst%3DK.%26aulast%3DWeaver%26aufirst%3DR.%26atitle%3DTime-dependent%2520CYP%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2007%26volume%3D3%26issue%3D1%26spage%3D51%26epage%3D66%26doi%3D10.1517%2F17425255.3.1.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zirvi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">burka, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guengerich, F. P.</span></span> <span> </span><span class="NLM_article-title">Mechanism of cytochrome P450 inhibition by cyclopropylamines</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">2050</span>– <span class="NLM_lpage">2052</span>, <span class="refDoi"> DOI: 10.1021/ja00371a056</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00371a056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADyaL38Xhtlykt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1982&pages=2050-2052&author=T.+L.+Macdonaldauthor=K.+Zirviauthor=L.+T.+burkaauthor=P.+Peymanauthor=F.+P.+Guengerich&title=Mechanism+of+cytochrome+P450+inhibition+by+cyclopropylamines&doi=10.1021%2Fja00371a056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of cytochrome P-450 inhibition by cyclopropylamines</span></div><div class="casAuthors">Macdonald, Timothy L.; Zirvi, Karimullah; Burka, Leo T.; Peyman, Pamela; Guengerich, F. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2050-2</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The cytochrome P-450 monooxygenases are subject to mechanism-based or suicide inhibition by numerous substrates as a function of the metab. of uniquely positioned olefinic, acetylenic, or cyclopropyl amine moieties.  Cyclopropylamines are also suicide inhibitors of mitochondrial monoamine oxidase and of plasma amine oxidase.  The mechanism-based inhibition of these distinct enzyme classes by cyclopropylamines has been postulated to be a consequence of α-hydroxylation to form a cyclopropylcarbinolamine, which reacts with enzyme-bound nucleophiles via a highly reactive iminium ion.  Apparently, an alternative mechanism, postulated to involve initial amine N oxidn. to a radical cation, is operative for the suicide inactivation of cytochrome P-450 by cyclopropylamines.  The inhibition of benzphetamine and aminopyrine N-demethylases was examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojGZ5OOi00QLVg90H21EOLACvtfcHk0lhUGSYoqH-Uuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xhtlykt70%253D&md5=5b6d5069752bf9ebd3f59fe3963329af</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fja00371a056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00371a056%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26aulast%3DZirvi%26aufirst%3DK.%26aulast%3Dburka%26aufirst%3DL.%2BT.%26aulast%3DPeyman%26aufirst%3DP.%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DMechanism%2520of%2520cytochrome%2520P450%2520inhibition%2520by%2520cyclopropylamines%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1982%26volume%3D104%26spage%3D2050%26epage%3D2052%26doi%3D10.1021%2Fja00371a056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alavi, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamsizadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azhdari-Zarmehri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roohbakhsh, A.</span></span> <span> </span><span class="NLM_article-title">Orphan G protein-coupled receptors: The role in CNS disorders</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2017.12.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1016%2Fj.biopha.2017.12.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=29268243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVelur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2018&pages=222-232&author=M.+S.+Alaviauthor=A.+Shamsizadehauthor=H.+Azhdari-Zarmehriauthor=A.+Roohbakhsh&title=Orphan+G+protein-coupled+receptors%3A+The+role+in+CNS+disorders&doi=10.1016%2Fj.biopha.2017.12.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Orphan G protein-coupled receptors: The role in CNS disorders</span></div><div class="casAuthors">Alavi, Mohaddeseh Sadat; Shamsizadeh, Ali; Azhdari-Zarmehri, Hassan; Roohbakhsh, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">222-232</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">There are various types of receptors in the central nervous system (CNS).  G protein-coupled receptors (GPCRs) have the highest expression with a wide range of physiol. functions.  A newer sub group of these receptors namely orphan GPCRs have been discovered.  GPR3, GPR6, GPR17, GPR26, GPR37, GPR39, GPR40, GPR50, GPR52, GPR54, GPR55, GPR85, GPR88, GPR103, and GPR139 are the selected orphan GPCRs for this article.  Their roles in the central nervous system have not been understood well so far.  However, recent studies show that they may have very important functions in the CNS.  Hence, in the present study, we reviewed most recent findings regarding the physiol. roles of the selected orphan GPCRs in the CNS.  After a brief presentation of each receptor, considering the results from genetic and pharmacol. manipulation of the receptors, their roles in the pathophysiol. of different diseases and disorders including anxiety, depression, schizophrenia, epilepsy, Alzheimer's disease, Parkinson's disease, and substance abuse will be discussed.  At present, our knowledge regarding the role of GPCRs in the brain is very limited.  However, previous limited studies show that orphan GPCRs have an important place in psychopharmacol. and these receptors are potential new targets for the treatment of major CNS diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSHrLncYbdvLVg90H21EOLACvtfcHk0liIRvbkYWjRKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVelur%252FP&md5=b3391b2988fac093bb66e376f88b5e1b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2017.12.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2017.12.056%26sid%3Dliteratum%253Aachs%26aulast%3DAlavi%26aufirst%3DM.%2BS.%26aulast%3DShamsizadeh%26aufirst%3DA.%26aulast%3DAzhdari-Zarmehri%26aufirst%3DH.%26aulast%3DRoohbakhsh%26aufirst%3DA.%26atitle%3DOrphan%2520G%2520protein-coupled%2520receptors%253A%2520The%2520role%2520in%2520CNS%2520disorders%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2018%26volume%3D98%26spage%3D222%26epage%3D232%26doi%3D10.1016%2Fj.biopha.2017.12.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isawi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span> <span> </span><span class="NLM_article-title">Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1080/03602532.2018.1428616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1080%2F03602532.2018.1428616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=29390908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1aiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=74-93&issue=1&author=P.+Moralesauthor=I.+Isawiauthor=P.+H.+Reggio&title=Towards+a+better+understanding+of+the+cannabinoid-related+orphan+receptors+GPR3%2C+GPR6%2C+and+GPR12&doi=10.1080%2F03602532.2018.1428616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12</span></div><div class="casAuthors">Morales, Paula; Isawi, Israa; Reggio, Patricia H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-93</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  GPR3, GPR6, and GPR12 are three orphan receptors that belong to the Class A family of G-protein-coupled receptors (GPCRs).  These GPCRs share over 60% of sequence similarity among them.  Because of their close phylogenetic relationship, GPR3, GPR6, and GPR12 share a high percentage of homol. with other lipid receptors such as the lysophospholipid and the cannabinoid receptors.  On the basis of sequence similarities at key structural motifs, these orphan receptors have been related to the cannabinoid family.  However, further exptl. data are required to confirm this assocn.  GPR3, GPR6, and GPR12 are predominantly expressed in mammalian brain.  Their high constitutive activation of adenylyl cyclase triggers increases in cAMP levels similar in amplitude to fully activated GPCRs.  This feature defines their physiol. role under certain pathol. conditions.  In this review, we aim to summarize the knowledge attained so far on the understanding of these receptors.  Expression patterns, pharmacol., physiopathol. relevance, and mols. targeting GPR3, GPR6, and GPR12 will be analyzed herein.  Interestingly, certain cannabinoid ligands have been reported to modulate these orphan receptors.  The current debate about sphingolipids as putative endogenous ligands will also be addressed.  A special focus will be on their potential role in the brain, particularly under neurol. conditions such as Parkinson or Alzheimer's disease.  Reported physiol. roles outside the central nervous system will also be covered.  This crit. overview may contribute to a further comprehension of the physiopathol. role of these orphan GPCRs, hopefully attracting more research towards a future therapeutic exploitation of these promising targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCCO33SWKr9LVg90H21EOLACvtfcHk0lhVMiXpS8hj5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1aiurw%253D&md5=8b586a7c398475b5347fb9abe7e40e09</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1080%2F03602532.2018.1428616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602532.2018.1428616%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DIsawi%26aufirst%3DI.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26atitle%3DTowards%2520a%2520better%2520understanding%2520of%2520the%2520cannabinoid-related%2520orphan%2520receptors%2520GPR3%252C%2520GPR6%252C%2520and%2520GPR12%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2018%26volume%3D50%26issue%3D1%26spage%3D74%26epage%3D93%26doi%3D10.1080%2F03602532.2018.1428616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, T. I.</span></span> <span> </span><span class="NLM_article-title">Molecular cloning and chromosomal localization of human genes encoding three closely related G protein-coupled receptors</span>. <i>Genomics</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1006/geno.1995.1154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1006%2Fgeno.1995.1154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=8530049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADyaK2MXnsVOnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1995&pages=347-349&issue=2&author=Z.+H.+Songauthor=W.+Modiauthor=T.+I.+Bonner&title=Molecular+cloning+and+chromosomal+localization+of+human+genes+encoding+three+closely+related+G+protein-coupled+receptors&doi=10.1006%2Fgeno.1995.1154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning and chromosomal localization of human genes encoding three closely related G protein-coupled receptors</span></div><div class="casAuthors">Song, Zhao-Hu; Modi, William; Bonner, Tom I.</div><div class="citationInfo"><span class="NLM_cas:title">Genomics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-9</span>CODEN:
                <span class="NLM_cas:coden">GNMCEP</span>;
        ISSN:<span class="NLM_cas:issn">0888-7543</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Cosmids contg. human genes for three orphan G protein-coupled receptors, GPR12, GPR6, and GPR3, were isolated using their rat homologs as probes.  Previous studies of the mouse and rat cDNAs have shown the receptors to be expressed primarily in brain but have failed to identify their ligands.  The three receptor proteins of 334, 363, and 330 amino acids, resp., are encoded by a single exon in each gene.  Excluding the divergent sequences preceding the first transmembrane domain, they have ∼60% amino acid identity with each other.  Fluorescence in situ hybridization of GPR12, GPR6, and GPR3 localized these three genes to human chromosomal regions 13q12, 6q21, and 1p34.4-p36.1, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAUji7jcKar7Vg90H21EOLACvtfcHk0lhVMiXpS8hj5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnsVOnurk%253D&md5=1801935467f79d6536ea83f60ee225ac</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1006%2Fgeno.1995.1154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fgeno.1995.1154%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%2BH.%26aulast%3DModi%26aufirst%3DW.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26atitle%3DMolecular%2520cloning%2520and%2520chromosomal%2520localization%2520of%2520human%2520genes%2520encoding%2520three%2520closely%2520related%2520G%2520protein-coupled%2520receptors%26jtitle%3DGenomics%26date%3D1995%26volume%3D28%26issue%3D2%26spage%3D347%26epage%3D349%26doi%3D10.1006%2Fgeno.1995.1154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lgLZCQbEWUZXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span> <span> </span><span class="NLM_article-title">Escape from Flatland 2: complexity and promiscuity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">515</span>, <span class="refDoi"> DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515&issue=3&author=F.+Lovering&title=Escape+from+Flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0lgLZCQbEWUZXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520Flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D3%26spage%3D515%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedregal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Grau, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudra, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, V. N.</span></span> <span> </span><span class="NLM_article-title">Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4955</span>– <span class="NLM_lpage">4967</span>, <span class="refDoi"> DOI: 10.1021/jm201629q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201629q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4955-4967&issue=11&author=C.+Pedregalauthor=E.+M.+Joshiauthor=M.+A.+Toledoauthor=C.+Lafuenteauthor=N.+Diazauthor=M.+A.+Martinez-Grauauthor=A.+Jimenezauthor=A.+Benitoauthor=A.+Navarroauthor=Z.+Chenauthor=D.+R.+Mudraauthor=S.+D.+Kahlauthor=K.+S.+Rashauthor=M.+A.+Statnickauthor=V.+N.+Barth&title=Development+of+LC-MS%2FMS-based+receptor+occupancy+tracers+and+positron+emission+tomography+radioligands+for+the+nociceptin%2Forphanin+FQ+%28NOP%29+receptor&doi=10.1021%2Fjm201629q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Development of LC-MS/MS-Based Receptor Occupancy Tracers and Positron Emission Tomography Radioligands for the Nociceptin/Orphanin FQ (NOP) Receptor</span></div><div class="casAuthors">Pedregal, Concepcion; Joshi, Elizabeth M.; Toledo, Miguel A.; Lafuente, Celia; Diaz, Nuria; Martinez-Grau, Maria A.; Jimenez, Alma; Benito, Ana; Navarro, Antonio; Chen, Zhaogen; Mudra, Daniel R.; Kahl, Steven D.; Rash, Karen S.; Statnick, Michael A.; Barth, Vanessa N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4955-4967</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Currently, a lack of sufficient tools has limited the understanding of the relation between neuropsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor.  Herein, we describe the discovery and development of an antagonist NOP receptor occupancy (RO) tracer and a novel positron emission tomog. (PET) radioligand suitable to probe the NOP receptor in human clin. studies.  A thorough structure-activity relation (SAR) around the high-affinity 3-(2'-fluoro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)-2-(2-halobenzyl)-N-alkylpropanamide scaffold identified a series of subnanomolar, highly selective NOP antagonists.  Subsequently, these unlabeled NOP ligands were evaluated in vivo by liq. chromatog.-tandem mass spectrometry (LC-MS/MS) in rat to det. brain uptake, kinetics and specific binding.  Three compds. were selected for evaluation in nonhuman primates as PET tracers.  Carbon-11 labeling yielded [11C]I, which exhibited minimal generation of central nervous system (CNS) penetrant radiometabolites, improved brain uptake, and was an excellent PET radioligand in both rat and monkey.  Currently [11C]I is being evaluated as a PET radiotracer for the NOP receptor in human subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9BUDm4qd1VrVg90H21EOLACvtfcHk0lgLZCQbEWUZXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqu7c%253D&md5=37ba5b3497d5300a487c179a668a9055</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm201629q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201629q%26sid%3Dliteratum%253Aachs%26aulast%3DPedregal%26aufirst%3DC.%26aulast%3DJoshi%26aufirst%3DE.%2BM.%26aulast%3DToledo%26aufirst%3DM.%2BA.%26aulast%3DLafuente%26aufirst%3DC.%26aulast%3DDiaz%26aufirst%3DN.%26aulast%3DMartinez-Grau%26aufirst%3DM.%2BA.%26aulast%3DJimenez%26aufirst%3DA.%26aulast%3DBenito%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMudra%26aufirst%3DD.%2BR.%26aulast%3DKahl%26aufirst%3DS.%2BD.%26aulast%3DRash%26aufirst%3DK.%2BS.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DBarth%26aufirst%3DV.%2BN.%26atitle%3DDevelopment%2520of%2520LC-MS%252FMS-based%2520receptor%2520occupancy%2520tracers%2520and%2520positron%2520emission%2520tomography%2520radioligands%2520for%2520the%2520nociceptin%252Forphanin%2520FQ%2520%2528NOP%2529%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D11%26spage%3D4955%26epage%3D4967%26doi%3D10.1021%2Fjm201629q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jesudason, C. D.</span>; <span class="NLM_string-name">DuBois, S.</span>; <span class="NLM_string-name">Johnson, M.</span>; <span class="NLM_string-name">Barth, V. N.</span>; <span class="NLM_string-name">Need, A. B.</span></span>, et al. In Vivo Receptor Occupancy in Rodents by LC-MS/MS. <a href="https://www.ncbi.nlm.nih.gov/books/NBK424998/" class="extLink">https://www.ncbi.nlm.nih.gov/books/NBK424998/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jesudason%2C+C.+D.%3B+DuBois%2C+S.%3B+Johnson%2C+M.%3B+Barth%2C+V.+N.%3B+Need%2C+A.+B.%2C+et+al.+In+Vivo+Receptor+Occupancy+in+Rodents+by+LC-MS%2FMS.+https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK424998%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DJesudason%26aufirst%3DC.%2BD." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuhara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kameda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, I.</span></span> <span> </span><span class="NLM_article-title">Animal Models for Parkinson’s Disease Research: Trends in the 2000s</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">5402</span>, <span class="refDoi"> DOI: 10.3390/ijms20215402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.3390%2Fijms20215402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFShtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=5402&issue=21&author=K.+Kinauthor=T.+Yasuharaauthor=M.+Kamedaauthor=I.+Date&title=Animal+Models+for+Parkinson%E2%80%99s+Disease+Research%3A+Trends+in+the+2000s&doi=10.3390%2Fijms20215402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models for Parkinson's disease research: trends in the 2000s</span></div><div class="casAuthors">Kin, Kyohei; Yasuhara, Takao; Kameda, Masahiro; Date, Isao</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5402</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is a chronic and progressive movement disorder and the second most common neurodegenerative disease.  Although many studies have been conducted, there is an unmet clin. need to develop new treatments because, currently, only symptomatic therapies are available.  To achieve this goal, clarification of the pathol. is required.  Attempts have been made to emulate human PD and various animal models have been developed over the decades.  Neurotoxin models have been commonly used for PD research.  Recently, advances in transgenic technol. have enabled the development of genetic models that help to identify new approaches in PD research.  However, PD animal model trends have not been investigated.  Revealing the trends for PD research will be valuable for increasing our understanding of the pos. and neg. aspects of each model.  In this article, we clarified the trends for animal models that were used to research PD in the 2000s, and we discussed each model based on these trends.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxq4Xfy28Z7rVg90H21EOLACvtfcHk0lgLZCQbEWUZXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFShtrg%253D&md5=e6be7b2028ee3c2dce42cb87f3f2b040</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3390%2Fijms20215402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20215402%26sid%3Dliteratum%253Aachs%26aulast%3DKin%26aufirst%3DK.%26aulast%3DYasuhara%26aufirst%3DT.%26aulast%3DKameda%26aufirst%3DM.%26aulast%3DDate%26aufirst%3DI.%26atitle%3DAnimal%2520Models%2520for%2520Parkinson%25E2%2580%2599s%2520Disease%2520Research%253A%2520Trends%2520in%2520the%25202000s%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26issue%3D21%26spage%3D5402%26doi%3D10.3390%2Fijms20215402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brice, N. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffer, H. H</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monenschein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, V. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burley, J R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheardown, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartkowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosea, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, L. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. H</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlton, M. B</span></span> <span> </span><span class="NLM_article-title">Development of CVN<sub>424</sub>: a selective and novel GPR6 inverse agonist effective in models of Parkinson’s Disease</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, <span class="refDoi"> DOI: 10.1124/jpet.120.000438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=10.1124%2Fjpet.120.000438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;key=33795395" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=N.+L+Briceauthor=H.+H+Schifferauthor=H.+Monenscheinauthor=V.+J+Mulliganauthor=K.+Pageauthor=J.+Powellauthor=X.+Xuauthor=T.+Cheungauthor=J+R.+Burleyauthor=H.+Sunauthor=L.+Dicksonauthor=S.+T+Murphyauthor=N.+Kaushalauthor=S.+Sheardownauthor=J.+Lawrenceauthor=Y.+Chenauthor=D.+Bartkowskiauthor=A.+Kantaauthor=J.+Russoauthor=N.+Hoseaauthor=L.+A+Dawsonauthor=S.+H+Hitchcockauthor=M.+B+Carlton&title=Development+of+CVN424%3A+a+selective+and+novel+GPR6+inverse+agonist+effective+in+models+of+Parkinson%E2%80%99s+Disease&doi=10.1124%2Fjpet.120.000438"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fjpet.120.000438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.120.000438%26sid%3Dliteratum%253Aachs%26aulast%3DBrice%26aufirst%3DN.%2BL%26aulast%3DSchiffer%26aufirst%3DH.%2BH%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DMulligan%26aufirst%3DV.%2BJ%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DCheung%26aufirst%3DT.%26aulast%3DBurley%26aufirst%3DJ%2BR.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DDickson%26aufirst%3DL.%26aulast%3DMurphy%26aufirst%3DS.%2BT%26aulast%3DKaushal%26aufirst%3DN.%26aulast%3DSheardown%26aufirst%3DS.%26aulast%3DLawrence%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBartkowski%26aufirst%3DD.%26aulast%3DKanta%26aufirst%3DA.%26aulast%3DRusso%26aufirst%3DJ.%26aulast%3DHosea%26aufirst%3DN.%26aulast%3DDawson%26aufirst%3DL.%2BA%26aulast%3DHitchcock%26aufirst%3DS.%2BH%26aulast%3DCarlton%26aufirst%3DM.%2BB%26atitle%3DDevelopment%2520of%2520CVN424%253A%2520a%2520selective%2520and%2520novel%2520GPR6%2520inverse%2520agonist%2520effective%2520in%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2021%26doi%3D10.1124%2Fjpet.120.000438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i55"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02081">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_27020"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02081?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02081</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Materials and Methods; preparation of key intermediates; characterization of lead compounds: <b>1</b>, <b>3e</b>, and <b>6h</b>; original pharmacology data for compound <b>3e</b> and lead compound <b>6h</b>; structure and validation data of radioligand [<sup>3</sup>H]-RL338; reference compound for cAMP TR-FRET assays: structure and in vitro pharmacology; compound <b>3e</b> in vitro pharmacology graphs (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02081/suppl_file/jm0c02081_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02081/suppl_file/jm0c02081_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02081/suppl_file/jm0c02081_si_001.pdf">jm0c02081_si_001.pdf (805.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02081/suppl_file/jm0c02081_si_002.csv">jm0c02081_si_002.csv (6.06 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02081&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02081%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-14" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02081" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67c770fb6f0722f0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
